var title_f40_46_41696="Phenylephrine: Pediatric drug information";
var content_f40_46_41696=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phenylephrine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/10/17572?source=see_link\">",
"       Phenylephrine (nasal): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/13/40147?source=see_link\">",
"       Phenylephrine (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/23/13686?source=see_link\">",
"       Phenylephrine (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/16/5379?source=see_link\">",
"       Phenylephrine (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12701 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-0E3ADE63EF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_46_41696=[""].join("\n");
var outline_f40_46_41696=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/10/17572?source=related_link\">",
"      Phenylephrine (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/13/40147?source=related_link\">",
"      Phenylephrine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/23/13686?source=related_link\">",
"      Phenylephrine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/16/5379?source=related_link\">",
"      Phenylephrine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_46_41697="Lymphomatoid papulosis arm";
var content_f40_46_41697=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lymphomatoid papulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin lesions in various states of development and regression.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_46_41697=[""].join("\n");
var outline_f40_46_41697=null;
var title_f40_46_41698="Patient information: Hepatitis A (The Basics)";
var content_f40_46_41698=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16201\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/54/40804\">",
"         Organs inside the abdomen (belly)",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/34/557\">",
"          Tips for safe food handling",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/22/10595\">",
"         Patient information: Food poisoning (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?25/41/26258\">",
"         Patient information: Hepatitis B (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/39/32370\">",
"         Patient information: Hepatitis C (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?26/42/27298\">",
"         Patient information: Staying healthy when you travel (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/22/28003\">",
"         Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/44/21187\">",
"         Patient information: Vaccines for travel (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?16/2/16421\">",
"         Patient information: General travel advice (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/61/22483\">",
"         Patient information: Hepatitis A (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hepatitis A (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hepatitis-a-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H29146073\">",
"      <span class=\"h1\">",
"       What is hepatitis A?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hepatitis A is an infection that harms the liver. The liver is a big organ in the upper right side of the belly (",
"      <a class=\"graphic graphic_figure graphicRef64960 \" href=\"mobipreview.htm?39/54/40804\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Hepatitis A is caused by a virus. When people have hepatitis A, the virus leaves their body in their bowel movements. If infected people do not wash their hands after they use the bathroom, they can have the virus on their hands. Then they can spread the virus to anything they touch, including food, water, and other people.",
"     </p>",
"     <p>",
"      People all over the world can get hepatitis A.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29146080\">",
"      <span class=\"h1\">",
"       What are the symptoms of hepatitis A?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In children, hepatitis A does not usually cause any symptoms. In adults, hepatitis A causes a flu-like illness that starts suddenly about a month after a person is infected.",
"     </p>",
"     <p>",
"      At first, symptoms usually include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling tired",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"       <li>",
"        Having no appetite",
"       </li>",
"       <li>",
"        Fever higher than 100.4&deg;F (38&deg;C)",
"       </li>",
"       <li>",
"        Pain under the ribs on the right side of the belly",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Later on, symptoms usually include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Dark-colored urine",
"       </li>",
"       <li>",
"        Light-colored bowel movements",
"       </li>",
"       <li>",
"        Jaundice, which is when the skin or white part of the eye turns yellow",
"       </li>",
"       <li>",
"        Itchy skin",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Rarely, hepatitis A can cause liver damage that can lead to death.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29146087\">",
"      <span class=\"h1\">",
"       How do people get hepatitis A?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People can get hepatitis A after they eat food or drink water with the virus in it. People can also get it if they touch something that has the virus on it and then touch their food or put their hands in their mouth.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29146094\">",
"      <span class=\"h1\">",
"       Is there a test for hepatitis A?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To check if you have hepatitis A, your doctor or nurse will do an exam and blood tests.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29146101\">",
"      <span class=\"h1\">",
"       How is hepatitis A treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most of the time, the infection will get better on its own. But there are things you can do at home to help your liver heal. You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Get plenty of rest &mdash; Do not return to work or school until your fever is gone, your appetite is back, and your skin and eyes are no longer yellow.",
"       </li>",
"       <li>",
"        Avoid drinking alcohol",
"       </li>",
"       <li>",
"        Avoid certain medicines &mdash; Your doctor or nurse will tell you which prescription and over-the-counter medicines to avoid.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In rare cases, people need to be treated in the hospital.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29146108\">",
"      <span class=\"h1\">",
"       When will I feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It can take a few months to feel better. Most people are completely better within 6 months of getting infected. Hepatitis A does",
"      <strong>",
"       not",
"      </strong>",
"      lead to lifelong liver problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29146115\">",
"      <span class=\"h1\">",
"       Can hepatitis A be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To help prevent getting or spreading hepatitis A, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wash your hands after going to the bathroom, changing diapers, and touching garbage or dirty clothes. Also, be sure to wash your hands before preparing food and eating.",
"       </li>",
"       <li>",
"        Get the",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/58/11169?source=see_link\">",
"         hepatitis A vaccine",
"        </a>",
"        &mdash; Vaccines are treatments that prevent infections. Doctors recommend that adults get the hepatitis A vaccine if they have a higher than normal chance of getting the infection. This includes adults who plan to travel to certain countries or have certain medical conditions.",
"       </li>",
"       <li>",
"        Make sure that your child gets the",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/58/11169?source=see_link\">",
"         hepatitis A vaccine",
"        </a>",
"        &mdash; Doctors recommend that all babies get the hepatitis A vaccine as 1 of their routine childhood vaccines.",
"       </li>",
"       <li>",
"        Pay attention to food safety (",
"        <a class=\"graphic graphic_table graphicRef60529 \" href=\"mobipreview.htm?0/34/557\">",
"         table 1",
"        </a>",
"        ):",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Don&rsquo;t drink unpasteurized milk or foods made with it",
"       </li>",
"       <li>",
"        Wash fruits and vegetables well before eating them",
"       </li>",
"       <li>",
"        Keep the refrigerator colder than 40&deg;F (4.4&deg;C) and the freezer below 0&deg;F (-17.8&deg;C)",
"       </li>",
"       <li>",
"        Cook meat and seafood until well done",
"       </li>",
"       <li>",
"        Cook eggs until the yolk is firm",
"       </li>",
"       <li>",
"        Wash hands, knives, and cutting boards after they touch raw food",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29146122\">",
"      <span class=\"h1\">",
"       What if I live with or was with someone who has hepatitis A?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you live with or were with someone who has hepatitis A, let your doctor or nurse know as soon as possible. If you never got the",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/58/11169?source=see_link\">",
"       hepatitis A vaccine",
"      </a>",
"      , you might need to get it. Or your doctor might give you a shot of medicine to help prevent you from getting the infection.",
"     </p>",
"     <p>",
"      You can catch hepatitis A from someone who is infected and is not yet having symptoms. You can also catch it from someone who has symptoms until the week after they develop jaundice (which is when the skin or white part of the eyes turn yellow). &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29146129\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/42/27298?source=see_link\">",
"       Patient information: Staying healthy when you travel (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/44/21187?source=see_link\">",
"       Patient information: Vaccines for travel (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/22/28003?source=see_link\">",
"       Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/22/10595?source=see_link\">",
"       Patient information: Food poisoning (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/41/26258?source=see_link\">",
"       Patient information: Hepatitis B (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/39/32370?source=see_link\">",
"       Patient information: Hepatitis C (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/61/22483?source=see_link\">",
"       Patient information: Hepatitis A (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/2/16421?source=see_link\">",
"       Patient information: General travel advice (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/46/41698?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16201 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.131.41.98-0FBBA5EC0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_46_41698=[""].join("\n");
var outline_f40_46_41698=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29146073\">",
"      What is hepatitis A?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29146080\">",
"      What are the symptoms of hepatitis A?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29146087\">",
"      How do people get hepatitis A?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29146094\">",
"      Is there a test for hepatitis A?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29146101\">",
"      How is hepatitis A treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29146108\">",
"      When will I feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29146115\">",
"      Can hepatitis A be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29146122\">",
"      What if I live with or was with someone who has hepatitis A?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29146129\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16201\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/54/40804\">",
"      Organs inside the abdomen (belly)",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/34/557\">",
"       Tips for safe food handling",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/22/10595?source=related_link\">",
"      Patient information: Food poisoning (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/2/16421?source=related_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/61/22483?source=related_link\">",
"      Patient information: Hepatitis A (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/41/26258?source=related_link\">",
"      Patient information: Hepatitis B (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/39/32370?source=related_link\">",
"      Patient information: Hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/42/27298?source=related_link\">",
"      Patient information: Staying healthy when you travel (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/22/28003?source=related_link\">",
"      Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/44/21187?source=related_link\">",
"      Patient information: Vaccines for travel (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_46_41699="Autism spectrum disorders";
var content_f40_46_41699=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Autism spectrum disorders (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/46/41699/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/46/41699/contributors\" id=\"au219\">",
"       Marilyn Augustyn, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/46/41699/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/46/41699/contributors\" id=\"se7400\">",
"       Marc C Patterson, MD, FRACP",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/46/41699/contributors\" id=\"se596\">",
"       Carolyn Bridgemohan, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/46/41699/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/46/41699/contributors\" id=\"de5754\">",
"       Mary M Torchia, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/46/41699?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      AUTISM OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Autism spectrum disorders (ASDs) are a group of developmental disorders that cause lifelong difficulties with socializing, communicating, and behavior. The term \"spectrum\" refers to the fact that some people have a few mild symptoms while others have severe symptoms that are disabling. There are several types of ASD; the most common include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Autistic disorder (classic autism, sometimes called early infantile autism, childhood autism, or Kanner's autism)",
"      </li>",
"      <li>",
"       Asperger disorder (also known as Asperger syndrome)",
"      </li>",
"      <li>",
"       Pervasive developmental disorder-not otherwise specified (PDD-NOS), including atypical autism",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     These disorders share some of the same symptoms, but differ in the age at which symptoms begin, the severity of the symptoms, and how the symptoms are expressed. This topic will discuss general information about ASDs, as well as the signs and symptoms of the most common type of ASD, autistic disorder.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2\">",
"     <span class=\"h2\">",
"      How does autism develop?",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is not clear how or why autism develops. The general consensus is that autism spectrum disorders are a genetic disorder that affects brain development and impairs the development of social and communication skills. This, in turn, leads to the typical symptoms of ASD. (See",
"     <a class=\"local\" href=\"#H5\">",
"      'Symptoms of autistic disorder'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Environmental factors such as toxic exposures before or after birth, complications during delivery, and infections before birth may be responsible for a small percentage of cases. In children with a genetic predisposition, environmental factors may further increase the child's risk of developing ASD. It is not currently possible to test a child's genes to determine if he or she is at risk for ASD.",
"    </p>",
"    <p>",
"     Some authors have attributed autism to vaccine exposure (particularly measles vaccine and thimerosal, a mercury preservative used in vaccines). However, the overwhelming majority of scientific studies do not support an association between immunizations and autism. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/42/18084?source=see_link\">",
"      \"Patient information: Why does my child need vaccines? (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      How common is autism?",
"     </span>",
"     &nbsp;&mdash;&nbsp;The number of children diagnosed with ASD in the United States and other countries has increased since the 1970s, and particularly since the late 1990s. It is not clear if the increase is related to changes in the criteria used to diagnose ASD or if the condition has become more common over time. Most experts agree that increased awareness of autism and changes in the definition of ASD account for much of the apparent increase in the prevalence of autism.",
"    </p>",
"    <p>",
"     Between 2 and 11 children per 1000 have autism spectrum disorder, and it affects more boys than girls (approximately four boys for every one girl). Approximately 2 to 8 percent of siblings of children with ASD also have the condition.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Medical conditions associated with autism",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of medical conditions associated with autism.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Between 45 and 60 percent of children with autism are intellectually disabled (previously called mentally retarded).",
"      </li>",
"      <li>",
"       Between 11 and 39 percent of children with ASD have seizures. The risk of seizures is higher in individuals with more severe intellectual disability (mental retardation). (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/26/419?source=see_link\">",
"        \"Patient information: Seizures in children (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       A minority (fewer than 10 to 25 percent) of cases of ASD are associated with a medical condition or syndrome, such as tuberous sclerosus, fragile X syndrome, Rett syndrome, phenylketonuria, fetal alcohol syndrome, or Angelman syndrome. These syndromes are usually diagnosed at or shortly after birth.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      SYMPTOMS OF AUTISTIC DISORDER",
"     </span>",
"    </p>",
"    <p>",
"     Symptoms of autistic disorder are usually recognized between two and three years of age, although they may be present earlier. By definition in the current diagnostic criteria, symptoms must be present by three years of age. Symptoms cluster into three broad areas: communication, socialization, and behavior.",
"    </p>",
"    <p>",
"     In approximately two-thirds of children with autism, the first sign is a lack of communication skills by two years of age. Reasons for parents to seek help are discussed below. (See",
"     <a class=\"local\" href=\"#H21\">",
"      'When to seek help'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H612017741\">",
"     <span class=\"h2\">",
"      Communication",
"     </span>",
"     &nbsp;&mdash;&nbsp;This is the most common concern of parents, which often leads the parent to seek medical attention. The child may lack the ability to speak or understand",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     may show no interest in communicating.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H612017761\">",
"     <span class=\"h3\">",
"      Nonverbal behaviors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Individuals with autism spectrum disorder (ASD) have difficulty using and interpreting nonverbal behaviors such as eye contact, facial expression, gestures, and body postures. For example, a child may not be able to understand the facial expressions associated with anger or annoyance.",
"    </p>",
"    <p>",
"     During infancy, parents may notice that the baby resists cuddling, avoids eye contact, or does not spread the arms in anticipation of being picked up; however, these behaviors are not universal.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H612017748\">",
"     <span class=\"h3\">",
"      Language",
"     </span>",
"     &nbsp;&mdash;&nbsp;A delayed or absent ability to speak is a feature of autism. Unlike children with a hearing impairment, children with ASD do not try to compensate for their lack of speech by using alternate means of communication, like gesturing or miming. In most individuals with ASD, the ability to understand is delayed even more than the ability to speak. Children may not respond to their name, and the parent may initially be concerned that the child has a hearing problem. A child may not be able to understand simple questions or directions.",
"    </p>",
"    <p>",
"     There is wide variability in the severity and quality of language problems in children with autism. The ability to speak never develops in approximately one-half of affected children. In others, the child is able to speak, but language is not used as a tool for communication (eg, it consists of repeating phrases or words spoken by others, called echolalia).",
"    </p>",
"    <p>",
"     Those who are able to speak may have difficulty starting or sustaining a conversation with others. Their language may have meaning only to people who are familiar with the autistic individual's communication style.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H612017777\">",
"     <span class=\"h2\">",
"      Socialization",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Social interaction",
"     </span>",
"     &nbsp;&mdash;&nbsp;Difficulty with or lack of interaction with family and friends is a hallmark of ASD. Components of social interaction include nonverbal behaviors, peer relationships, joint attention, and social reciprocity (which are explained below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Peer relationships",
"     </span>",
"     &nbsp;&mdash;&nbsp;Individuals with ASD often have a hard time learning to interact with other people. Younger children may have little or no interest in developing friendships. They may prefer to play alone rather than playing with others, and may involve others in activities only as tools or \"mechanical\" aids (ie, using the hand of a parent to obtain a desired object without making eye contact).",
"    </p>",
"    <p>",
"     Older children may become more interested in talking or socializing with other people, but may not understand social conventions or the needs of others. As an example, the child may continue talking about a topic of their own interest with complete disregard for the interests of the listener.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Joint attention",
"     </span>",
"     &nbsp;&mdash;&nbsp;Individuals with ASD are not interested in sharing activities, interests, or achievements; this is referred to as impaired joint attention.",
"    </p>",
"    <p>",
"     Joint attention is a normal behavior in which an infant or toddler tries to share interest, amusement, or fear with a caretaker. The child does this by purposefully looking back and forth between an object and the eyes of the caretaker (usually by 8 to 10 months of age), or by pointing to the object (usually by 14 to 16 months of age). Older children with ASD may not show or bring an object to the caretaker.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Social referencing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Individuals with ASD are sometimes not able to share a pleasurable activity with others. As an example, the child may prefer to play alone amidst a crowd of children engaged in the same activity.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Behavior",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Preoccupations",
"     </span>",
"     &nbsp;&mdash;&nbsp;Younger children may be preoccupied with peculiar sensory objects or experiences, such as spinning objects, shiny surfaces, the edge of objects, lights, odors, or sniffing or licking nonfood objects.",
"    </p>",
"    <p>",
"     Older children may be preoccupied with the weather, dates, schedules, phone numbers, license plates, cartoon characters, or other items (eg, dinosaurs, dogs, planes).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H133601364\">",
"     <span class=\"h3\">",
"      Rituals",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many children with ASD have specific routines or rituals that must be followed exactly. These may occur as a part of daily life, such as the need to always eat particular foods in a specific order, or to follow the same route from one place to another without deviation. Changes in routine can be upsetting or frustrating, even causing the child to have a tantrum or meltdown.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Motor mannerisms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Another behavioral feature of ASD is repetitive body movements, such as hand or finger flapping or twisting, rocking, swaying, dipping, or walking on tip-toe. These behaviors are seen in 37 to 95 percent of individuals with ASD, and commonly begin during the preschool years. These behaviors are often lifelong.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8567867\">",
"     <span class=\"h3\">",
"      Play",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lack of varied, spontaneous make-believe play or imitation is a characteristic feature of autism. Children with autism spectrum disorder may line up an exact number of playthings in the same manner, without awareness of what the toys represent. They may focus on parts of toys rather than the function of the toy. They may not engage in pretend play, which usually develops by two years of age. Even if pretend play develops, the child may simply be mimicking what has been seen on television or in books.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H612017806\">",
"     <span class=\"h2\">",
"      Other common areas of challenge",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Cognitive skills",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cognitive skills include the ability to think, remember, and process information. In children with autism, these skills are often uneven, regardless of the child's level of intelligence. The person can often perform tasks that require memorization or putting things together (eg, puzzles), but may have difficulty with tasks that require higher-level skills, such as reasoning, interpretation, or abstract thinking.",
"    </p>",
"    <p>",
"     Some individuals have special skills (ie, \"savant\" skills) in memory, mathematics, music, art, or puzzles, despite significant difficulties in other areas. Other special skills can include calendar calculation (determining the day of the week for a given date) and hyperlexia (the ability to read written words that are far above the person's reading level). However, the person may not understand what is being read or the purpose of reading.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Sensory perception",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many people with ASD perceive sounds, tastes, or touch differently. For example, the person may be overly sensitive to normal noise levels or have no response to loud noises.",
"    </p>",
"    <p>",
"     Other examples include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Refusal to eat foods with certain tastes or textures, or eating only foods with certain tastes and textures. These dietary obsessions can cause gastrointestinal symptoms, such as weight loss, diarrhea, or constipation.",
"      </li>",
"      <li>",
"       Resistance to being touched or increased sensitivity to certain kinds of touch; light touch may be experienced as painful, whereas deep pressure may provide a sense of calm. This may include resistance to the feel of certain clothing textures or colors next to the skin.",
"      </li>",
"      <li>",
"       Apparent indifference to pain.",
"      </li>",
"      <li>",
"       Hypersensitivity to certain frequencies or types of sound (eg, distant fire engines) and lack of response to sounds close by or sounds that would startle other children (eg, firecrackers).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Macrocephaly",
"     </span>",
"     &nbsp;&mdash;&nbsp;Approximately one-fourth of children with ASD have a larger than normal-size head. The medical term for this is macrocephaly. This may be related to abnormalities in early brain development, which contribute to the signs and symptoms of autism discussed above.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      AUTISM DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     If a child has symptoms of autism spectrum disorder (ASD),",
"     <span class=\"nowrap\">",
"      s/he",
"     </span>",
"     is usually evaluated by a team that has expertise in diagnosing and managing the condition. This team often includes a child psychologist, developmental-behavioral pediatrician, neurologist, psychiatrist, speech therapist, and other professionals.",
"    </p>",
"    <p>",
"     The evaluation usually includes a complete medical history (of the child and family), physical examination, neurologic examination, and testing of the child's social, language, and cognitive skills. In addition, the parent(s) will have time to discuss the child's behavior and any other concerns.",
"    </p>",
"    <p>",
"     The purpose of the evaluation includes the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Determine if the child has ASD or if another condition could be causing the child's symptoms.",
"      </li>",
"      <li>",
"       Determine if the child has any ASD-associated medical problems that should be evaluated or treated.",
"      </li>",
"      <li>",
"       Determine the child's strengths, weaknesses, and level of functioning.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHEN TO SEEK HELP",
"     </span>",
"    </p>",
"    <p>",
"     Some common symptoms of autism spectrum disorder (ASD) are listed in the Table (",
"     <a class=\"graphic graphic_table graphicRef77412 \" href=\"mobipreview.htm?31/33/32283\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Parents who notice that their child has one or more symptoms of ASD should talk the child's healthcare provider. The provider should screen the child for ASD.",
"    </p>",
"    <p>",
"     If the provider's evaluation raises red flags for autism, the child should be referred for a complete evaluation for ASD. Early diagnosis and treatment of ASD can modify some autistic behaviors and improve socialization. (See",
"     <a class=\"local\" href=\"#H20\">",
"      'Autism diagnosis'",
"     </a>",
"     above.)",
"    </p>",
"    <p>",
"     Even before the complete evaluation, the child should be referred for a hearing test (if not done previously) and for early intervention services. Early intervention is a support and treatment system that provides appropriate therapies for children with disabilities. It can help to minimize delays and maximize the child's chance of reaching normal milestones in development. Even if the child is not diagnosed with autism, early intervention services can help to address parents' concerns (eg, delayed language skills, temper tantrums).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      AUTISM TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Autism cannot be cured. However, a healthcare provider can work with parents to develop a treatment plan to help the child reach his or her full potential. The optimal treatment plan depends upon the child's age, diagnosis, underlying medical problems, and other individual factors.",
"    </p>",
"    <p>",
"     The American Academy of Pediatrics recommends a plan that provides structure, direction, and organization for the child [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/46/41699/abstract/1\">",
"      1",
"     </a>",
"     ]. In the United States, services are often provided through an early intervention program and then subsequently through the public school system after the age of three years, administered by the individual states. Information about services for children with autism is available through the",
"     <a class=\"external\" href=\"file://www.nichcy.org/\">",
"      National Dissemination Center for Children with Disabilities",
"     </a>",
"     .",
"    </p>",
"    <p>",
"     Other resources for parents and providers are listed below. (See",
"     <a class=\"local\" href=\"#H23\">",
"      'Where to get more information'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413397441\">",
"     <span class=\"h2\">",
"      Patient-level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23442745\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/37/38481?source=see_link\">",
"      Patient information: Autism (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/18/24865?source=see_link\">",
"      Patient information: Asperger syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/47/38641?source=see_link\">",
"      Patient information: Learning disabilities (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/4/12355?source=see_link\">",
"      Patient information: Fragile X syndrome (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23442760\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/42/18084?source=see_link\">",
"      Patient information: Why does my child need vaccines? (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/26/419?source=see_link\">",
"      Patient information: Seizures in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Professional-level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/36/21066?source=see_link\">",
"      Autism and chronic disease: Little evidence for thimerosal as a contributing factor",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26857?source=see_link\">",
"      Autism and chronic disease: Little evidence for vaccines as a contributing factor",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/41/664?source=see_link\">",
"      Clinical features of autism spectrum disorders",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/3/38969?source=see_link\">",
"      Diagnosis of autism spectrum disorders",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/1/14361?source=see_link\">",
"      Screening tools for autism spectrum disorders",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/17/35097?source=see_link\">",
"      Surveillance and screening for autism spectrum disorders in primary care",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4698?source=see_link\">",
"      Terminology, epidemiology, and pathogenesis of autism spectrum disorders",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Mental Health",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nimh.nih.gov/health/topics/autism-spectrum-disorders-pervasive-developmental-disorders/index.shtml\">",
"      www.nimh.nih.gov/health/topics/autism-spectrum-disorders-pervasive-developmental-disorders/index.shtml",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Medline Plus",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/autism.html\">",
"      www.nlm.nih.gov/medlineplus/autism.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Neurological Disorders and Stroke",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ninds.nih.gov/disorders/autism/detail_autism.htm\">",
"      www.ninds.nih.gov/disorders/autism/detail_autism.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       United States Center for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/ncbddd/autism/index.htm\">",
"      www.cdc.gov/ncbddd/autism/index.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Autism Speaks",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.autismspeaks.org/\">",
"      www.autismspeaks.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Autism Society of America",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.autism-society.org/\">",
"      www.autism-society.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Autism Spectrum Disorders Video Glossary, an online resource for parents and providers with video clips showing early red flags for autism",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.autismspeaks.org/video/glossary.php\">",
"      www.autismspeaks.org/video/glossary.php",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       First Signs",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.firstsigns.org/\">",
"      www.firstsigns.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Learn the Signs. Act Early.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/ncbddd/autism/actearly\">",
"      www.cdc.gov/ncbddd/autism/actearly",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The United Kingdom's National Autistic Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nas.org.uk/\">",
"      www.nas.org.uk",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Federation for Children with Special Needs",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.fcsn.org/\">",
"      www.fcsn.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Asperger's Association of New England",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://aane.autistics.org/\">",
"      aane.autistics.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/46/41699/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 29, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/46/41699?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41699/abstract/1\">",
"      Myers SM, Johnson CP, American Academy of Pediatrics Council on Children With Disabilities. Management of children with autism spectrum disorders. Pediatrics 2007; 120:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41699/abstract/2\">",
"      Johnson CP, Myers SM, American Academy of Pediatrics Council on Children With Disabilities. Identification and evaluation of children with autism spectrum disorders. Pediatrics 2007; 120:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41699/abstract/3\">",
"      Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators, Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Autism diagnosis in children and young people: Recognition, referral and diagnosis of children and young people on the autism spectrum file://publications.nice.org.uk/autism-diagnosis-in-children-and-young-people-cg128.",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f40_46_41699=[""].join("\n");
var outline_f40_46_41699=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           AUTISM OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           SYMPTOMS OF AUTISTIC DISORDER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           AUTISM DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHEN TO SEEK HELP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           AUTISM TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/33/32283\" title=\"table 1\">",
"           Signs of autism PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f40_46_41700="Acute pneumonitis SLE chest x-ray and CT scan";
var content_f40_46_41700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F88484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F88484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    Acute pneumonitis on chest radiography and computerized tomography imaging in systemic lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The chest x-ray performed on this 41-year-old female shows a diffuse interstitial pattern, and the CT scan through the chest shows multicentric ground glass changes centered around the bronchovascular bundle compatible with acute lupus pneumonitis.",
"    <div class=\"footnotes\">",
"     CT: computerized tomography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_46_41700=[""].join("\n");
var outline_f40_46_41700=null;
var title_f40_46_41701="Relative risks of major complications of CKD";
var content_f40_46_41701=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F68921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F68921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Relative risks of major complications of chronic kidney disease based upon categorical meta-analysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 804px; background-image: url(data:image/gif;base64,R0lGODlh/AEkA+YAAP///yy3hf8AAP+ZM/zuIQAAAIiIiDMzM93d3SIiIhEREbu7u0RERO7u7pmZmWZmZszMzHd3d1VVVaqqqhdiR0M/CUQAACCGYkQpDgYYEogAAGY9FAwxIyafcwklG2VfDRJJNRpuUDMAAN0AAN2FLIZ/EohSGyIAAGYAAAMMCbsAANrOHTMfChEAACmrfBEKA5kAACIUB8x6Ke4AAJlcH+6PMMq+GndHGLmvGFUAABEQAjIwByOSartwJXcAAHZvDyIgBFUzER16WeveH8wAAFRPCw89LJePFKoAABVVPqpmIqifFgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAD8ASQDAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocSLCgLwUFIEAooCCagQISDEqcaGhBgQIMBiFUyLDYhI6IHkaUUMAAgAMlKaoE+OBiAQSCNi5sSOwjzUMiC6E0ubLnPoQIecoEWcgAwo4oLx6AcDIlyQgAHl5s2IDkRZ6DSEpIgHEC14wAHHDF2KDBxQgYXRaIgHaqg6gQ/wGQNGD1IoOUFhP43PvOQYEEfvUCGHpz0EOwRf82Nfn04QFCdxcA4Co569rJlyl/1Ov3gFmXEWwWsvgy59zFAD4+bomVr2t0dw00QCiZsFyXBlC+HeTg7lTUT/0WOBABAgK1Vwmd3rm45QMAnxcmFCQaAIS6CU2nZI4ZggIFDV6LN3cc+XPbOgvsBmBRAQTRzJ9GbXmxPMxDy7eXdA79onSmqYEUVHTamcTdQ1w9N96C4iAoiF8NoUfIYYOI9lBD/KEElSD2oRSRXBMop5+BJW0W1nDRCdJefwUsQBoEBQIQG4cuAcjgjd1whRVCDkg44VEN+YZSQxB8pWFbf73VAP99GN0nSH4kmiSWXWX5N4hvEUiVFIxxnTbBUeGRhBiOZJbpClchmqnmmqaYyOabcMYp55x01mnnnXjmqeeefPbp55/iISfooIQWauihiCaq6KKMNuroo5BGqpYpklZq6aWYZqrpppFSUgCgsHxaiqirkIqKqaeygiqlnoL6yqqgwMqqKrKSUusot4aSayK7uipKr5kA+4mwnBBbrKqltuorsqO2Yqwmz0LLbCrRAlDtsphcG4m2l3CrLK3TpjqJt9iOO2uyjHykoHVJJWCAVMM5yasjKDkJrwTlJccIsPUa5hK+arU2byP9CnJvviktUi255W57LriMMMAAeAAgoID/gnQZIBhx+zaygAIH8BRBAkwhwIBFb30UnsIegywyyRWfrF6AKyvS68chCzJyyTKnXEDNiCzcMLUPE73IcUW+lVtRejXgbseMPCCBWDGlOcjMRjXSq9RUD2a1IFgXNvAiXAumwNfWKi32IUIPfQrDUKOryNIGZGTAuga7hPfYicw2wWySvVSISwdUxvIifgNurbzWKmW4zYwkrkDgjBP+eNDfum1r0eIqMlZ9GjMNwAOPxZ2IcBedtx7YDniHNuaLoF6A6oO3frbWjMhOOyHquW46JHBrfvjm4R5i0coMRGDxhxlvvDfbEW94/MiSmYxyau79fkjyKv5MfczXf2kj/9+IcM+e9wlU3zP240NvrijcieLb64ikKEp1kGwkC/7ax+os2R8KS0MWkJSQha5iT4OcIpA2iKcx6QHH2Y3GGGeIXDFQEA7UWwQNlgAKDu5o08GgSR64wah0UIGSyBWSkhSJ+MElgJnwy5giZyWE0A8RaIFhIvjnCP0dgjs+tERODMFDFOLqfxBLotGW6DBFoAUq7QEaI1z4iSdCwn6RyGEjisiIIKZHYPcjSv+GhUQmds6MnHOECi8zGMElZThM8RBKPLMYpxVgAjmRI4piNpWE+essAfpNhdSyIQgMyT9H+VsN7wiXqcCLkfd6EFDE2JQHJOAxkWwjBD5DJezMJv8hM8qLdXyTgK995ok5gYBvStQRChnxV2U8oyzfJrcmJsKKnUmMXjSEmp3MKI+XYY4w/QgALbYEKlo8hB3fQpkUoUSR07GhYwiRzIcwpiQLSUADePjGkDklJV68y3OAmBDVjK4kTtPmTAjBybXkBE2DPNseX6mrWNKylrNs1vtuqZbShWWVDYlPMBmCkbxFRKAR+AxMXMgVn+klmYNowAoNYCJn3jFFNhQOcZiSzM9dRAJoeQ43E+bRuOhPY/9CjSYxg4AEgEd2VhKE/d6ZOpPYhDZj9ETwbJlPfSrxnilcxBNJ85b2vAcp34TKGxUAE2BeM6H1USkGZ2YiiAriLgf/ZWXTrPRMjEKSSQjo6MwGEdIAiY07DS3ERhwj0biQk6NpiUhg6hfTnIQ1KQ/4iN5y2omdAi8SC7iPxSqDgKSsDnaHGCyHDGuItsBsAVxRwGGvxs6jHAAmH/tL+xogpPBoiSmQZchhjQUvnvgGY0qRImX3icPLtISpFkLqU5vCluG8EDiZmZmOqBmXYxYzLoTYiR1ls5HyxJGRDf2k1ezjSrTQ0QChUQyEvqizPUJXk2jJCFZllDD9SYeRnzSJyWo2U+AKwjk28Q4j6em/4inCAQe4bCMrI4GIqGx4iWnRk+z7s0JIgCn1HYxJjuc+Q3BMASaJgD85xICyuGshTFka/4LPB7RawReM1PmZxhpgsQlA+CQbqmDmDmHFpjxGSLK9jVJToiOnqphdf0nrhEBTXR1+KcYp0ShXGSkcCdgQSYCpWFJCZJSLlPKcw6Fk/Ir8lxAVt4BxufHPfIgSwYwypRGtK0TaKYFttvIvquVdGsdclAOcbHCVuZ21LidiXqU5TfolcZe7Sz9YOa11/bVIIkL2EaYsxCxC+dqtIOCc9oUOpFd9V+nqhlie1sJiIRQFZfbh10aj0RAtmeyawVaZsZIPzZxmHX3W9bGm9rHOmC6ons/X0ousZ2m3IWgDpGJDMUdsdjTSLwNM+wBGm9DSj6j0JeAVZFG05Xn2EHab8f8ZEjNfLs5qjvOneffmUBdCLO378LL9+4A/n+8QpJNi1gahbbApgtCzy/ZLEC0jRRtshqsNqvCIR++fvje+TopzgO/L3qvRl79SZAAdCVFYeJubNx86QEQmrOBCFPZ5H8NKwT+IiAsX4sx93nCHP8yxAjt63mT0qb0XEdhG4rqwrh4jvJ6Dck/n2iUI6HGYrUUIQyoFswiBGSFkpxf68ETmFD8ETJ9T2qumLm/z3PZfQQ5LkV+63j2FOpnxy3SdTv2II3c6UKNO9aofS+tbD7vYr95eeXvd6mAne8izLvW08/XslVD24DhF97rb/e5439SI4R4stccqAIAPvOAHT/j/whu+8AUggOIXz/jGO/7xkId8AQZA+cpb/vKYz7zmNV8AAXj+86APvehHT/rRt43vm5C7rUt1+Na7/vUBSHzkZ0/72hNg8pvPve53P4DOl/73wA/+6VHfd7fbCvbIT37sbc/85ise97yPvvR9H/zqW9/zwyd+t/w+LOV7v/Wyd774Iw996Zs/99S/vvpLn33tx537UbGsA0hjF3jJ12bfzz/hwz/+/jO+/OcXgJeXfutXgKDXfu7HWk3XCBpTGRHwABZhLxsTYkGjfxYIePznf/4HgALYgQRogAaIgMCTd5PyJqoXbxUxFm8hWaMhOBwEHQnEKxdogRmogePHgR0Y/4AfCILrJ4LBNoPKd4KURmYs+CXHIRlSAYFqsQArty9AmH81aIPOh4M5aH47yIPX54Nq9ITIJ4T64IWygjAvwYLnpYQSODoLVoFcGIRSqIFUWIXRd4VYWH1aqDVr+HpemA9gmAhkqDNkKAFmaBjOozDJ1wEpcAGFZ4iI2IXO9wMV4HgroBYlwHxveHkywAIXsQGWiIkFoIlxaH0joBYaEHoWcBEoYH116IR3CH5wsoeIEFqKEX9KMX8u+GsIhGFXg3wUcBGLKHi7WAC9iIfNdxGP2HiRuALiV4mWRwM3MAAyUAAysIzN+IzRyHtyGHqhOAKjpwEnMAMj0AJIQId7t/8tq8iKJgh/fRWEwSh4wJh8URh5JVCMjBeJF1EEw3h+NQCNmZeP1bh71wh6oXgRORB6OeADnmcBoyh84wg85Xh4eYgPrsh67riOgdeOjNh88Rh5NqADk2h7yoh5GNCMmReS07d+RNACCXmQCWkBp6iQCphCDWl4ytY1n0CT1hCRtKKOMkmRDul8GRl5FdCRtfeRlVcDLOCJl2eUSGmNBYiQoFeQKimOL0mOMbl/jEB/fZg7VuYJNokJOXMINmdezFZ2OTmRgNcBFhl7PCmTPimPH/CIJfADBLCROECJ0dcDL0ADlrcBGDAAeKmXVmh9GmCQJ6kCAoACFiAA3OiN4Cj/lWbnKVVplSQnKg8xc4bQlZyAmZQgHLiYAFBhMbhofF8nka/3iwUAAgGAlohomqgJe+/4eGqBjG9JADgABBchl3bJexugFprIlwOwmy6xlOhnfSpwAhdhkIeZmAJQigXQki75mOMSmYO3K6t2HDDhEjDTI0khGVTTAGZGcGmREtZZMS9xHHi1nQI0JJLBWVSCNAlAMni1PZ3JEwegaej4fhUXZoolZCmHMKFpLdLJlm3Yf0QJh5w3hyCYioQYoBh4laJiSYUgNQL0FqQTFtp0AHtzHFDhFxwmONapoXAxQo/RI5IxMu0mCCFzHA8QJs9xHfKJCEViZhTIdn11OgqA/y8zpm8AN56qyKDsOKAEaqAeiKAhuJA/6KPUSTj3EQFHkRFdQzXa+Tzj+aEeWp6Cs2pQKhjWaR48ahS9Vj5YgRvttiSRRqOjGRIJ8F/UVjWcli86VEE+Op1AeoNCKoD/SKSmZ6RbiKQOeiJImD5R4aSCAaXDcULgCRNUiqhWilmikqWC8GfrRSNOQmgMoE2GsGtgSSoPgGz3qaeD0BKGE2eiuh7e8Z8FEKc/OqdTWKc6iKc96Kk9GqBJajDu0XDeKagPwhl6IQEDJ6nkiQBmESJogQDjiaWcQRMPoF3PZQA8ygBF1V8Xh2GAdov2VE9zk6bjA21w9jiYKoOoioGquv+qrBqYrpqFsLqgDDqrfmhzIIOrFvquMtKrUyo4UnEXxHqljXqsN8dHwxFYLlh0O7eElzkWb8p1Z3ptN0pBOkoz1+UdbMY73wqu4Zqb4/qJ5YqK54p/fHqObucAqtWELVdUYzGjcBqxrzmxjVegFdt7F4uxU8mQG8smOEktEbt8KDuUK2uxLQt8Cqqx6dqKnQotNXuyN/t8OcuUO8uzGeutP8uxbUcpQ1u0tKeyFXunO9uzTCurQDsqJNi1Xvu1YKt3L3ukTSuzQRssQ1uzNiu1kne0uoe1ali2azKzp5K2Ucu2beu2mwe3bBOnD3kPdPs2dmuyeJu3ept5fFtBX7v/tU87KoP7rURbtFTLqombgEpnrY7AZPVJfxhhfx4EsSartpF7s5Nbp5VruauHdQwIqMUUiC8IYuiKqqd6t4WbsofLeUuLuh63gCmYclnJaoIIg/8JoKFLu7W7eKUrpKeruzTndkXIVPqVhJzLhHsVu34rusdru7eLecuru4FLnmphMeuxqREYvBVqvUiKvdmLvNvLvbnLvKnLu2q1Oky6G4BYvq+Loehrgb/omuq7vrfXvgP4vvB7cI0Li4KhubR4htSateDnEhRQeC6Qlq43u8iXBBxgeB2QARl8kczniJAoiRSrez3gEn2JeTdwwtZIwAX8vY7rmiEQAEJQAC5A/3g8YMF46I4F0MGD5wIesMPuOIwFII+Ld4zJeH4k8AJKMIAFoML+yMLw68LHB8MBQAEpAHhGcBEe4AIZcBGtWcHKRwE8LHgeAAIgMMYV3JYhXI/3aH7PSAKYZwJO/LZQzLxSjCtdqMWrucUB4AEUcAE4DMbJJ8aExwEZfMZBjJFE3HgbKZRTa34xUAAmkHlyPH117L1nmy1dGAI8kAJCEAAgoBYgAMjuGMZojJZqgcY9qcizF5QjzHs1EAOAaXmVHIeX3Dhey7iqW5Z4GMNCkAI8QAF8DHik3IWmHHiIjMyqvMrM95MEMJtxOZc6UJceGX0bMMlJPMm+SXm1vMJjq/9Gx/u3yfYwLbchWhJmEYAY54xkF1GyvQx4FJABHZDFFxECxey/eXwRHQDKY5zMrinEFyGbj1ibt9nGu0cDkVwAQUB526wWcPzE36w14azLvBtgLeVh09FxvFNQ1pHRULGpDpy+xpu9yWug3WstE+20u6xwT5Ili2ZwvgZrjEYfrAu6kPu/61vScHjSowuk4lwPOAmLCpAlYDFBMPduSG2L57U2gSzShAvAASzAlcfTKW22aYdgMg3TRf3ShLBqNi27OE3SUj3Vt9zTA/rT9BC4E9MAHEeygfqoHn0STJGs7gzWIx3OY015VF27M7mVnaCZ0oCT5bEUSNerV3PU62z/FYQ9OI8ru1Ad1WO914WbpG7xCIAdQ35dCbAYml85CC3FqWu3yzRbvE8NwDpdhZKNt+pamY5w2Zjg2o8wG8/KZpypExczdqE92jd913yd171X1lWdCNUpONjJFNp5EdzZNN/p2eEpXlV6r+eJ3OnJEOvpGw3mnvB5dIPg1RKAi926XyCdyUtHmnZd2jnt26nNtuoKoYQgoT1CoSN6oRl6GRw6r/cKFdaEhgJUonrRrSk6OyxqHTBUQvr7ogazGqCNdo07xbtt3mKd1+kttZQdL35oF/AKpSAjpc9t38War/C6pWoBQf96MWCEOp6Jy1jRrV4BE+EtmqkXtjAe4zI+/+MlCJ0pFNyv+Cl+8adI6K6EegCGytyKeq9D3uG5Cq+Q+jU8ah3JaqmHoGaXyhOPFIsLfrB1S9qQ+9innYMRLrl9Gn8QYKvf+aS6KheGbd/B+ltE/m3v2iPnpayexawu6KwUZgiclYaQAUYtXuWp5yyN7bdajt7AzddfXkzuMSRjPqhlHq81Y9+NZK9G3uaWhahC4q/3AbB/1GVCJ7CfmuA16uK68udIGugQPuiTTdGYy8vlneVQveUeaOqqjepkyQgKzLm7pqT7K6thjdelHtH7guNmcscTwroPiL+2qNFxu+qO3eqC7usKA+xl4sKwuIKHZeyh4zTD29Tpuuu93f/rNr4t0E4mLvy8R9hISugS1KvdPqvsgM7s3v5x4E7oKi2/zB2+fUi+tRg657vu18vbk93s3w484Y4j406/f+i6x+7p2q7r/q7aAA/vAi/vVn3AY5HA8mftWhqDfYt8ikh4F5ACBZABPGDMyYfBHu8SyyygH7zIz6wWH/DKm3eJmXh5JXwRc7y3Zb24857quu16v0iRKRDBSeABJO+aQKzBnuzBQznEkTcEQHAEMK95zOiM+oh5SbzEEB3wBdxvCq7qeLiON1zD9yzIupjyAXDD+/zPrAx5JQAEBh19/Jh5b+zNWr/1wDbrV96F61jMgJz2ZA97hFx4XRzBSl97zmz/jDqwBG/PeySJeZE8yXQP8XZ/97md964J9jQcAGMPfsdseFwcw2rfzCyveLO5+LmnlJsXy7OMfrdsucIe6maZmu0Y9AEw9EUP+DyMyCAQwYZI+MK49s9cjDZQANQc9Zn3l3vZl9c8ANkc+eM9+W/X56m2V58zQ+Vc2Ja58ITHmrKPiB8f8iOPz0avz/wcACHQxQVgBInskS4h0IpXAfYorrsHnDPvmwh9EQvt/MEG/WoECACCg4SFhoeIggWJAA0JDgCPiBISAAgJExAFEAAHEYkFAaKjpKWmp6inoamsra4BBQSys7S1tre4uAUDvL2+v8DBwsGLjKDGyMnKy8zN/87P0NHS04rUysWIBgmCCQUFBwiFB5UAEhEGB4IGDKCv7u+w8PKtsbn29/gEu8P8/f7YzQBaG0iwoMGDCKcJTAhg4SAECiYQajAOgbcCCBZ0K6DgHDsA2trNG1lqFcmTsPKpXClrn7+XMHk5TDaToc2bOHPqrJaz5oOPhNYlUmAAnTqghkyinKd0qbx6LKPmchmz6rCaxrDu3Mq1q1dEWgnO1LRA0AIGDSgaQMRAQQNNnDyJdPqU7kioUvPSomq1r6+wYL8KHkyYK2BrMxmQs3TAG9pCFr9xAuntQIO5dt01zewKr169fP36PZy0sOnTqBHrJH1wM+dUrl+j8vxZav9o0VZZE9Kd9KLv38CDCw+eurhx3tCQD4wtu2TzV7Rrs7yNO6Zy5YOoV79qvPtp7AEFM38uajz5lNJBbxd9XeF6697jDwbPjL4088/x50+v/n3u5O759498BHZl3zXDJajgggw26OCDEEYo4YQUVkjcM/RpJ2AvBxboIU2riXcebCPCxl9eGm74S3v3qchPhx/GGFhPIpZoin7NRXfiPSm6KBOALfpIjIxEthbiVzi+lqSSO0bVo48sRvOkfzAa4sA2CV1ZpEJHerVkZl+C2eR0QvYTZXJlAhPWAhcpAIkyWmaJ5UAHrKWOb3YGddEng9TJUJWMsGaAApU5wOZFDBj/cBE4Wdl4o6M3jrnSlCqeiWGaKyLD5p2XJRMnQp9O44A3eQqVCAOQTFBAWaMWkKeRNCqjTVkARPAAm+Gog6VcgUJKSph26SipLZRuaKkzxW63ZjEWhXNRApw4oEBjqwKgJUVIWcQAqZZg1C0CFlH7ALWsTstRWQ1sWwBaFkGQALTiHpLoIKYi460g8yYE6DGIaOQNJG4Wgiu92zjy6iHAOpWwwsPmkyyVQEqJ6V+aFvPAnII8UIm0kIxrbQIUPQBZAZ+M2kCz31r0iaJreSxtWRFsk2+dFj1wmQQiQ7AYIflS5s3OhhhAK74HF7TvjIcEPIECFpWlaAG3+rbA01Db/+vrKAsvJWzDszz83rEBTcxhxZXlGgGh634siJbSHiDyyOE0i7Lc3m6qdpzN/vYAyiAp8EDRRBsCAVENcSvIBG8O0jOsOM0U2UUQJf5A1LmCtI3HjV4dj+bocT2V2GpGjCboy1pb7awgsRMn298kULkgc2MUO7h1F8M2lpo0UIBED90LAAQ/gWzI4ooDbgCfPAO+XJeGBDzI2W/iPLCugrid+dVZo7S1516vB3Z9oA9Qet8QRJAOtmrfvY0ElhEyu+4SRSB77WtvI23G7DDQflF8owoAm51KnuLKsgAFDE1xQAucvpgnsI1gaVCFmp7lYJcA5SniHR1IwQVMcYEUFP8gAzzQDDySwAFUdCADJdQMS35QAVusYAfeqMAQVDIlGbDAGxv4xQZ8k8MBYShAYhtfrRQAgcZMS3VYuh2+2gc7b6HsaduiXTjsxja0MQoB6jrAAvhGtYO1yhswuwjg9Ga6ixxQLAzcCo4o4I0NliIFFAhAEjwgQs0UIIWlcIEH7viO7e2lAC2sxQ92QIAV6OAINIQJDW4wABkUQAbBqEEMaPCS7y2je6PZkiapcTSE1UgzbhwFDwrgggBcAEdLogAeSeEBEIBglfRgSQkCSYsjAOEIQ9CBDRJZlRo8MhgmiAFMLHmN8HVyk/I5ZiGUeT3ohFIUp4RmAToAHXio0hT/HCjhK/soS1rO4oUf0EERJmUVDDASGCR4gRKGKbpLkQ6Z8ERWGneypAI8MwCjLGU0q/mOa5KiA7+BpYlWMktbFOEHsqgAQh0WkxqwoIfA2AAG4PPDIAUxnhi9xjxXAw97igKgG4SjHOnIT3f4MwDbHEVKodPNWXyghUUg5BB2sFB8TKkHL6BkLyTKC0f2gKLytOjEmJnR72x0AdS60zcCmDHfiGwjaQOLSS8CggCA1JQeBGEdoXMRaq4UpQIdqMMusgICvLSQMATkDBn6kh1eJIc8HQAGglAVYtLEmEXNK9Ju4pCaDQIunUBeIRwBCUk0E1LZO4kfG4bJ6tjVXnjV/6tkszPPCCDFKKnLBpY2wiipai6xJFnssBqLm8dmJbKTlSxReVKItpTNVNp4XK4gwjtBUCSB2eEcaO/iOXuQlj3tRJaFIJTaya62IYeQgJ3chtl6EeInQUPKMnXLuc71lljho1hFi8vdZM4THZfxBGB5RQiymAUtasEMYqsrWkn9NpPb7a58i3PcmUjAMZd5GhN5thgEUOsxnsUee6+ri+yOLb7zTXBh6vtJX+2WKQS+xXv7YloFW5ivG+0JdXUbYewaWHzBvbCIM2yQ4yJsw5/tcC0m/B8Ej/jFGI6Vl1CMPRXv5cMgdjGMd8w4vg73x0AOspCHTOQi+ybEPE6yav9kbCAO27glOBafAKZM5Spb+cpYzjKWK6zkLmuUyYZx8pNZnBstm/nMaBYAl73MZn41rsGIfTKUcVyANNv5zmpGcpv3bC8S81XMNiZzXfFMaDOvGWFGFg6fvcPgZUDwG4byTaIW9boTp1jOgrZOoTd95UMnhdObNvGi6+PnoCSAVraSYEgCe1hHtXdMmR4mqGft6WXOmtCiHvWX39yvjQAscWbxXUgM1mobvbpJsa7krTld690s+8651nWfwUwIpTHtdN6Imhmp9rZeXXrMUa7zs3Gt52uMO83RlnagNvo4b0RuEJNT9eXSUewSHXtHyf7HufHc7Ozs+8zpVvdebVL/E+cJAnqCkJ6wd9XtADtYzvoI97/t3G9FTFzLARd4aag9CH8V4IFWjHTlVn0JCzYEgxrEpjdSztKVsNAWH/DNB3jpDxvi8Bc2LwBE9Z1mFVzEAldWgQi8QfFy0+TiWT5mqAyydPk2esavYKNHUTFHFdIQkLkYwi1p3o9FNvKXvfC6IyGpbDyPoAVIqPIICoACfhvdXkjfMtk4AmxjNJ0gd38G1fi090P0/XfUwu2SeQ11UKbCCFVtuUoKiosSAIGcvQT7L3xJdp7fmQgFGEGVfQB0t+u4PnHvdMU4BSeMMd300fCfqsqi+mq1NlXVSsAnIGJyKZX6Tx29pyhC8EFq/yo+H4x3oQ6WAPmYmFMYx5f1nU9QAA1Y2QIt8IYINI/mijck9FYeH8qeFS1zVetaB8jWurg1u3Blm1zWMpcBG6Eudm3iXUXMNigq7TuEhaOC1av78jjO0T7qfhQUkAFWt3jeRAtnVXz+4FA71wsKOGh4NgMnAANVlgPOJwAi0HbV93ZZgX1VNj4XUwgak34dkw5XEjIjUzIFcDJOND8r4yoA4DLrFzMAMDMGUDM3kzOCJzSFoIOJwIPuEn6CZTS3py+591H21AEeQE1JkAIDCHy0dIA2UAA4QCYvgVM6xQs8ZYVllmYo4Hxn53woAHQaIAIzYIE+gG4aGCgcSGXLUv82B4c2SFQ/6Wc9cJMyKyhF/2M79oMleeNUXOQ3yoM4hSCIimA4AECIM2gADfAAm4AQT2cIl/ARUCVd/5NUPrNfSTFV3lBVIOUCRuANGfB/qjApZGVWgVQB40SF/uBWN8dTrKhzyodmMMB8BZADUxaGU5YD3mABZZiBn3dJazhlpTMqTnNqmbU69tM6lVZ+d4gyVLSHgpA7u+M+vgM8DCA8QRGEx8MI2xiN2DA5jrhRFBFVhgWJVeONcRGEuwFoKpZvZhKM2ZeGoACP4zMo5XM+4Zc+SsQ+TPU+0yg/ePiM6Yc/M7g/NXgv/gNA/NVagocvO6M7a1Fy4ch/bgNdkeD/hoRgWUFBb841Xd8WaBIHj2woj2BBj6P3hvF3RPoIjQUZQLPjM1HkjHqYfm6IRZWxRffSRcvkVIVzEQ1XiD75MT+zQBzHAOxgkbZVEZDjWt+AALCFern1ke0YkiKZZ79obsGYcRq3G2nUblF1FIWgXNXzNxxJiVFZY5hGlSJpfeK2hlq5lawVY4gAXWeRFn6ykeEVAeOljmf5cGlJZ1UpjCSJMCYJl/NBYtDlX/hlCPe1LvlVGUzlkWgJboAZmGxZmIaJJEPoiOzYYe74IoFplUElJZiZmQayma3RmRH2mVcRmpeZlaapmfynYVLpmWpZmqR2H7gZm6h5H3DmahDH/5rC0JZrOZifBpu8aRirkWjM2ZzO+ZzQqSDGuZPRmZzKOZuN85cfJpzE4JrTaZ3z9YiGoZ0Gxp1q4p1XCZ4wJp5qRJ7ZZZ4rgp6jqZ5exp705J7GdJvIOZ/0qWT22YMhdyiOQTWdBQr4STr66Zbf2Z+p9Z9+Z4y1QjkEUz18uRsHGkQJyoHWx6B55aAe92sCs3CNgH+BcqFDlaHYt6EcmlEOam1N4zPaBkbcZi8miinw+RfyGR4rmmT/6ZXvljESSj2YU6KUuZ0oGnoquqPw1KLAhnDlEKQT1Ak/mRQ1miY3yiE5mptKup4Z5nEgF0EiagkkChYrYUhTWAsl4A07sP9LbFVzNwSLvtADFzFRwwQTcuoNdNoLd1oAeWp5aTYCJ9B5VDYCQ1cAZ4iG6bml3eWg2Ql83nCmsxCFu1QChNSmXcdIYxcM6bROlWQVm6qp6hSLaDYDQyeouWiLgJp2vsifimphjMpX0wGpsrAEBbBLUbhWPGIVlBcMjkQCdVoVvcqrBeCrZZdmF4iLVSYCtigAOXCoALegrbqkvWk0sWpQ3qADBYCrvlVO5/QLMVAAJmAdVfGt4QoM5KppaWYBQIesVKYCtNgCzmpo0IoMubMMYpkQhEMQmEUgEbAz+0qUhGcg1dp4OsB1/dCAwiBJV2gmujpJkeSwxWpma+cbplr/ZS1Qgc+aqM2gKm+zasqwfobQr8sAWOXViASBM4SxNMhwlwk3pSU2rWIxsCsghbOAAzpQAgY7DFq4UxO1AeGaTuX6DzDhswMAtAPgij/7AkH7jniGrOwqANDXixnLqtLgCAdAb5Qwsil4CCwLDSpbEPkqGCLLCLozGYIQtgArl4QgoB+hX5FJQZKIKAbqqN4wczM7hTFXADibs8LwinA1UTTwrQVAV7/qD4HrDYTLU4c7uOh6Z04LdBMrAkRQdBq7DObztd63FlSzAOniGNaSDuZwtgsgP97QAFAkDkZkPuVwEbVSCehwQFRzCd7gOrrTDQxwQJqAforperbVmNtA/7rgoDvUEjMFUAmq0g2VUK/roCreMAG7Wy7eoAAlSy6YNbacRGK0tZeGMI6SqH9UWqTleaRxl6S/swm5owmam4K8a5TdMrqfgH+587UTwA66MzS6wyeeoCqEUCf5aGpma1u7U0CQQIfqsH4SkD8wgxT60ymxFQkGsDQDbBmDUiuMEhH3Uw4RULb4ksCaAAnW2zdlccC5oxFvO6+XxAia4JRlaQgVGbdNObcgSWfii3TkC1Wb8LVGoSgVVK9lWycanMOV4Ai+YbZfCz8NcF9apDvf0Dy15QDUghGm0rVjaw5UU7x/tbVnyzt1MrZ+YhR3GRFjGxGDo1Q/w8WvMsUZvP87EDp4alsI3aC5bes6S3mUSHFbMDyVMlyZVZmk2tApYJy8YyotgLXAN5yCRfQJoUuyO0hvqhJAGqMqg3Mw+WoREjHBoavBfbIWo6IzuGVeZ6u5TOMnGmwOGgyOciE/pou1O4OybFJbnaDJjXgAHSGE2ElYzSV+khYUZqkIVVomVyoTWXrC1KAJtcW/YvSCs9sxjpER0ru63RA/pUu6LjgIoQsS6cBZ95iHwPZFE8BZlRARh9jMADy7ZRF/H/c6jMgRCNAqSdyImDsBzBtVmvBx6cC8mUAtrnMo3RBASvxxqEZvaMRxf2MJRKG9h0CX6NW1y9TLQvLLUmaZJqykH8z/EBDxv2xMcIdwJUN5iSX8guywuwCGMAwNJTN8ceTLodV8Ewp90X8iHiPtIg5NnLu5a9HqqjC7HC9dKSU9cSdd0x/yqgSX08ay0//W038lzsZwrwSByTKy0slARGNcba6cDF/rm9gJq+D7nkS9b0YNllOMWyBbshZtDPKL1IwgzR+B1saAttPA1FqbWVdcaYjwtRNduZwUnXid13q91xIS0cn1CU59xR3dDGNb14jgJy+K2LyLE1XNDEaR0n2jDGZ8vVdNcK4ZmmqG2TK9nzqqDFf7M40BMsrLDpggzfBzvFbsxAAAzhWtugfQDX5izrwbzxPw2XfZmK/ywyCj2yfz/1+E0MjEO8vug37p/H2+FjMJINyDoNEFAAm4/YLv68oSkNxpU80sS9vfsC608tw0jdFIctngbZnB3N1kSzK1Ai1wccGknILym4LmEw5gjMifMC9yYd4x0wCE08iDoMH3e961shb6e8U/Ew7zXLzhoJEhmw5G2QCq8jq3WytI4Qlskjjhx+C+M+HPA+CLcAAToDtMpQDsQBZAPBHuHDDWcw6HSBpA/SfhvceaPd4gogx0nbzuTQ4RobIGQA6ubScR4SeWJRTwowkHp1wPBNC/08wzXuAcsZFSqg7pQIfxJwGvIxfr19hVLAE6cxEOkNIa3NgpreRuccNIrcHxuwluUf9ezWzGYC7MAWsYLb6WLw7Rdj3ZXvwJqCyy1p3GnDA5Xa4ATJPiqVw9RbEN/iVYtyzoffzX5RvCn+DJ3JAnQb61H5y1gyB7eagzQGE3kw4UiX440vvBKmvHugPOTJ6IjbAJna6lbWwMj3YAkYYoBCrXtibeb06PMD5tySDKjZjIs6vga0G6+A3PcltAAMw7j/0JZSu7jeHK9nzJm9C5YCTVuhLsulLgEhBAuYNZXWvOrtOYsvw7G3EO9Lbt4Q7tq5Ljpv48F7EY5DUI9gzOoa4ui50Vm4k6ESpvFLqBtL7vLi7nVMsQht26jnbmcNnNg03Lbb62vrbadYfvxKaG/A7/57WuoHZtDZDt7tjICN4+1tJW0Tf97wwfzi/6NDF67kGp7/0e8bbu753t0wnWo7/xoy8IpSExpPOo8lkZ53vs1y7/0xlmcEMUPTTPcCh/ZijgG8/nDS2gAhRnZz63i0FXqNBmdoFqZUd/ERhYfXcmdERnZVy/2UnH884Q2AVC9stwKBy/FWOM7iydtg00uwUMpiPHh2NKmFyY9VnmAyLQ9GaHdmrHdrh2Z6RaABVLZRAogehmZ2uH94MK+NBmwpTOjWNusjfh1snVkKfOCZbvDNReGEKh1FxS2SzOhd5wAkyPZTnA+BhHaJhHfVPGeYUG9ll2rIU/ZRpwAlOfZrCP/2W7//gVXxCNbRPB/wxlTQ3D/xWhS+qUnfD0RGgo0AJXBgMFcAKuD3B4xnwYO2XQJ33Vb2h2pq4C8LSD6vd8j2bbXwDTV2Xnn/6r2vLPcNofBzXhELunvO6MEe2v/Q1rYc4iAwgGBQUMAIaGBwcFCg6DBQYNjhEAEoMGhwCRExMFCQUPCIeRgxERCQkKkwCChJgAiYuUlgAKlgueCQiRihIIigULr54HlxC/D6uDhZgOngUOso8ACRMIBQ2u2drbBdve3+Dd4OPk3ALn6Onq5yoF6+caJ+/v7vPzMycw6Tka5yIo9tTVCyhghKNBFtahSEgw3UCC/PwBRBdRwL+GAv/ElcOkcaMrTg0MHIAQyYGBBBAMaTqZkhgABsEiFCowyVQDBcgMTSgUKZhKmq4iHHh1CUCES5wwgRRJ8hkml68YNOCEYGcmYKKAGkXajcEkX6GITWBkCKbRmTUT3MwJwGrPQwucGjra9tq1CUM9fuuoVy/fvoAPPQwogoiAhQULqBghYoQAHy0wZpSMot+IFv0QaxAxw6IPyYMbIj7MkIhiyedCz9vcWcRnzZw9Y/xbjrZHoZQuRYKgYMIhkC53sxokAYK4CBJEinI2KKVOBSofOEKmIKVxR9AP4U5+1bmh6t3bKmjAvID3sYauD4LeO5ol5IaGFyh+PHneTOW9S1D/BUD9IvTwBZaNbQJ6Q2CBtUmWwyCFJabCDAsWcIIKoEkGwwmD5HDOaBFa0NlsqG3I0GgWaBiiavN02BmHCH1I0IF7IXjAJO2hp0BRRg1FliANSCABJsoRZcB46ZmnTZAPDHWTAcZhcxI22cxIi2/oHdIkAHHNRZ93QOb1pJXX0IIjJar42CUiBgwJpXFcHiLBMquopd2PUCFoCIx2CuaNTIcwB6chcSkT3yAHQKkNiiEmmpqijNLT6KPoIAppQ3hyg2BvV8LXyCAT7JdMJ0MZM0gunu7WwC9DReDImJ5+qggECNQSQQMMOOLTdxNk+uMhsdIUpEuqzuKmKrTaGqQD/7W00l5/v5A6iamoGrUqJhA4M2utgyzAwCVGJsCfgJXmaZughiQAzTex5mqklOZMyqik7gYEb7zzzEuvQIGFm+e+/Pbr778Ak6MvggQaAKczB4SijXEIBGmwgfeeGLHEE1dYMaX5Bqzxxhx37LFHAxdY8J+ZHNCLIwp7csnDcUJ88YsvUxozzDPXm/HHOOes884ifzxyNixnQ55JXpLMUc31Ip200uvYW3HIevIs9dRUSw31zUcuo20Dp44JwAOXxMrkut+64vTEZ6PNdNNrO4R11XDHLfe+VwM2Lsq+KGOoIc0QN2gBhbrc9mSDL1o44YPXXffcjDde9eJ+TZ32vf+TU3444m0r7vjmnHcOAOQgS3545fSSHq/pk2ru+eqsS+6z6IWjnvrlsj+qeuu4584x6BvxDu7otAcfe74HFW/88cgnr/zyzDfv/PPQRy/99NRT73P12Gev/fbcd++997qHL/745Jdv/vnop6/++uy37/778Mcv//z012///fjnr//+/Pfv//8ADKAAB0jAAhrwgAhMoAIXyMAGOvCBEIygBCdIwQpa8IIYzKAGN8jBDnrwgyAMoQhHSMISmvCEKEyhClfIwha68IUwjKEMZ0jDGtrwhjjMoQ53yMMe+vCHVBtFm3QmiF3NzTjZwaEQ+YUt33ijiPxShBMDVqtzJRD/OatSWDmECMWddRFnnEhiNpCYDDpJQ4SKuESgOnXGnxgpT40w2iFqAYEvIkhVqviFI5zkDO4Ea1TQGMV6+HMTOSHQGtlBAAOmSI4lTs2OHgujN8j4lDaCMI3kkYvQmrMvPI4DkgJSQBLTCKRWAMABqQJKXMazROnASVVeIyAk/0gWVTGgVg0QVbLqOJ9MVGIR0KhFMATxAEESAht946R0iCPJ64Skl3ocySs+kYD7yEICnlhkNvnmDKlM8wHloQknJNGfWBTxl5boJS0KoMULprFWRalEMRSxS1UdoFbg6dG0PJESYv4GO8b0Jh2hSMpKzIoUNNGnsODyiUOQ0k3q/9SOVmqhC05O81zWkKMA5bmNQCHgj9fwxAK4CE1pSNGT/MRErR6AREPVij/NHMQzjZiMBEyTUJgw6DSAIlJO2LQRQ4mmJDGRSQeQkaDSuMl4GkFTdy7ClLK4hEiFaE9pFaJWwRApSt84l4iWpaEDLeklDGpMmWBFpKXEkR4B9ylShMKTQL3KG6XDH1EmkKPUQqd5VLUrn8qVlydjp7RY2gnjeIk5gU2FA0ahxZheA4oOwFYsHppTk1rWANJBBmMfOtQGgHRs0EFqPB9RK0Y6dT0Kk6dfqdpLQSTMeGNLQFysKa1dncQRPwqrGceaUE5ao3hjUtUUKcs3dNoUpHlxJP9d5yjGAkKyFpBoDl910om/FvG3b22oIuCZjEJNdwIRSBYrGhsLZxZxlRCQJHENwVFSpjGzcs1bUYZaq90eVayA6kR1N/hOtkZ1tdJtLeCw64paecKKXf2Raz3bS91Ok7cHNRKBj9TG9fKKjngMVCAtKkXmJrComVhktgIFgelmgo6/BeyDp+kbVhDJli/x6oFfyqtBVEWmRZSkIKBj4fZe1q9xfegqEfGITIK2jDHGkTNiaUFMegIZ8ryJeVI8XddOc1cS8M2mbBqUXsK4vutUMXwVEWHn8IK9jIwLW4j7AFXE5bhAkY4CKmokV9ZYowJEADoN0DBCBdiIm/qFihX/SpYTqzNvgJvPOGfRgGX2cpnLnGmME81jS7L3sitOpjcpi60IjKUTKrvvjz4dph13kJSBMgBHA/3n7mbC0QxImaVrCwBEn9nB1SIEmR3ZaEfE2hUK4PJN9+iAP/ZCWnkEnDFvhAlYAjF/y/0hIvdGNU9urJDUfrb8pDxEHZpYbh3WWBW1Te5ym/vc6E63utfN7na7+93wjre8503vx33v3vjOt773ze/r8fvfAA+4wAP+Np35ri8HR7jVeJbwcLhuZw0PHcMnbreHG3zhFL+4xyIucY1DHOMejxzIc8bx2owcZyU/lMVJfnKUZ1zkL3d5zGUe8o2lXGAzf13OO3a7/4/7/Oc11znPV07zoAud5RVvuTY4wRZRdSJNjkjYOMKlCC0OJ7ALjRE5qn6Iq/826wYqB9f/Np+vz3pARzd6NphupWZBnVDttNTWBUt2rJ8d7XO3Om7NzmS8j2PsbbV73zlScKSD45ZEilVOVH0SRJRN5eNYgAKgYoqUKDIu0ADJ1MkhecqjpNYwcYrmHR75yRel8qDHfF2ybba0G/4biMeG4uOTHC6zS+vg6PzpP3950YeJ9Lk3/Vx4H/rM/x7339D98C1f/NUDH+ZA34Y1qgWNIHXdpuQZfNTA8QAJNANXZqt+c+XOfe9zeVmCET/Ox9H9708p/KsYv993R3RtTP/fXKugbeOzv3n2mx/8HKF+/Vd+7od+dyKAz+cN7Xd+puUUQzKA0Kd2Z/IwmOUKw8EWyLcNNzEBNxEMdCcYhHIrGagNG9iBnxN3USeCYQcOJagAHoiCIQiBNld/QDMUFIiBbYWD5OcNLfiCZhODMkiCvWGCH3gnQJiAQsiBLniCPwg4Kgh5Cqd0rlAeDSNs8WFTSbJ+37Apg0AdCPY5RmWAK7iFB+GF4ccbprWD28CFYPWFz4CGQRgwNxeHU3gQVWiBWEhbaqgNbGiGAQiHdMgMZUgLbhiGaQiF3tCHhHiGYoiIHRd92RAXUOIVsWJbtYcIOjh/2+AV+eVZspV6ogf/HkiYDZyIJddgCsHQe5kniiNIim52ip+oiuLRbYS3cTSICZJYFhFQibTXeK+Qia13eK/oianYfGNBi7UIe8OIiqC4isi4fd5QipLIjLJ4jKOohZDoCt13CMiCJaiSJlyGAAmgfZ8DDtPXJ5fgaKAgFycRd5qYDedYLuk4HdZwLu14jTXmHeP4NfTIjrnQigAzh/hoCNvIN9CxAN/oi+JIjjASj9Mwj11Yj1fojsHoDQ65j+ookXFCkckofVyFkf1oj/84hhH4ekVnkifpenJ4i/S3c0OXjdgogTPoki0pk/0ikABZkzapMTjpiL3DkjMJky+5k3QDlDwphUOJkiaH/5RBSZQBSZM3aZQrCZVHKZQDqZMpqZK2aJVRyZRVyZVfqZQxKZbesAAKEys+gWhf6JMXlpa/sJbB8nm3AEw7KGUDhiW18HlEhS2BwwrSNJeFBo3kMBxFgS2LRyisV45bSZWuYJaGgJaP+ZaBCJm1JpldVlhY4gmBWZGGdpeSh5l7iZiukhKA6YZ6QZhf1VCukpg955SnlAihwAo+YSajR5KlhBWUMGrHx14pYSbMlovv6HhikiOuoEhcM45skn/DCZx3koh18hGPpRbpkpy3x5lN6ZqoJHWyyV66mZiC2XXZwp3Ol1O9mVtqtJvfKZzMhhuYYJzZl5zK8Zu7SSCo1P93SyGdmEI2e7iUjCkSZsERPrEsuGmbZhOgTjSgQSEBkVAUjaiYrjA0V5Il2yAWRtIkZ2SABwIBmdUmjdcq2+IwGtWTDgqW+fefgmGgd/KE1lmgAIigzaagF3qItAGhYSKh2kCh1mEXDMpIGbqheEgmZZEmRbOfY5mV2qhJAJqiBziQuNmkDgBpcDFnn1ILMpoNdiahcSGOg2BFQfJLtfBMT8Wj5LBSjxme21IWYLMMvhicT+mV/LiWn+MTTsqkciqnT9qFURqb61EAVXqkhYCl7OQMXJoXXvpYeyqm40CmtWamhZmmV0ikgZiUT3RPKoibAqqiHTkgKBqn2dAMbZL/nGwqAYSFDTaKCUlCbQ8IJlzSo5/wqezkoUIaHyGqlYv5Df5ZqZvqomyqpO/Hqa7gqa4AqivKXqNqitpwqhYoRsI6omPko9TyqqrwoUPKlkVKq50KmycqnrUJqb5Km+jJAIHTnve0gw6wKyYznOzJKwegg5KHI75AMvT5nC8RDJxQR/ipLi3xeM1Zq9iJrbzqrd65r9wwm91ZYOGqrrPKjeZqnsQpruzKbJEJr87pNWZRr08ynfpJrZGKlZGnp3iqlnR4gZW5pcVZPAiwKQq6g04ndZ+pl9x4EFgoLChLbfRZPMiAmpN2mMrGrV3JmLjosQ0FstcoskJbY3Y4syqL/yqh0LJtwoYxe0ZIm6mCOIg4a5h/c7DDWq38aq3XaaQcO5U+6y8iuqtfK6k/6aZtSqJpS5ZiK5Vry7Zdu7X8qbZtG7Z165oE47b/MrZZa7Zyq7V+G7iCW7aEe7d027N4i7heGw4D17iO+7iQ6zz+FrmUW7mW+2+Fh3IBsLmc27me+7mgG7qgWwCiW7qme7qbWwADsLqs27qu+7qwG7uxWwAEULu2e7u4m7u6u7u6K6J8azaoG7zCGwCkO7zGW7q0y7vKu7zMSwDJ27zQC72tSXLHW72fW7zWm73EK7vc273eu7rPG73iy7u+Kznam73Ye77HG77j2764y77u677Tq/+56ru+9Vu9qvu9+ru/AwC/8Tu+5Ws192u86TvAqOu//yu+CJzAzTu/PmPAwlvAEIy8/FvB3bvADLy8AcxwE3zAHXzAGRy/GBzCu+vA2zAkhOIAgaIMwyF1e/HBpivBMOy5+WvBNuy6I0zCubvBg5ksB6DCB7EtUceRgjHDoivDRpy6OgzASxy9Jgw0n2gUD5Cl1yecL5zE14vFo3vDXMy6OdzEtcvD4HASPhEBU/yBvlidh6LFNMzGNAzG0gvHzGvCc+kUm2mKVod9+3jFbky8fcy5NdzFNvzFYCzGuCioi4iLaKzHDPnHfuzIhFzIcqzBmfsdq2gNw9SFKwwMIhv/DpDsyNsryDccyUtsyHN0yVjBCmdsLNMxdZ8MyZOswbFMvpVsduwUmA9wxnn8NXo4IK/8x4EsyvxLyjpsyotqh7isy1WchZ4MzKBMzMU8yyVcyYk8F4UmqlT8qL/YzH2MxEkczMKsv9AcwsZczUZxzcqszevKzepLAYPgwffbARlQABQAwtLcu/e8w9Rcx1yGwoADxLtca3vMDcF7ASlQABnAA57rzgXgAQoNz8GbBBzwuRfgCBMdvOAcuzLAAoOwAa7bA46AAftLyDawA4PwAbr7AxXgxLTKz/HhwwBdxQKtfd5Mw45Qz5/rAgVwARgdvAzd0B0AuhIdwdD7AQeB/9K2uwImXQAVMARxPL47UAK2WwSDsAM2wNJJx8GomwL1nAQe0Lk8UAAKTQFfDdGnOwgXDbodkAJCgNH6SwM3MAAyUAAyALsk8AJKIM7QewQ/QAA2UABXfbuDsNLSy7U2h9EhEABCUAAu8LlhHcE+nQGb6wFJALpGgNP2HL1DAARHcLs/sAMEsAI60NkNLL44MAhSTQBLoAMrQAA7gNQNTM08h7ph3dgV3bmLrdC1bdanSwFp7dgFENQHXME1QNewO9ckoNfiOwSAnbslQNix/bcbh9gBQAEpsLlGMAge4ALzXAAgwNuiSwGSzd31fAHdHQIh4AjCHcPjWwJAgLtHwP/ZQ6ADgT3H7VsBqb0CBSDV+I3VUajVpnvbAVDR6x0A2V0AB93YZz28vh2684zZZ13BGBDXrxsDBWACIz2+FdDXzg3dc2zYPInR2s3TZN3YHkABAg7eofvT3x0AKZDYQnDdHADh7B29or0EuKvUH6ADReDE953aBFAERbADO9DahZ3VEEfbjD3gSGzdPS28DR663J3Yw62/NcACHh27NRADNKDczTsEr727z+3fhbs7iM0DbB0AIHAQIJDiC4664q3mX90BxdMBM07U0fsBHl67RcDhG/7U4tvfBFACoD3ohR7d/53kW93Vc77TnGvQNH7EDJ7WIDDRIFDPax3poZv/0bDbAy/Q5ay7ASK9ARh+1xj+vYSMA6N9u3puu2N+5INr5gcM4ynAAyX+6DXdxnAu2QHgAd/94p175xgdvX+NA7bb6kNOAGDO4fat4aldAqxNAB9w6B+O5L/KepQJsnzHxwF+0AkdAHTO02tOz5At4oMQ1JUeACHQ3UYQwfq7AQfh0aI+ADRg4QUQBBnevEbtCCjd6s7rCEZOydK9WPa3hCPrFNtuINRd3RnQAQdeACHg5jEc2Zsrzyje3ZIt7JnNvBXQ48e+0ko92E5d2tF72oPw3gRQAVVd39We6L+qAMcGnrgJsNZAxBzxy90czhY8zhlczsgS839DsKtX8wKD//NuzPM9n8/vK9txUhxJ2qvA8HVN5cvODMk6X8FIn8DlfIVOn61Qb5a4xc5snOswnPVar/SCzfQEOaBNaqdWArEEXfXAfPXDjPa2u/WHIB230vZLmh5wv8Zy3812f/eD77xMfxJdz6uXqlI0bfRjT/f5bvd4j/irmqsieKYKH/hHX/jOW/gm/PPuOPPdaQCTwBuYeieOr8WcDvmva/YiTKugr6na+lilb/Bx383PzPmuL7/UTPAW2MogW8f6evOa//is7727374+n21EK5nCL/aqn/ue7/lqH+LFr/rHj/zUL92zff1YnPzKv/0uT73e/83Zf8HiX+aHXf5GDP5MPP/4TyzruG/15y+77k/mcfvA7D/D9w8IBIKDhIUFhYiJiouKBQCPkJGSkgWVlpeYmZqbnJ2en6ChoqOkpaanopOqq6yrqK+wsbKztLW2ra2OuLu8rgG/wMHCw8TFxIeMycqMyMvOzwUD0tPU1dbX2Ne6vdyq293grAXG5OXmAePn6uvoz+7L0dny8/Tf3fbh+ZDp7P3Fze8CIgIosCCBePQSKpSGT9+uhg7B8fNHEdjEihUJGgyIcKHHbBAfRhx5EWM/jRvdoUzprOPHl9RCjpwkcyaukibX4cypbiVLZS5hwqwpzqa+nTzL+fzJjClHoVAZGhU5VWJSf0ivGlvqNFH/0KgLibrqZkBBpQMOFlxiYMDSAQQ3tbLj2tVQXWhghYq1ufdR2bNp17Y9CzeXXJ2Hdd5tmXfoUW4GEix4FOGB2sIAIj86ECFuYnN0Fx8UDbTxy74kIUumbLkAZs0AOHv+TC4r7V+hF381LQ91pJALElRyAEAB8UiXIWlukMDA7NvHSCfLfXc3b2y+HQIXXoC4cUnJ/SYAwNy5Yej/0G+Vzux62Mervk9QgKDA5MGtLS0YXODBQ/XRsdeIgI24p1B28KkiH332ZVZJfpXsZ4l/zwGIm4XDUFeXdQbGlKAk9V2CwHePPNDaa+M9cMB/GFpEoFcvDtRhPVXlskqIlox4/xwAJoaXWYorVmihbbdp2BWHMw6AIAAhkUgZiRKcqNx4sVEojlYUVHKOkU5xyRSSMy4ZTpM7AhABlFKKt5mVvlyVJZHoaNVBBgVQsGWMhiTZ24fgcUflXwWg5SNsCDR3HmiW2DmMCwVc0JM7P1SAyAqXlNASpJIW8sElHzCWUA+WYFDNBpdskJCYErESXCV/mhVoYCg+Uqh5bSJaiaLCMOroluq8WYAHHRCTBAeKvbODpYMswSWY1NDwQiU0SGNCJSzU8F4+qJLUUwgBCFGAC8PwACdu0BSQKSGUrvAOdZWci8gQQBzh6UIkvKDENTXEEC2NNY7Vby/jFsCtt+AKI/8uYudQkMEvHiRBjBG4guYODpUgS0AFlTy10A3RmvDCADIUIMMALNxw7Zj/ArxtABSk8IsRlXjgAp0FgHDnMyW4KwillRQBjTs5L1ICEHh5FDIJ15gQw4Ep09Q0i6Bx2/LLMc9cic2g9brwzHZeQHMIIVgSrMTvVGAxARRr/JESH5vAgrSiMo3t00L+E7OjFMgcgAcUXDBuOzjrTIgNOpzdVOCKrKDDEkUrFEMBJlxT772n0r2P5VdueTfLevPtN8Lm+Ip1CgO7zEHESgVkNiFpr/sSCTHca0LcSp+cKubebMtDCkIEAMIlIHz+KOKLrA4P0IIL8kHyizBLTb77UrP/QdyVY55tRAGHsHvvv1sS/N/jKuy7BwF0gEkHpxfrjvGCtK7SRzK8sK/bcNt+D+65b1k6D3kXHIDwN3NG0JQnqRL8gACEw8GliEeA5QnCBgVQYOPmsYHI1Sty05NGyHpgv6ZdTzsrE0IK+Ke3XwAwawlb2N5sRrpgpG946zub+yZID6WNTIMiI5nJ5IYySCDgAJXojIMC1QBVRIAByjlLER9wCZqsjGUZ6ADMKhGCE6auJZZQlwNxAIRKHHCB8MhiAzNVAZ+9LyE0eFwBgiCNDA4AA2zsYMq+8cMg+kWJRkTiHYnIoyZS4okKk6Ilqgg+rf1iTn2j2cJeGMBlUKwS/0S7mCXkRcN5qBFaA5hWAaolR158QwISAEChJgCBAkAgNkL8TQH0WMpTysZEmWsR4PAkCC/9xHnu+aAnIwFKUSaAlKZEJU1W+YhWChOWtWrR3w5jS5bg8jpL+sYBQgkACUTAAEEygB4loU2/ZBOJTCzAav4oy1nSspkpeSZvdEmVzVDTmtj0yzYj0c3MfLOP4pwMOWW5TLmgcyPqNE00kcMdBVxTj5HBUWHqyVAqlUgBTiznPw0y0YIEtDHsvAlBK2HQhipUniD9USQeANF9KrOc5KJlLfUEEj5BQgEGiGdm5qkchN4TEmqJKD9VWkueHoSl2MEdRGAq03py06Yhff9ETk2KoX5qpaICuWheBjoJBiigAcaUzSTqmdXOHOCUD6Apk1AKVY74VKpgyaiNqnrVrqqCq8GUzVd5JFanJsWudz0rULXxoRDNdYgHKCIlcgTYIkrgLKdk6pDOqte9VkOtRfEhYvcY2GFWAi6DqexhA5XY35AVpebEE1qjQlX8eVaijOXpaKECWX+Zdh+fJWtjHTuN0r52rKhV7WxpqySh3ha2EgVtWV3HW6nM7be43aluVVtc41qutSoLrmyZ21zbvhavORmuSnZLW+g6DbnYNUl4xctdx0bTFuhNr3rXy972CrW98I2vfOc7X5fib7wZEW559+pdSiA3uSedrkr/V6sX+wo1trkdcHN7a73/4pciD4bwfoFqXdNG+CT6pW5x+/sbByNYuQquroGt92FlTpilHL4ceEvc1BPrqcKtAJSgBOMWzCSzqRkO8YZ9CxlXzdgSbKlx3dRz4ZO4OEkwXkVk9FmZQVFJq7EMcILPueAUP6IvS2aNkzeTyhsPKcdUFvFxVbGq7hSnTADYcnmGjJ4iz+XIYeIxmbnjHTSr2VCHkjKIw7zjMU9iQfW5z4PUoh/+sMnLAHKz+vjMWysziRWAbhB+CB0hQ0NNzybWcKMNjKPLOqlHrpkSj4KUZxwLmNHdlTOIMKEjSIA6Viq6tKmnLNoqj9hJZkLTlqvE/2boKBqGqDavqiWB6zMdJ0q7PsChdcqTN/HqKnOqUyNrLeYezplVfvExrETtS1rl7xwdSMGugnGBFBQgAzzoCTuGNQy/VYJYwFZGpBKBgx1kbF7zAFUlqNfGUlXvuaryU7YBs+tZlXoriSKGrtSdMEsAS1jwnvYiHmmuQqzA3uYaAr4VAqrIDSAI1Lrhv2/32/BVYtzASIGdkkC+Z2su4sMId+8k3ryKW7wAnTojveyFL32N/GmO/rZSBvatcBUyhQxz2DAgtuhlKI5xg/jBDgigOEqWxmjPihzbkMYCU/GQ5LddZqMMVnQrboUdFIA52cdGNgEKbt7EXcjRkra0n/970MP6Y5nLAjBFmdEMa0oxJNf+97WwVYLttXkHBNU1iCPEawg6sMHG51GvNFoQcm/0uN0BhveeoPx/6fAb4s++jrQXg06oSzwDB1EBHVRiB4y/uuMwb43JfR3onVfK5vq3t74dPXTe+0ULRRgARrZ9GV003MU/oAMzwoNeMYhc9KURhCCwgAVIuz03gs5s0HxeXOAye3pKr/ZgzIxbNBea4IqArB3kXPYKgZ413Lj5f3Ffsf/QHu98Bzzxjz90CwMC5GM+l4A+qbce7gAvVkcARfBFFfBF8DcPNIAJJkA/mfQ22sd5K6YTu2I+jqJyAcByDNcrEQcCxAICdhJuBxj/IG43CA5UAjugcTsAgdOhEBU0ABc0AG60QZ3UL/d3WlHTLSPEeyb0e+UgPisUAC0EDMZ3RcrwAZaiOJbiQEUwdUMwg5OXENPnMUizARhYf+00UpfgH9xBTJFQRwUgRJklWEJHDqJTPmNXbueWbi5nKwUQLCYYACFAM0bQdMwgRg7EgO2icc+HRmoUR24ERx7haA0RTg8CAGVIU2iohniEaMeAfoE0RQLjf8dgSOWTAYlUCYu0giyYDI7XMwREdRhXAYQYgY7jcRgQcj2oUazAHMSRAGgGCb00Sm5liW0GZtTWZwBXi7gIibn4CLv4S73Yhl92asG4aX62VVTCHW8h/wnThIzXdFPMmGjAGCME5hgNxgqwQY02FhvvlI1J1X3NSGveaGvReIYKMAGR0ADTpFBl1lEI5VDqyI3O2I7VRjchMSLyCAn0KAH2WFAHpSa+6Gvd+CLfeBojFlZbJVYvFVPauI9E1pAE8pAfwYisIJFHBWkWmY74l5H96JDuaG2SUEr6tAAM0AD06G2RYFVYFVddVpK/eJIbmZIAuQosqVQvGZOrQJPLiJE5yY4o+Y/3owoMQE2iBESrxIayMlmFFWWztmfPmGrhWFVOiYYvuWqcRVlSiZMMqZMCwpGLOGLPxWKLpWlaOYwlx5aJBmcdkmQkJl1IuZNKeXcbyE8aef+WPLmUcYmXWOmPwtiTfYlpLeaWwvaO9yWXREaXBuKRiXmVmaZj0Dgm9LWZnNmZnhkK7/WZojmapBlfagmQkNlmZyUArNmarvmasBmbshmblDmYfmmW7IGWs7hWtqmYbTlgsxmcwjmcAlCbYZeaviaZuXSaQIecRbKaxBmd0mmc1+WctKFdlcRfzOlB1vkZ2NkS0hmew0mdFtadifGdhXiYgskLMhYYQMYf1Xhw/JiXZyme9imb5Blj2kZpqwSf5WiUZUmfuRmY26caTJYmIiVM8mmSAiodBXCfEOqa+alk49RkoaaQULaQRfKXA7qXGnhtZoZraXahIrVmC3qUhen/kBG6ohOaZnR2ZuBBosuBZ1a5jimql+pZoPFBHPMRaEMEIfZhab22objpoCsaoS0aaYLWH/wpIY84pNfJoQ5KoB8KljnyaQiqGbEGpd4ppaTxoEd6nxPaaa6BpVu2pScaoDcKmB66SzsaCcaGjFn6ZMtGlkTaoF8apmI6bJFQbLomo3TKpb2iJSiUFNFGisGAnq6onY6pVAKXGfsJqLJCo9tYDOH2eYckbqBzDuxGDHNSfgioDDaAce/HepVQqtMRniNwAhYQmz7QqtHZomXWKgQnqd2WpomacIsydnXohg43er/QqemHCJtiCahKdUDAPF7xER5TAKIygZZQd2BI/4u96au8Ggxvgqmk93IK5wEFAKr/4AxHcEAQJHmDMDRD8HTgGZ0zIAIFAKsS+q7TyaePmXcEY3Sb6oYq1DAPg6jCYCQKWAhXaHPpiUYFED3UEAReN628eZwc+A/a+n8JA6oeAAJ5GG/KMAQFYK6C0ICCwD6pGp0igAIoAK+uqQEmK5wtupZ5NzV8VzV/16vGID6D5zVUZHh3OKyKMDSI4H6BWLD0wAKaRw2gkn0MG1nVqhQRe62FOrHDwAEnCK6luAwPWAjGUwHH2gjRaQGtWrKxibLzupUOaysegDed43v5OrPBp4SlU3z+mqjuoK6EUAGS8rOLChLP4qzUUDJp2f+od+l5EJu2bqh2BGgJUvuvz3CFx+qxF2M4zUOcI4AJKSsAYBur9Hpg+rM9/Oc9nJghhiSAcFiATah6zmC3VIcJyponC/ECHFR50uAs1rKbSDu2W9KB18q0gUd+wHCxv8C7x8cIOKADC/iCQJCui7Ou0um1AqC8lDu5s7myqGmvQ1hCoCe4xICEFcu2LvS2LuIMECRBY0QIptseC6GwOMhz+TK0R+ta4AGVYikJjtgfkAhkNVoMb+iBLLO2Tat7h+c7MOe7TpgMxXqq4StJOAcN4qm8ynsJI0CcE7oA7luVYjgh81sJFHllgBRFmkhI1jsMSIhINntubuuHxeN8BZz/ilmYDSTAApWwQ0oTu7LLvpJlJUU5j8VYjILKTF4qGmCqp+GZn/VBwza5CrZojLJmo5cZbIyqkpBwRPR0kfQ0jYRRvwy6prnpw+KZn06sHFDMbeRIxSiaxFnZmEz8CFZFGB5FWKIUj/N4jRoapUWap1gctnA5kz6GAGl8WbLCxgTpxpUaxouJmW8JdrpoHspWVBQJkvR0wQBmmYF8TnNMx4gpCRJgyA+AyKqgyDUFxmoqxoaZmYTsTUXEGTUMAD+ZZkF5ADIJhL45l6oVyZYrtlw8yhFQyqfskjCpypx8p1Y8pW0ahrxkwUW0hlzpQ1D5lW/cpXHMw7DswJe7WV9J/8yS0JTGLMy7DMd4ysNU6qZJO5+9LMfNHJzQ25yE6clJmaNVWp3l/MiiFc4qe7l/28qRyZhLHMr1epvZrBvuLM7wzLL4/M3a/MvUSruO/JuQvM/42c/R+8/mjKOgfA+lGdESPdGvEJoUfdEYndF+VMb33NBsWl0IndCybGH0zF8LpiQhTZvbOUfLrBsn3cMp3Zrj7EElTWEvHdOvaZf+7NEdCtI4LdMKDXQ1jWI3/dOsqdMLzdO+7NNGPdNzNNQvVtRNvdID9yr8GWRTjKvXqZy5ZNRHHdT0FKnvKWS5ANVIJtU/jdRRfKDJdpMA+pxmHSZeXZxgLR5sbasZ6g1xXf+XaI3TdllmdRajsWKi1+ydXA1Ncy2rLyqid7bKlLDXk9nXMW2XSvqjTSqkWm3YkN3VXp2kPMogSwqkTiq/N7HZ0CTZKZ1kZNpqJTKno3bErizI3ZXYl7vaZiqpaCoOpr1OqB3SlF0mcVpNrs1rmX2eh71OtD3SLwXcfxorxK3bsm1evY3Qf/2o7VlwlPrWwXCpw9A9hPq7izCqBDw4pJqd1yADLFwACysNK7xvMDwPMD2cq5qyKmAJzqvSyu2o2AaptercBgfdT3gJhfADkMSxNbgQzoJJNRCLm/Te9fASHSct1OLg8C2dIqABrjnfAhC5DPzOfrvT1oqpFmtkyzD/rgi0sYRg4uWawtZAAyYTMiI3ADfwNq57KtLZrvIamyPQAkjgzPltPaWbtQwoeUVgwuSrEByTSR9DAhhQA+m7iPCTdSCTQ3wbFsRZ3wWA4ayJ4ymrAScwnlTtg3Mh4qIYsRnyDhpr4IOQ5iyODTWQQ9OQRjRQAy8Q471h4SR730RQAA0M5j/+XKULSeA74EbePDDBNtUgtFC+c5Z3gfVj5Vur5QIwsswrADPQAjDg5xyNuYBbDCCwd+CdDFWbCKMOtPSAATs0DSu8AS8QRzZOnFy7vM57Alkey3V8Xe/AfPSmA7F34B4BO5QjLV94INAnfZEzO9Iira8O61oe65Xu/wMi4OObHs/eZwydC7fOoLiJoO3mjS9dZw1BsEOofiCQK7mxOQMnkOmaPslh9w4zJAiOp+ZHrhDxg7BeSOHwjeAUaIHIDunMvuHmDvAqIO32zOm1e0hj5wHpBsChmgzBO7yS8vBxl2/yIz2iYn0DUANVXg8JDKteiwIYvuOSzs9/DpDOsAOS50CUokAVEIM6lxA2pOrffhowMX0wrkOLKJ0WMPKy3po5cN+waZeFokeROAkQXAnvm8z5ezVw6Ch9R4ehnggDfMAONPVCLiMJQSqWYCoZ1N7Oiu/a0PGs6bUwQOsFkAO2zu4gkgBET7/ti/QSrNfLUASvJ3krzzNidP+32HBJBwutlaDsD/4S05dJE57zw4nlBfDlram89U0Eab+ebWyGODwJQQwJpQxcAO3SVZbct97Hkn+MokTapjzErrDbAjXd+5xkygaSXwyn84TJSs9Mxy1QnK/2kLD6bR8o5bjF3kSSv2H6GIX67gxjDABO81SQCnXGut9QhW3cwD9VtY97VWX8bWyQOaL8b8H8pR/dJr35ne1SZPr6NFXJawL7f5ycz59W0c+XZ4gJ4k/Jlmz+NJH+pCX84azTEonLQvnEtAwIEAUQAAcRAIiJiQUBjY6PkJGSk5IFBJeYmZqbnJ2dBQOhoqOkpaanpwUCq6ytrq+wsbAFirW2t7j/uLS5DwwACwwNDQcGtQYHDYURgoSGuZae0dLToKjW19gD1dnc3aqy4OHiu7nP5b0ACAcFBcG2EuzuBuzIz5T3+PkB0NP9/pjbugm09k2cwYOryJVbyBCRQlvo1MVLVgteu2TzCtTT9a8jtYEgUQUMSVIbwpPjGt56qLLlQkb6Ysrk57HmppElQRZEydMVS5cufwIdusim0Uw4cwpMqpTbzp5QhTKUShQoTJlY79E8apNpU2xPofKkWlVX2bMOuR71+pVgW51i45I1h7bs1ax4IW1V25HtW1Nh4yKcW9dh4ap7+fbz+5cU48aiAgs2SHjlYaJ382pOrPgj5GySJ4er/1yX9OWinft+Br0arOixiNnJnk27tu3buHPr3s27t+/fwIMLH+77dDniyJMrX868ufPniI0Hbe2WukjrIl+jNH2W++nHkMGH176d/ODo0lWK/7uePfZU5g96R59+6vtS7d+Gju+Tf0rM9TWU31cDEngffv6NFmAt8x1WoFIPQpjgaBPK0mCDhUVYkoYbHuhYhbFgaNWCL3kYmYmRgRiiiq9c6JIBCtDjwAKzMZCRRgiUiCKHJPEY0n4JihjUizFqNGONNx6Q43EoatOkSSz2FyUrLqpkQAILIBLBAzQuCcCViDjD5I5P+gjXlAmRuEhLV2YJwJZdJgKmMjqaaOZAQP8GiWaaAOKyQALsOACAAoIqEiciYDaQQDFj2llmmXsKIGRLUv0Z6KCFJnLolwkAoCijzzR551KRShpplbcQCsAECiBQQJYZcTnbAjc+YB+ZokK656Tq5aIqq67Cyo6sstEqm611ejiqN6XmyR+qtbg6GwKqIvKArF6C+cABtzqaq6inqmnYLdLKRm2m126qLbfJHrisU82G22eqmb5ZrQTYytlpIciGiuu/dsqrplTVanlvvojue0C/uny7Y7y70meLpQXsC6OM6u6LwKKNXnMDOzHIQMrHBYTsFDcysMDOBqRsMBvLrGXTg2wYmEJCDDXDa9AIs2nQChEisIOCfOL/AlApoBUjWuQBR2arMcf+cuOybKGY8EIBOZ/cTQyz0SAKBu05C0ML7MAgwAhBF+BDKxoUoAJlBp0wm9kqpL2KBey08LaC8xatCHhBiBxEEKQEPsDgWmNDww0DyFCAyKXUEIPXMXdDwgtKkFKDylm7tnMBI8ACw9pEFEAEZUXziphAG8AcCg0FUL5USI6TEMrUeBrkg9katCBADjmcfQISq8DAzt4UIlT6CDwP/YoPIvw3lOqYDXQD4aZcnzg3NTxuigkxeDNQ7aSw0Hrn1zh7tmzBwzKD6aiLS/30rIPcwwAsmPBjSBjAfEP+YTsJEnwngvblYG0DRILb4IYQCwzN/wcWiEUOnAcOaPnNIQLpwQtsVwoNchAsA8EA40pxucxtDxtc098oMFCzDaCPICghQgt89goLrC1+A7sgg0KygRdo42pYm91AlLDBAYCPBLDL3UFGMDwBqEBuBWiBD1TgNp4hr4IIGWDoLEC2AoggdAIw3gnAWEGJ6VA8NDBZKdIIucphY3Oua9kLq9MNycmOBLSZI2B4YgEasmIGIqCg9Eg0P6uEZGYDeMH9Lic7EA4kBirk2mxIZRAZms0VM0QBba64ooOcgIY5oGEg2XaCQQ5Jh4vgBgZYUANR4PF+q2yl+GT2gka6MBSOu98ssbEB/V1Of7cURTBBcxANkE5vAv9AQQRV0IJLEk1+qExlN1ggslsGgWUl3CU3rCZLUSSRkuHQwAlO5wouzoAVVmSgOHp3TgFoQATnFIEP0BY6H/iOb9O7BY3igSh6UCRaCfAFAJDWjqhZA4+zIcErESqbD9LxGlNb2QCCiQHsadMaaWQH9oY5UT3u0SBPZMcNlZnM2QjSQqnTp2wEmpGNAFSgBBXoSgQSBHZQcwAkUFkBRnjCa9TgBSocxTeZJQ4olo1nXiTnKtI5DoPMYIatyAE7LDCDGUi1ACfg5CzMGC0FTIAZdKrFMAo60Ho1DGDK0hWaCkkXXFDrq4MIqyLGClOzzhSt7oLYWrmqCEEg4BiIkmn/IhaGjoHSw0u2eJcj8Xof9ZmHrWbJhV8B+yXBhulaMD2sQd2l1rUKbES4AFQxDMDSBJQLAQzwRWERMQwJbLaxjwJXxKAZ2gKMtrSnTS0AVuupA7j2rN562Kk+e0pcKMoBlCWtIsrFTzlZ9m8OC27AZpvDXBw3uYJlLlkD+9r3KNZzuyIupW7xgGJQywBgFRNEfAEMYRCju9j5bvo6GyXIWgYi5lUAeuOq3lqgo73DAFVio6ssvU7JgohwANJ+29J/+tcXErkIfK0j34cWmLqEvIWC2cFgf+IiIuuQMHDTKtvwYri4qKxwKmIr3L3SNpoqBgx96yveXkXTaATmbIkP/5zSG8cYPzNmkWPJg2C//dgxLJ6ui6sL4xw31sD15WvqnOzdIIPIvom9MY4Z610oCzk2zwmzmMdM5jKXOXVmTrOa18xmNktZfsONs4mXnGEfy9mzd45y386YZxr3WUVYZpCWh6wdQhfay4B+88D+DGhEX7nHMGb0lR1doSKnTtKVpvSEAv23QWN605oOkqJtcTEj7TMeSULsSj6tJ1Y/C9INKTXTTt2OVL/E1c8KtX8sfYs2aQlhnArTIY6D6/gY+jXHngyn12QlLP06Y8K+9ZzxPG0959NPSBNUwRAB7U9Jm9rgPnCN03O0S237FwVwmqeg9oxiP1bXr96zIn7Vqv9XfWlYtDbWsKbibiLD29iwrgW9g3XvAhCLHfo2OL+r7WeGJ1reiNDuuRKRrnTra7fsIrbDG91vZAc8ERIvWMXVva2Fh7vhJ3/4temliAgcDNr8+ra4O47scUuHYPVyeaHwBfOFyRzlM994pd9MMYstrWkXTwe7V32SESCTFVT0ozrDoUnZCBJtIh1M008QwVZgvQBUlc8S0xZ2V0DwPC+eGNKMjjGLJyziS09sA7+Btyi+jYpTnTosnL63rztTAHhj2wItFA6+LzVtlzRq16su9RaBwwfsGGcYu3jJq4qAnIxHKcQvjZC2DV4AMixA45OHkBmc4O/AEx7x9A4OQIL/3ezRc/rfsai72DfTJ69/JpNTfJCqw97rLVg97WPh+b2lXoHt9H3xjjd8WBR/FccvwDlP3woUSJ70sMjB6VK/O3f6TosCGKX1lRqiUS/I0IOX/SdPQmhxuqKA0L9hUw8SSJK2Aganfyr5mw8O/MNA/6+gAV2HQ3UWaeIAPW3jChP0M6AzfxW0N8GXEG+DgN+QQJ83C+MAgau3QFD0Re+jVRh4gO2zCgO0Pj7TRx9oSuNlZ9vxNkzkM+undQjhdMK3CiEVRfKHfeBgARFkf+gUSC0wgg5YeEAohKwggGi3e3wWTmNkPKwgRmQkN6MXgg8ogQkBA+I0Ak5IRSrAVJ1U/4WSsjcF4EyAlANU1EVTSCXiwExkxESrBzwi8EVnyA5pKCnmFyDo9zbG0zMy2HsDCAtQxXp7Rxt/eEB3k4P8JwuGCHiI6E5/iE8FyHvhYFTsQEqtYHqzR4UWooESSIkFUHWyAYIJkYGrEIFhyDYWUDok2IBfGAv4p1SWtArvJIuXV4Gs2CJ3WB956AoxKHYHUTrI44OA1wLtNIQGYX8klQPRA0iN2IrgoIwCwIzJNIBIqHuRuIQG4YT0JAD2lEw+43R1qIajYXzBg3xPuBNeqIkhQo4CgHwqQFWA5DO3Z47OWE7wdITX532hgwLRM4/SV36b9yYyFVO1cGos5WG6cP8SnveJrdCLghgLFiCEJIVUl9eHfrgKE0l2xaiDsvB1YWd/s0FGZZR2tRABA7lSBYmSBedScncQTmhVkaeHUGSE9Sh4QnM2iHd/6HiBjicLCzk0foeTU3VOIXV7hBcLSCUbTDQ3gMcOFVmUmUglUtZcZbUQb5Vew8Z0KcdxQrdpH+cQ25UAdtVVcNUMWdmSWzlpNKdsb6ZciIA0SoILk8UubqmVQZeWmXZieJgLdQmXqpYIc8ldCdmVoLaWgsFrdclavnVab2lblfV2g4mXhUmYu/aVgpkIrcWYhnVbkGmXQPeZQmZzL8GXz5WYcyWW2NVulLlr//ZYlvmYxvBcrIX/mnQpmw5hmIfZmkTWlgIFYO+lCOWVDvqFlaopma22mgBHkorglr4pYLuVX/tllsV5l9QJmo+2edMSYe6gCBtWAB2mEQ7GILgpF7pZaJaZnSG2nYnQnd/JkuKJnMZWnh4XkIsGn+82nlHxmvVpnKyJnz3Ba/tZnaHpn7ChnEZGoGMhn6IBoISEoOXhoEl4jReUbLkJoRZpbaBlgPyZaxZKgOfnafbpbx2qgurRZiZ6oiiaor2BZiraoi76omqmZTI6ozRaozZ6oziaozq6ozzaoz76o0AapEI6pERapEZ6pEiapEq6pEzapE76pFAapVI6pVRapVZ6pViapVq6pVza/6Ve+qVgGqZiOqZkWqZmeqZomqZquqZs2qZu+qZwGqdyOqd0Wqd2eqd4mqd6uqd82qd++qeAGqiCOqiEWqiGeqiImqiKuqiM2qiO+qiQGqmSOqmUWqmWeqmYmqmauqmc2qme+qmgGqqiOqqkWqqmeqqomqpcug7OeQuseqTUYlposTGtoqq2ihYxogBAMQEFoKsM8aqA2au1AKx1MQ+/dQvwcJZnsQ4ToClUGQHeuW4FEAE34pi8apuFGmLx8JcXJAi+OhQSwACy0ayvuk8TwKuy8Zt66gCyMZa5wKvfWg7EmgvzKqQ0IlgPYC5aEq3iiiwNwA7/tA6EsKjM+ibbVf+k7CpQE4AMrKooBSAo8Oop4tqqdSquMSJTpaYA/xpXMVKth3AjxxomtuWwcKWrDSCuvWpb8Jqvjllw0QoPxUAj+9JPrrUOErAOyGARh/Cqybqx0Cqu+yKu9TIP9ZKrLQutEvCzmAmw69myilqwvJoAPjutDWAR1ZIRuVoIBpcA3NKdDJAj3TkIEICytuWtNOKrQuuyIQsAEzusttW2qyKsnhIj3Cqn0rJPOTIPMrWxhBAj5yq381AMMKsIrNq23goAg8uq8NoAERu4iKuyGrFbTntvNTutWlsM0LqzjtmzsxEBzOoqM4sI4jqwAMCuYpk0BhsjUru0BfBPgrC2h1r/sPkaARvLDp7rmMwatYwrrNp6APd6bwzgrf8EKM2KCIf7uUnjuIObCDHiJoOVsjIVsY1ZvHeqt5ertZnCt4NSAH/rqwTFYYQLvcbbqxubI4orrILQut8brYACAQqgscsZrTxruZl7vZwbV5Q7D8q6Dv80sQ3QvAbbrqzrutFKsLNhK9orLTkCrQ/AwHGrq8DKsrJRb70aAYKCNMF5uPNQXpa7viEbI6QrsuxQqw+cCMSbp+vbKeuQvezQt9wrvYDirtpaq8LLDuYLubqavg5rVvMAKAxDufZLv5Y7v7TbwsyrAICiaqMbcbVhK0g7DyS8sQQMu4ZasKxLCApssA2s/3ARG8EKpwgT4HKBggC3a3CH+78KsMQxjAtw+7ykFbklPLfwe6d4mw4IZ70m/LD/y71nu6/1YABnuQ4RAK3ccryOKVoRq8OEjBGHUC4hDMREbLCHkK+2Isjaay3gawwP20/7wq66irRsC8dS3LQUm63cO1dGfL3Myq7cAsXX+8CEMAEhu8aY/ACH+7hwvMhfcpYySwgQwLAj68MlfLKTW6f5KlP9+iVFoqvs6p1+G8qWW2oJQL3XK1qHCwGAkgCIjL5MK83FCw+lKb+bK8SHgM3tYMmpDADp67zO+luixbwPC8oOKwHVyigCy6hWzFqpXLUjXCjQqhFJQ6wOoK0GgP+u7GAAteudDXDL6Aoq3lwLE0C25OqY+1TQs8E0t1oXJwwUy9sQrIwL+XwW11qq+UrFGa2lUburE9ES9QpySFy3LUGrMJ2pRaLQJ33TOJ3TOr3TPN3TPv3TQB3UQj3URF3URt3TMJrUSr3UycGiTP3UUB3Vs5GL5AZjPnbVKaafEmqgXK2EWt1WWR3WYn1GVt3VXm3WH1rWZE2fW33WaL2XY53Waj2hWB3XXx1Zc21kdb3WfN3Wb13Vea3Xdm1jgf3XgD3Ybn1zg1bYhq3YiD0Vi80QvNovv8wOi2Jro9kQ65AtsiEBzFXKgqbZbqe2ny0gKrHZctLZpZ3Zid3aiTD/2YAZYpedrjM9Lr862iC72qy9EKjdTxym28dx2rit2rMB2sy2co+tCKkFv9SCLAZAzwqjrPe1EAugAL8ZAQmAxQxAIxDbupDNENV93dmdDtu9ybwantNdDuHNKNit3dwdt+gd2q4t1+Ww3MnQ3IgC3dG227mw3loy3qj13uf93dRt3ewN4OXd3fEt3+pt4P/t3ubt3cHN1vTtVoMgll+ScW/nbfz9YRKgYIjgVQwiKDBi2gzxAB++LyL+NyQer2DNCyke4tRsNC1O4H49366CzSSu4cHG4RO+ECgO4oMy45tc4jYO40K+4otQ40fu4UlO5Ez+4xma3IjSyr5gAD9c/ysmXg7/OwH/myWjDZYawc4vfgtd/uVGo2rpSuZ4bV1eheZhbjT0wOZZ1tiOXQ6ApVxYrsn71uS2cOYKAOZqPudb7uZeHuhpziCE7udi9eaIHudrzuiSPt/f+1ehG2wlN+kJdsCYMuLuO+NtjgvNvG/n9rCfXuiizuml7gCn3uG6GNnlUOlzcnGZ7uq1MOoKt+qtbuvcqepmZepKLuWpfiydzuK7XuaETeU0QhEMEAHUwmD6HXO8ngjNzm2ti91ZEuDmrQCPnN5sPGzLju3kLeDcrulsC+7X7mzaDrHlLuxwzdjOyuzOrgDQPic+N+2ii+4NIO7rvirt7u62UO3otv/v6p7g/t7tdV7f+s7vBs8qCN9pFP7uHr6euroAIUYMc7Ixxm00Vom/A1UMEvwArlIoV1LbZJHjJgzyxzLyCWPyHU+6HBPyLM8pM71stk3lKE7xv3DxBpDxcZfwFg7zKj8sM1/y+I7ybzn0Blf0sgrwy+XxMb/ym0zzTm/uEi/YVH71d50hsE7X8H7jWp/sfY31Y0/2Zh/2W28cNu/tZ2/nEP/1aD/fr571DtL1be/2l7H2DI5iZY/3dQ/3cy/3ge/1dH/YhD/lfS/4d574YJ/3dp/2ar/Xd2/1g98QC7Ak1OImEeaub28LmR9xIWZX/zzelnJuxz23mlXdFfPIxAz/nitJCKX/60BxI4yCss6NkEBf4Ydv+ZiP6OkQ+pL++b9/KSVp2bAPKKZ/83uMI7+guqyPsn9MD8ffq7L/IrJR+33eYKG+goC/ngcQlxnhJhLgWgPu9OGPCOMP3xVBCOmvXwPP9tHm/p4bLcHwKWAFWO6/7J1/6+oKCACCghMFDQYJDQgKExAFEAAHEYOUAAWVmJmam4OXnJ+gn56hDgcHCAAGBQULghISAIUNopqqrK6wspUSkK8ACgYAC4aZo5WSv8ERB5UIDA0NCQaOkAbMwMLEnZulwZmyiIqM1JGTxaHn6OrqxpvWDK2Ut78TgvOb7ZXzjPbxmBESGhTwxg9T/z4A0Rw4mjVs0wEDhSAtHCiooD1OEB4UeACJEiIAEswxMGBNkAEGmg6uY7eyJSeVld7561exnqWZ6VLGK3ivEkCBBG3qy5RwYTaHEB8BmBhUHkaNHGMmACmSJLNUKHOuhOlyKyiNDorFm1cg7MuXY8c60Lhx0AIFqGwpKCDUaSWNKBtmQ5BgldlUVyWsmntoMF27nxi0BYBgVauRghg8OGlyqtau6Lhizvy1rFialv6mRAu6LNsHbuGmMlx3290CeT0N4+t3UEmQhgsXmFtXc+TFjW9BBiCZcirLBrv63kwLlEx9O232vAy9JmhKDhJ0HEQueSYJHInpvXtglkcFlP+6X9yUceN2QY4QhIxs1WRW78xDLc8/2vkBeNXRc11/Oll3EybZvbeUUvjtEh5DBz1QXkzoccfgepq0F1V6BchX1W3GNbjOfvyJyEkpp3QSjy+6nIXPirloMwgDE1KCwH8EAuAALJHAgs0yzRyAWiVvecMYjogh+FAlAEYUziKNKIUMdSWaWCUoJKKICmgsypijQTDG4iVxNQ5y431DDbKjIAf4qMxVZgqJSZFxomkJN0tS0uQjT44jpTlW6nelV+ssENcqbd1YW3OY2JLoAYuaiegqCDiwSkA5QgBpASm+VYB2lViK6FRseSMqpkmGOmlbjnqj2GK2lJnmoFTS+iX/KIautgpqinrGaEyI8rqpaIytWuml5jWo6SqdzgUqdpOSuoqpyM6K4KqotfobrMwma+2ItnIWrovj4lMuued+Oy6JtLJbpbvvpnurvPBiKK+69N4baLr15tdvS//6q2+q+ga8mcHKJTwwwfkubO/ACLsUsaAOP3zvxABXfKfD/WKcMccaewwuyA1XLLK4JKcMsXKrtuzyyzDHLPPMNNds880456zzzjwjenHPQAct9NBEF230zgqbHMDSTDft9NNQRw11AVJXbfXVSxdAwNZcd+3112CHHXYBA5Rt9tlop6322mqfPO/FWMctdwBUz2131XXfrbfTWovt99+Ad6yx/yV7F5614Yb3DfjijHNNNtuQRy6527XSi/jeeV9ud+aay61446CLLXjInW9e+uahpy665Ky3fjbl+/J7uuez01471p+rrvvoSt9uNee+T6378I67bvzkFw8OfPBNL888084/Tzfxw/MeigFzcerAMIiOhGiKL0k/tfjCU7/78eivDTu+7mR/wPaTes/slviQz7f99+MPvfmqW/8JIvGIwANmYxvLTKl++qNbArPGv/6l74GvSx46ACgIARKwMmwCVEoWGL3ndZB5uWtg4JI2p754RgHEuuBxECINUXBwgdMTIegeB8EHro9hgliACcOCQiJ1qIAsNNIGE/jB4BXRd/8hlKHoSFiJHk4ALrewxQAntQBHDSl8RIRhEpU4thpC8IauyYQTodgKKXLPMVbE0gvXSEQuLs5/kprUIv7ygCnS7yMSUmMWOejGN3rRhhLERHAQNcdB1FGFeIQTAvV3xNs1snZb7KPjmEiJHg4iApYEDyINeMUhao4Cq8Bd6TqQgQJQAHeS/BsN/2g8MFpsEJasYCbtCMRIdLIYpQPlER95NVKaUpR8TOXYKOkWE1oGe8yC3x0twxchGiRukzrl01xQgAtAM266LIAHOgC1JHDAc4yzwQ5W8QGvfWBS5fQj60jAglVgoAZpI0EMMNA6V24sEzpcxTHdp8xaNhOLV4v/JtSoaU1gXi2b2+zmN68ZNw6sAgRQI+VCUbk4HCCqAl+rADkZB8eCQTMEARBCAVzwNB48spEUyMDSPJAEqBlBmhQF3BF+QAAbFMAGYBsCEI7A0dbdgAUDIMELaIC2GrSTnqyzpz1xiTuQipSkTjOp7Q6q0gCw1KUwDSg2M+CCDqRACE5zgQcKMNGAhm4FOlhC10oAhCGgVa0jlJjyPhoACqRgaUZYhQdcUMoCQFSrWEtpAPh6ygv0NQQhQBQ3zQq6IdwUbGxt3CohR4MY0KAGL5AB2liwgQ0gFXkl4xhd7YpXvfL1oQa1mmAJGwDDrgKxik1t1YzQ0gBwIKtWBQEI/8r6u9DZdAVdKwJNCVCBEryRmHDDnV6tSYG9WpUCFzgpNhH11xQ49a63BSfoKjBcr71Vsq1j5wZeEAS0YYCenq1nIEWrXG0y17kegK50A0vdpVk3pNjFLd4aKk0O/HVpHPjmbrXLOCAUwLhdK+7WKpBOVSLXck3lwVcDAIJJgSC6U1WtSkHggQB0YFUdyC40GzeEHTTYnBgFL+uCcIOyYaDFZSPBqj4LOaXONcITrjB1McxQqlK4wx+eVIj1K7VG0hbAMA0yonhb5NDplKdcE+6CEexguZKuqfjlQXOh2tr5+ji3Abgv00Qc07/hQAdQ3toHUmxTHMywdUEAqlFbnP9es9UZtPy6cUCvq2XnLo3HspWaYMEsZiRnuGop7WqOyzrgES/uA8ZFq3HXTAC2ujWtx7VyJhzgLTMpIB69CssgKbLI34G0rhnoQF5fC2jAfpmU0O2rSsnMWMCdE1HlpDRxixC6ybKNne6E550HMOwarzdUnRbEIkA9rGIhypn6oCuqVY2oELT6d1tdGqxdW4BZEzlqj3SoX5fWaHIzucmLO4KBC8BrAuhaowU4sd86KggHKEAC9NNVmGTRmHyX2n68PF0khelrVuL5XDCxN7494hhciEkRP9QjI7WoRWEOU9O1SAAv5BGdfgySR/8mX8BLN/BUFtzgxg5tJhCxcRX/GYgVH3fhHmfOSIuDjd6v8QdZ1MIdbIRcfCPvXMkleXKUq+/YmtCIztNij79AwOeexF/QNTf1yw3djTivTMtBw5OZDCfqAK+4zb9WdKOnzcacYPl79iEdr0NbHmyceDDHPkmMh+re/j4QSGJ0iEk8HSfRprnU6e61sps9girHDt7B5HBw+P3TAJU6xedOeJxzulHBOlJt8lkADTJV7m0kfPEOf/ByJTzZaQy1MEzo+WcKPuyUp3vWER73wYt+a4Yn/QDQ3jvQ+972op+96WsP8NvjXveR4z17fw/70Af/wbJ7vciNT4Dck175C6t64ibv/Mqz7GjgD7/4x0/+ov2s//zoT7/61y9+6NNe+kCnvvUPj32IEV/kYn++3e0Pf+ldHevIl3J5dmXMh3+xN3bCty73F3/GN39mV38e1X8elH/et38RWIAMeHsOaHQQmFwY6H8UKHvuRyHJdEaw4Sjg83MgeIAIGIBs04G1wE8mKD+ckneB94ETyIIWl4CVEUC0hEHlIHM4CELy54JHl3jukAA+uEkZJISSt4D+14APxnk8lEIRt0LR8HZwJ4FE2IBG2DZIV0y1EUs5dIUfkYVO2HxDaERSaIEVERZP1BhltCsmWEWZl4YG2H2V94VnF4ZvGAtkpCtThCh2uCsS94RcyIYaiFyj1iGxdEhmSCqKBP92eVhzXsiHiDeAgmQsj/iDK5RHeAh03GeJ+vcxYiQamGQWmhSJbHJLrvdJoeRql+NL38Y3RYiJZgODZJiKruCJH2FLobg3uhRohUOLxJiBFWiKJaRPJiGDrMgYLaSCTyNQ01RNPaZaiJJQT+NNBPY34rRRX7MCQJBi6iQ5MoYoJnA2wFYA75RUfrh6zJgKzrhMyhaNlAhuiEJkBHWNiJaNi+U03MiPVSNu/6VtY1UAtVVmfmNRq0COW8OQBeCQ8zaCCohlT1VSXqZhK5WQTfNS3eg3M1VTj9U1JRaRKmaOBUACavNTQTVU7oiEHmhqITVSGHloglZVV/U0HimQUZP/aF4FVkxjBEbgYRkAlLXGON8VjpgWV8qYfaN1VwGwanvVVwVZZNnGWtwGW6vwj3jjZCPJNSama+UYOedYAOV1NpV1WZn1kpq4fDJJWlFpWlR5jE+zWhlQWIeVWFtJl05zZLaVVR4wlFHJkV0JOr8FNofJlITSe7+zXHUFX/Jlkz1ZX2F2XX/5kYDDXV5TARglloFzPDLwAuloNuJFXuoFkxAWUI65Zc91bftFX6hVmfh1mTwJNSLmX03DbSlAmOhWYAcGNgZGZVXWlPy3ZxIGVjr2UK5plYG1YUAGYrTWW4xTYvK2AqsikatzPBgwmmXDYi4GY8n3jtFnnDlmYcsJ/27ZxmEeBp21OI1x45fRyTQp0J7N42Q7lVP3qZgjw5h4w2es+WcZiWg4CVGFRpsKKTZnlmbu5pCeqUqtYwItFpo9QGz0FGcDMGdsiXB6JpNCkAJ9xmXnOT7NuVIEemqGVpt1yVU/SWFlxQEpwGXSaWuRpgOT1pkzKpxLhHG9Yg6xkmwAEAH30aMAwBar8IoyOW2rVgDWFqA3qW13yW3ehplhc2sb5ZkNOm+t0wMxsAowll7r2I6lty42sik82i2ZAKS2YaZEmg+NpKRLk1LUxmpM2pNVtW2yZqCyaDUEaW7rqU08IKVgo26r0G6UJqjsxlEk5At8ESWQcECdABvw8f8nQ+qKnQCFHnSLuLh766WoCcCoQagPkLogjToJdSSNIDSKwJeMi9kjrhABIGIn9mESV0EZbKGERqqGqbqHmaqpodUmrfqqK5cVwFqrgKd9hWOsxxqCCEhCnKcAriqsCTBIW2Ic1IocQ1ohW7iGSISpuKh8zfqslSGtsYoVQCgID4CtlZqISKSsNkdvwACsjSKss4om45Gu2upI3IqJHfiu8xqssjquZXirlYiIpKiq+6knCtAA5OCotpEVCzsJBwAJDwCryKo3FWux+cqHEMgACfuw/iqqQRixQ0qxlnqqOkhwJBQcIqsrsmIPhMSysyAYnKIghKOu+HqJmap8Ktv/EUIKqpQCs7gxswIriiWriKW4qk5ps5CUsV8Ig+NJsFBbfIvohqkZtdOHs90qnu93r5DErjtIkeFysaZzsgS3q7zalknLtbMjtqgztcR5gVaLjLqas1o7fEq7tl6LshLDfnzbt377tzBzfoA7uIRbuOEHtrbCtpIpt7LXhmhbnHEbhVirr4jbLkW7rQ3ouBpKgJF7qZOrsZU7KIqLop6rgZprehuKq1KrgWbLg4l7uTdrum67ufw5sKsbfK1bucikPTOIgjaYrZ3bhbJ7tKirDrv7Pr37Pb9rr8FrtLi7q65LQT/qiwbUejfYvJg7vAYrphNkq9PLhJ9qqkaUt2UL/71TuEO/YIX0iIaRp7pXq70iiJpUmL4+tL72eI8rqIeyl7tUO0ZyKIh1mEbBmIP6i4Cny72nCIj/a0ZUJMDta7vv+7x064aNWEjmSr1DOomfh72xG3wHHLaaUMGdyISg+MBEW8Dtyr9v+4eXNEvgKycmLIyxiG2dY4xHWXkfnLibsIsu/IwwLL5zM4x5ajg2HKMSnLVUy3n7VILP+E9AnDX5OFDWyJdNg1BcyTQBeaBh843x5l2TgqOiAzriiJ0E8ANkfHGPK4af0oxMTI/QqIX2AE1RXI0FNcSTqVdXvDRZfMN/Y8bhOE4F0F2fuU6Twp0utgobcJorXLX9OZMwuv80UkW6VYyTvBmV9Fmf6UZTNoVTXGOdwDVDJDZO2NmQklW3FblnjlyTksw0g5aTfXnJ+8NRJuk1RcBr4ghXg4ySKpk2JhADNSBUSpChB5u2bwmVUnla42bHUGOXePlaelkAeVw+JPaVBGCdgypZjROWZFwCZ3xzphy2T1la2oTMVYmeI4qVeRlbfOw33Pw1O9BuUjaWkFOWZ2k23jkA2ynMLMG5eLOakBmi7gmbyXxfHYqnRrw4momYNMpRjMOZCwpZ3Ux23/y67eUB70VS8QXQ+XNQlEnQ+QWoYdPOXoMD66YDgoylxhOahpzP+JzIYYoybtmfx0lh5jmny+ycfar/WPHZm4BDnX6jYG+0ONZ8UV8j0pmWxjEp0+W5Yzadoj+W01u50+AGOkYNNgstz6zD0t0JY1otgEgLuY3coR/KNBrdPNlGaCZq0IUJOAnaNZRWApqsA24W1KCja2JZ1cNJuzFdZP7pZ122uE6N1k0j1dK8OEbtmRWgA0PQU6wDoQMgoRQ6AL38yy8QzC9NMa+ReSYUqnGyCmXKKT4ax1iGpNVW1tBz1na6ClHqaLaGTg9N0qtw0vMWOnadYpPyyXldvJltiJttJztqEmaKv9N4anCapEsK2E4zaKndbWrN06qEKMBFada8A5yM1WujpVxaNnWGAYisyF9NCQkBAAlA/yyDwKmeyrDA676Ma8Czq9tEMd7iTd4Ot6geK9wmi8I7qMLfXUsmlIJswiMhAa8brN6SC7/LiporJN7zcwwA7qr9at/jS7Ymp9/DbCMWgRBtIq3fWq1P3LUSTnQ53C6bACXgneGEtOHQ2uF4++F9tIEoh3MTG687XB/kCuHryuJYF+KiuwkxHhOwCks0HiJDm78FO7dIvMKOEA8L8AwNkCeYwLEKK6k27kjka3I6fiUqkeQ5xOROziQdK+UDDsHrncLm64YMAHK98gzNwCw8G9xhfsJF3rjtjcBMguabouY2wubADdoqLnBVTnQUvs+1C+e5KufES+fETOCle8SUS/+1T6vowuvBcw7C/CzmBc7ooOvoW8vBS5u5k67DlU7ot2vkjb7Ij27pi47Dny7ioU7khd6CZQ4whjvrtF7rOSO4tp7ruq7roYvlsNvprBvrep3oqB7ppJ7ppr7pkO68x960E225dytwTGuErgvtaivtn+vsCK7sxc7s+yvsFQ63y569mK7tSM3I3U7uzU7tuuuM3eO7A3zfcQ7rE3zuK+fuq0CD/v3mrj7q317v+71y3mtBPmy96Z3uHbzuLui0UrGEBR/vEY7f5Qvw4Z5D6EuGewFE7NvnJPfnLR7olI5PF6++Gn+//E7A807mFC/omOC/UUSHDXyHMYzyr67yRz7/7JUEh4HIwITowBwvdB4PgODO8nkuRyPMiiX881QX9Fzk4gbXgSJMRxic9FPu4RI/4UMP002Eij3sxj9c9bBJxXNTxGtd7uyOmjysihgMjDN/N0JMw5pD9s797zdf8fC4xvLYxv5k8tfbz6ugj1OszHXpjwoF0iNN1F0DkRFdeK7TA+1UcPJEY17t3kRiTGzMu03M9wePj38vxXUM99iIx4XP2maG+FzDxfKG0ub4+GB6Njcg+ZNP9GDN16kcVU2d3JSMVYYPNknpXUuZy2RZAC6dNkbFjt5N+bMPbk5Fk7aP3JO8kbpP+kL9+wQQkpvM2JLDkkJFVK9j/Mcv++JO//twecxzKfi4P1h32VrpvJfr7DeJ6TXv76Cs8/psw1nF9oLPLrrhHJfjDAgZBQUgAYaHiIcFiYyHFBkBLhkUAReCBSEhgwUdjYwFBKGio6ShNgUrpQRDBTaqqgUDsrO0tDQxNDUvMrUDJhi9wbIFAMXGx8jIxMnMzc7Px4ueiZseFwEUHi4BHhQX0tOI4OHYm4UBKSEBQikBHJTkiq+vQAUlqvX386SxwrUYLwaxIEELA7ANwPzRWgatoUOGDiNKHBeu2rVs27p9i6eIY7lB59Kta/fOYwBQ+0jle1XhR8pR/RTKIsFiw4sgwX7JXChRWc+fDSlOw8QjhZAAIDYR2v/oUainR0g9BOiglFPJpi9JDQFyRNXWrlljygxiQlbNWSSqJpQJEWjPtm7jAnDaiKhRpEpBMOVIlxFUEFKpKu1wlW/WUV+17vhwOJRYhUFuyMIguZbOncPiwpULtC81dex4YDy0N55nRFC5FRJ5qLDpwx/urdBx70MFArEJzNb38rE/EyxqDGAhGSEt45g3c3amfHnE04pApxCtjTT0jhxTe1itrjU8w1lz78Z9G4cOsI19CwvCYkAN4gOQ+1q7szk05QsODCpmYNCBBsg8oNQDACSwCQPMNdXdIx0YsUkIpZFzHTaQTDWJJYNA4pqEhx1RTwFFhGIbAR4OEuJh6q3/NwgGwskXH30K2edcNM3ktx8A/RXwX4ADFnhggnwtmEGDD0ZYkUepdXDhJRp+91pWJYIo4m0fKMVYWJgNQNOKLSakFEH1acYMAgUQWAwEBUAAwAERNNNAAg4UGOd9JtVpmp14DtXYnlhm6WdyMz40ZpnGoKkmm27CKWdQeTYqjqOQnsTnpPOk+Oelmbm1WQQIGmPAAfx1mowBCRRjoI4IABkpnhOu+gmlsPKD6ay9yBjoXMxwesynoTZDqqn+pdpMq65iV2ydKMUaq6W0ZmnrsMwwoECwBnRKKpmDCIuAAhMc08ABEqh6LF/jIqusssw2G+atz2wmLbXWJoBtAdpy/+stuOKWe6S+4J1LabrqxihmMhIYUMwBD/CKo6jHPMBwr8Pye6fEHPr7b8C0PjvjZgUfnDCoCzPj8KgPR0Pxvid7kqzFewKMcTAaJ7PZpwCyaeiabSKD5gLFLMBAA98aHHHKdRGtMsuTuvxyLTEvN/OONqeJczI79/xz0PkafZLWryLd8tKXNk0jMxIM8jOO/gGIDAPhFoOAfgWcPTTXhhA77spe9wb2n2LLpVzZcQOY445rtw3A22arzYzdxTLeeN7p7e1n38VQHqjjq2KeOeQoSu4su+2C/hbdxpKON+evKC255ZZvTHrdr9eNut6eryu6zLc/F7vmkZ4+u6y1s/81cO50vs47pL7/Lorqe7f+k/NO7x67pMqnHrzwmhLPqPHTJ18982BDP5H2xZveffXWX+8P61W17/778Mcv//z012///fjnr//+/G9CvjH9C6AAB0jAAhrwgPwb3v9khr5SgC986otRBIUhvucscFgNBN4EayWADnrwgyAMoQhHOMICkPCEKEyhAFh3wcVlECYbhFkMazVDniywgpp54fJquBAV+vCHHTQhEIdIQha2UBk6dAwPZ/HApTURYzgMyhGRmMQnQpGIWBShELPIRSNOsXJJJIAVAzZGdZUxYxeMYmfCeMaMcfGNK4RjFr3oEANMS0cOWIBSGJAjVN2HjUv/HEYgB9BGTKkxdBKxo3/yuMc+HkBYzAFkILcoxyFSspI+pCM0SMUzAETgAXqE5K+m1i5JLrGQhpxkGhOZgE5+MpSeKhUpI1nFQV4Skyq8JS5PqMljLOBUcVLAnIwBS/6U6k1Co6UOURk2W6ryhs745SCCOcye0SuWAEDmH2s5yV0CUZfe1KICkSFMAExAAWTiWY5AqZQF9NFMpeTmKZ15ylU2o5znTCfayqTHTbhzE/BU5guZybdwZtKgKeyl26qyrWE+gJ2iLNUDQBbPZdJznvWE5qCU0lBjPLSYOJIoRQWaQYJODqEJRSkvx3mMchojAi6VAESxuaaAulCePDSp/7Oe+b/muLQYMJ2TTEE6SoRt06LdVGkRlVpClhLzVLJUJB6JKksEJCCZN33JDwYBBFeMYqsF6Grn/ESCGMBoSwWoTHL81AMWDCIYZYWRBDGTlk2UBS1uTevnNMoMaRYgqnc8ACMj6rarVjQlFRiEDnBQitkwdqxZimsvMDCIDZxUhSMQwSB8IMIRnMACPwTnCGGgFBWQdhMnCK1T03iYIriiCCcShWsJAFvI7uQ9BYBREHBSViXslK4FsGwwcCvX9UW2AGCqxW61FAPf2o58h3wLn36wA1KUYBCP7RNmiGuZGNSABC9wbn18mIMcCMCzSADhDDQL2oP+EAapFWEOUP+g2ux9EYx7+kFsSaFf28qkJi4aDk4GEJnf7uQGxTXLBgI8153UtQADngULBlzg52ovuhPhUxGuxI/s0g4zANZtZTBw1/GqUATmFUAOOPtBEaAABe3NJRBPWwANfFAFBRhBfTtzX/wexjypKAWQ/esPg7yoFj2IwSBeoFa2ZAkgAknuAIzMYOP+SQYvKPEAkrzkJq/Pnvf1XimOENYgdzhymKEyjEg8GeGaOIUqOMEgWsDiDloAtDAOLRZJSwQPiqDOuVztDRvjIa+SotBolsmDVySMLBt4LHc9y0zU8ugna5kWjrYw8TD8HD6VAAiw8HBKXLbo3NKiwmxODhFbYOP/Do6gKjFGoWhlrYIOwqAFM/imoHt6mArsYAiiWEEBGOtrYCc6S8hxEUCEs1bMAEc48HFRlSmYJRNIBss9OPIslg0ovn5RzMHeQSp+oAPdDHt5ot4H+JINDBN4F7ziZcsQLYBrAeTZg/eW8Q9zAAMB3DrXMzhBq3f8PGdYtVOnilsybLSMwSmOgS8RtlJWIGwcSHwTZlb3pditJYHwotKQ4ZK2ZTFtGWKGy3o9cl1Z8HFN5645BweW2RYON/6kjaSvGEIRuMrYihPguoPg8Kg3nhDkUDa4l03hqwsggj7bO9b5TukPNTDnfgtAAyfIta7tm4xvKXxRg4LnzRCFQZzW/1Cnzc4pmJHhdYRX8xhkErvUyJ7VgdqSqSXEewgVWtOR+ciPx9CVp0BWLZyjD+31uejZ134MhPn9VI9EhuD5Q/iSAdCUOdX73jX/QYUyAEF+L8a3JDAvBLwLVYUPqeG/p/iz8xS60QI9w0Zf+tM/MvWjrHtJ7855D84apb2c18w99bCO1VRhqdd9AxHv5Em+/sLJEP7XIWYM4yMM+Zb3sd2T2vs4dp/vxRiZz4B2AKziCGoRGHvOlH/41s+Q+V/2djLEf7XyI4NmOFP/6pUH//V1P4j/B34AMDKIEzgEkzj7RDjsx3rO14BqJ38BgiAFKDfHADhn43D79zv9R0H/5/99vSeA0IV5rueAiweBLQRuqLOBMNOBv4dQIHhhIvh+7rdBnIY7PYaCnKOCHBSAAbhrIWh2MkiC78d4R4SDkKODTMOCPch13xaDMYSEC/F8m9Zjc+GENKiE36cZCLSFXNiFXviFB5RGYDiGZFiGZuiFPnhh3PeBWPiBRHiCbNSGbJiFTDhFUDgMcsh5LWhQNegTNxiHPBiIbliHRbiGepiHeteHYxNmgPh9iIh3L7hphqh5e8iHS9hTVGiEeVOJ4cSJ3uSJuBSJnhJYjHQgjgRJwzKJifiITKWIANQTUiVY/WQ2p3hUA8WKrXiJBRcRnARUM2VMB7N+qXhKuKhUoIj/Sa5YOazkSr+oerNUdstUjCp1jJUEfn5FTchAVdlkWO2iipAojS74hj0DTADwU9ZEWNp0WCUFji6oi2/hDPiETgWgToPATv70TkHhjbkoiHoojuUYJ/k0j/tkj4PwT/UYFI04h45Ihzy2UZvQUeHXjL8yUflIjPx4iAwJew6ZLT/1UdcEjBRpi+t4kZTojuNzT9UUVMUwVB/pjEbVjRa5kDLZjyZYDOaokgDAkoRVUyK5fOxoiRn5jjUCVfxBitp4ONw4jIpWFVJ2dC+Qbao2RCIwcFTHdFrnXkA0lR00AxYwCCJwlfrmQ7c2CFZXlV9JcNA3lIMAWIt0lFZlflT0/xKJVQCLRQrmEVaGNmpEpJUdlAODYAFgKXVZOXBy9pffNGMtQJYCwJVeGZgrRYgneCnuJgw30B5R6UM4VmMdRAQF0Gd/dpg/lJmtNgKAGXADF5Yq5AP9pgEtIACc6ZmAJmv+yGv5VV2jQBsEQF0oAkSi2UFYl2sWEJuyxpuDQJhWZ0lApJpX15qkOQOmiZYnGWZ/ogs0sB5uJm/z1moaIAK+GWuC+UMWcJodxJdYCURI0Jrb2Z3Q+XKZqGFCdwrAhgNGeIzh2UE+kHVXx516lp0eVJgioGP7OUTnCULkmVBpKIl+UpnBQAMFEANSFiNEVJ9X115YB5pAJKEelJ4W+v9D6DWhvhlfgVaTg9YhZTYK8hkK8plxlRKho6lZBdAC+lmePoShW4liG+pDHZqhMRqiDSmdxwWVOREDzsKivqmfGuCdw8mf+HaWN5pCRNACZWmkSFpEs/mDjfFpowCfBHCiYUGkIFReTZpCNKqeAepDT3qc9sakmXSgL+cnQbAWadEDNEEQN/ACQ6qkrykAn1mmM9qi9EVEnoh1TueanamnwkmlIkqbKbEC4pab5eZzuKmbXaqkGVoAtcanKiShKlCaBfqdKSSoHpRZf7p1PepLP5KAD2cMMfd30yczWdIDBdBycVoDQTAIMQCk2ImZqOWbjRmmJJSZBZBaNBasvjr/QoWpmGbpmIiKiQt3qhgYfQmAcKe6gFqxc2HVc+d2l2I1qbo6CPElZyeApqgJZ7uaWX+prEv1Q8daADAwrCBqoJCpqtyif2ynH25XkZlHkqsYlFNocPM6d8IoevZqKm9HrRr4k51okhbkDGiCANiXDI4nrYC3OPpojAi7S8mIKwxLLw+LDBErc5EHjbeor9/IrwvLDAZiMLgnLw/5eQM4e/iilGd3sRirsLfTHCkbMiFVe7J3L4YDcdFIsvs4iKXadXDSsQu1R7uSfXNRsdNIs8g4m2/iAEh7OFXBMMkHtCM7kxhJtLsYIAazLQZAr/OHIOOHNTL7flCLjDYrOpuR/zCHowBjC7DNQH/kB5eXV0VrW41tex/M4ACn0jbPWraHAzcU6KoxqZCKS4lvCLiDILg3JzISaLipGg0J2bWLm4hserNOC3x7C0cZm7EGOzvUyLdCO42b67ad246nC3xVCoN627qea7KCcoOrC5Rcq7mJaqVbm7n76rVC6aP5mru/S5PMyoixS7wlC7wTcYbO+7zQG73wI4bSW73We71dmLqgU7qg+7ndS7tum4m3m7ABKIUn+22yy7rKa4yvi6DD67uQaL61G2bpi7vwy767q4aJi7l6KL9SdIP1S77ri7r5674zG8Cf6L9+m0hG2UibELLMgcA1K8FRW8Cj2JYOHP8s9zG+n8iCCoxIddRKvniUdDcsFMy2JyxHobuMI9ySRRWwiPu+/EuJH8wc0USO5ggA2piOETzAT5vCoOuP1/iP2ejCx5SUafuE3vtGd0hIghaP+rROsziP+HgfQPy9PhyOIgrFAinF7VTFMCnDJVm+GVW0qspQHSmRIhUUV8zESzxH4ih9EDmAajyAI5XEV9jGXVTD0IKSgRdTdcyT7aLHc/TGWLTCfvxSgEzCNhXDB5zFLsjHi3PDa1mUGLyTbznIQDQCLXCp6yquvLSXreauxSpCY8muHoQEx+iJp2x1flkAgLmeN0vJf2XJU2XEhYW3APQnJlAAuLplAREDLZf/qz/El4xplaUcQq2cyquMbEpxnRvwzN1mxicIRFV5qR7EmQA6rijUm186qtx8QsrJmnY2CICanKuJnvgZnLIcvrabJQzqy7XgaAp6mSrkzc35nJgqzulczs08nbgwXAHtcvOLvpaEzXYGzp6aqeKJY9sczik0oB2EY+dMRAN6n7mmoTyqkcIrE0oQXvI8CzJQAMIBq3d6oeKppykdyhbdmhP9z34ymUG6V9ScRoCK0Of50AstpuK5p/uMQjkqABSNnEPUoeb6ojsqmxbMuTsBq3Ia0rJg0luGXPbcpyCk0TKKWSeQXi8NqH8Cb3AVXjT9tQb9TQgtcESN0h/0b2lt/6ZQemOrPERnGkJguqZLrbo7Ec1KAaQjXdJKQ5+niQJqmtUoNNceNNTf9CfTVnK1or3sssrYzJromq5qvZVo3dafegKD2tWYjUKgetWW2s7bK75kJc9xOgD0bJlvBp5+esjWrNkghNih5ScjDaTIUduTI2iTl3APM4vWErmLY82bQF8zwGoV3a3EenX42dkn9MkC0JWK+dPGqhT9Bq6g/JjHmwy7Pa3WNHyD68gOZtry3APBPMwQGpq7SsrSLULODd2oPNtPFmHahgHyTdD/KzPTpyjPsC0TQLYyQ8iuDeCWJI7DB3b+2t90i8cTxL1Y/IGSbIPMkHyQh4rH0LBVq/8MAs7cy2u8HE0yxjDhzWDhlcccHDzB3/fgfhjhD0N7DwksKhsvPXy/Fpvhov3YzpC12QQupefiOpt74K3ENA7fD1jTOru0iUK1I27CkGy/MwyJ/ojjRc52R5vkFLu/Y3ziZUzW99cpZ2t/DRO2cuvfGL7kAizjriuiqdfl5ge3Yivm0VDioejBWR68yvCQE5iqjlsAkKsjlQtAQU7YG864NclRd44Meb7nCvjjeUzmCTzn0VnWTR7oV87hadnRavvnuYTiiwjpkx7pQ0vp/WrpQM7oGKvprwjApB7nmK7U2W2HcI7CWD7kWl6Eq56kqV6N7dumVl68/evoz4G9wB6Q7MKeP9Q77MZ+7MhOhcq+7Mze7M7+7NAe7dI+7dRe7dZ+7die7dq+7dze7d7+7eAe7uI+7uRe7uZ+7uie7uq+7uze7u7+7vAe7/I+7/Re7/Z+7/ie7/q+7/ze7/7+7wAf8AI/8ARf8AZ/8Aif8Aq/8Azf8A7/8BAf8RI/8RRf8RZ/8Rif8Rq/8Rzf8R5f8IEAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Summary of categorical meta-analysis (adjusted relative risk [RR]) for general population cohorts with albumin-to-creatinine ratio (ACR). Mortality is reported for general population cohorts assessing albuminuria as urine ACR. Kidney outcomes are reported for general population cohorts assessing albuminuria as either urine ACR or dipstick. Estimated glomerular filtration rate (eGFR) and albuminuria are expressed as categorical variables. All results are adjusted for covariates and compared with the reference cell (Ref). Each cell represents a pooled relative risk from a meta-analysis; bold numbers indicate statistical significance at p&lt;0.05. Incidence rates per 1000 person-years for the reference cells are 7.0 for all-cause mortality, 4.5 for cardiovascular disease mortality, 0.04 for kidney failure, 0.98 for acute kidney injury (AKI), and 2.02 for kidney disease progression. Absolute risk can be computed by multiplying the relative risks in each cell by the incidence rate in the reference cell. Colors reflect the ranking of adjusted relative risk. The point estimates for each cell were ranked from 1 to 28 (the lowest RR having rank number 1, and the highest number 28). The categories with rank numbers 1 through 8 are green, rank numbers 9 through 14 are yellow, the rank numbers 15 through 21 are orange, and the rank numbers 22 through 28 are colored red. (For the outcome of kidney disease progression, two cells with RR of 1.0 are also green, leaving fewer cells as orange.)",
"    <div class=\"footnotes\">",
"     * Dipstick included (-, &plusmn;, +, &ge;++).",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from Macmillan Publishers Ltd: Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2010; 80:17. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_46_41701=[""].join("\n");
var outline_f40_46_41701=null;
var title_f40_46_41702="Insulin secretion and pancreatic beta-cell function";
var content_f40_46_41702=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Insulin secretion and pancreatic beta-cell function",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/46/41702/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/46/41702/contributors\">",
"     R Paul Robertson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/46/41702/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/46/41702/contributors\">",
"     Irl B Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/46/41702/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/46/41702/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/46/41702/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/46/41702/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin is a peptide hormone composed of 51 amino acids that is synthesized, packaged, and secreted in pancreatic beta cells. The mechanisms of insulin secretion and measurements of beta cell function in normal subjects and patients with various diseases will be reviewed here. The function of the insulin receptor after binding insulin and the mechanisms of insulin action are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/23/6522?source=see_link\">",
"     \"Structure and function of the insulin receptor\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25511?source=see_link\">",
"     \"Insulin action\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic beta cells are found in the islets of Langerhans, which are of various size and contain a few hundred to a few thousand endocrine cells. Islets are anatomically and functionally separate from pancreatic exocrine tissue (which secretes pancreatic enzymes and fluid directly into ducts that drain into the duodenum). Normal subjects have about one million islets that in total weigh 1 to 2 grams and constitute 1 to 2 percent of the mass of the pancreas.",
"   </p>",
"   <p>",
"    Islets vary in size from 50 to 300 micrometers in diameter. They are composed of several types of cells. At least 70 percent are beta cells, which are localized in the core of the islet. These cells are surrounded by alpha cells that secrete glucagon, smaller numbers of delta cells that secrete somatostatin, and PP cells that secrete pancreatic polypeptide (",
"    <a class=\"graphic graphic_figure graphicRef80502 \" href=\"mobipreview.htm?20/60/21447\">",
"     figure 1",
"    </a>",
"    ). All of the cells communicate with each other through extracellular spaces and through gap junctions. This arrangement allows cellular products secreted from one cell type to influence the function of downstream cells. As an example, insulin secreted from beta cells suppresses glucagon secreted from alpha cells.",
"   </p>",
"   <p>",
"    A neurovascular bundle containing arterioles and sympathetic and parasympathetic nerves enters each islet through the central core of beta cells. The arterioles branch to form capillaries that pass between the cells to the periphery of the islet and then enter the portal venous circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INSULIN SYNTHESIS AND SECRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin is synthesized as preproinsulin in the ribosomes of the rough endoplasmic reticulum. Preproinsulin is then cleaved to proinsulin, which is transported to the Golgi apparatus where it is packaged into secretory granules located close to the cell membrane. Proinsulin is cleaved into equimolar amounts of insulin and C-peptide in the secretory granules (",
"    <a class=\"graphic graphic_figure graphicRef60309 \" href=\"mobipreview.htm?3/62/4066\">",
"     figure 2",
"    </a>",
"    ). The process of insulin secretion involves fusion of the secretory granules with the cell membrane and exocytosis of insulin, C-peptide, and proinsulin.",
"   </p>",
"   <p>",
"    Basal (unstimulated) insulin secretion is pulsatile, with a periodicity of 9 to 14 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/1\">",
"     1",
"    </a>",
"    ]. Loss of pulsatile secretion is one of the earliest signs of beta-cell dysfunction in patients destined to have type 1 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Role of glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary regulator of insulin secretion is glucose, which acts both directly and indirectly by augmenting the action of other insulin secretagogues. Glucose is taken up by the beta cells via glucose transporters (GLUT2), the expression of which is increased by chronic exposure to high glucose concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. It is then phosphorylated to glucose-6-phosphate by an islet-specific glucokinase (",
"    <a class=\"graphic graphic_figure graphicRef68962 \" href=\"mobipreview.htm?29/3/29757\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucokinase acts as a glucose sensor of the beta cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Mutations in this enzyme lead to one of the forms of maturity-onset diabetes of the young (MODY2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/7\">",
"     7",
"    </a>",
"    ], while deletion of one of the glucokinase genes in mice reduces insulin secretion, and deletion of both genes causes perinatal death due to severe hyperglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Glucokinase-deficient islets respond almost normally to arginine and partially to sulfonylurea drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link&amp;anchor=H9#H9\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\", section on 'Maturity onset diabetes of the young'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The subsequent metabolism of glucose increases cellular ATP concentrations and closes ATP-dependent potassium (KATP) channels in the beta-cell membrane, causing membrane depolarization and influx of calcium. The rise in intracellular free calcium promotes margination of the secretory granules, their fusion with the cell membrane, and release of their contents into the extracellular space. The importance of the KATP channels in the regulation of insulin release is illustrated by two observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transgenic mice in which the KATP channels have reduced sensitivity to ATP and therefore remain open, develop hypoinsulinemia, severe hyperglycemia, and ketoacidosis within two days after birth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The extracellular surface of the KATP channels contains receptors that bind sulfonylureas (and other insulin secretagogues like",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/25/4503?source=see_link\">",
"       repaglinide",
"      </a>",
"      ) that facilitate closure of the channels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/11\">",
"       11",
"      </a>",
"      ]. These drugs are useful in the treatment of type 2 diabetes because they increase insulin secretion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35559?source=see_link\">",
"       \"Sulfonylureas and meglitinides in the treatment of diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The KATP channel mentioned above is also an important regulator of insulin release. This channel is a functional complex of the sulfonylurea 1 receptor (SUR1) and an inward rectifier potassium channel subunit, Kir6.2. Mutations in either the SUR1 gene or the Kir6.2 gene lead to loss of KATP activity; as a result, the cell is persistently depolarized, resulting in calcium influx, high cytosolic calcium concentrations, and release of insulin, resulting in a syndrome called persistent hyperinsulinemic hypoglycemia of infancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/12\">",
"     12",
"    </a>",
"    ]. Mutations in Kir6.2 and, to a smaller extent, SUR1, have also been identified in patients with permanent neonatal diabetes mellitus; treatment with sulfonylurea medication can restore insulin sensitivity in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3866?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37816?source=see_link\">",
"     \"Neonatal hyperglycemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, beta cells have membrane receptors for various peptides, hormones, and neurotransmitters that can modulate the secretion of insulin. Other factors within the beta cells also contribute to insulin release including hepatocyte nuclear factors 4-alpha, 1-alpha, and 1-beta; mutations in these proteins have been associated with MODY1, MODY3, and MODY5, respectively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link&amp;anchor=H9#H9\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\", section on 'Maturity onset diabetes of the young'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The beta cells also have insulin receptors that may participate in the regulation of glucose-induced insulin secretion. Mice with an inactivated insulin receptor gene in the beta cells have a selective loss of insulin secretion in response to glucose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Insulin response to glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid increases in blood glucose concentration (eg, after bolus intravenous administration of glucose) cause a rapid burst of insulin secretion that peaks within three to five minutes and subsides within 10 minutes (called \"first-phase\" insulin release) (",
"    <a class=\"graphic graphic_figure graphicRef54816 \" href=\"mobipreview.htm?38/15/39166\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. This burst is probably due to the release of insulin from granules that were directly adjacent to the cell membrane. If the blood glucose concentration remains high, then the rise in insulin secretion is sustained (often called \"second-phase\" insulin release). This sustained increase is due to the release of both stored insulin and newly synthesized insulin. A decrease followed by an absence of first-phase insulin secretion in response to intravenous glucose is an early feature of beta-cell dysfunction in patients with type 2 diabetes, occurring when fasting blood glucose concentrations range between 100 to 115",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.6 to 6.4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to directly stimulating insulin release, glucose potentiates the effects of other insulin secretagogues. As an example, the amount of insulin released in response to the intravenous administration of arginine varies with the blood glucose concentration at the time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/19\">",
"     19",
"    </a>",
"    ]. The acute insulin response to arginine increases in an approximately linear manner as blood glucose concentrations increase from 100 to 300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.6 to 16.7",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    reaching a plateau above 450",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (25",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef70528 \" href=\"mobipreview.htm?6/14/6382\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/20\">",
"     20",
"    </a>",
"    ]. In contrast, rising blood glucose concentrations cause progressive suppression of the serum glucagon response to arginine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MEASURES OF INSULIN SECRETION AND BETA-CELL MASS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several metabolic methods of measuring insulin secretion and estimating beta cell mass, including fasting blood sugar, serum insulin concentration, oral and intravenous glucose tolerance tests, and arginine stimulation. In human experiments, measurements of the acute serum insulin response to glucose (AIRgluc) and arginine (AIRarg) correlate well with estimates of beta cell mass, accounting for 64 to 72 percent of the variation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/21\">",
"     21",
"    </a>",
"    ]. These correlations reliably describe the relationship between the mass of islets transplanted in recipients who have undergone pancreas resection and auto islet intrahepatic transplantation to the metabolic measures of Airgluc and AIRarg. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Acute serum insulin response to glucose'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12\">",
"     'Acute serum insulin responses to nonglucose stimuli'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although these tests provide a better estimate of beta cell mass than fasting blood glucose and oral glucose tolerance tests (OGTT), methodologies with greater sensitivity are needed. One methodology, PET scanning, is being developed to assess beta cell mass. Results are preliminary and comparisons with traditional metabolic measurements are necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/63/7162?source=see_link\">",
"     \"Pancreas and islet transplantation in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fasting blood glucose and hemoglobin A1C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of fasting blood glucose has been the conventional method for screening for diabetes, although it is a very insensitive measure of beta cell mass. More than 70 percent of the beta-cell mass can be lost (eg, through partial pancreatectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/22\">",
"     22",
"    </a>",
"    ]) in rats without any change in fasting blood glucose concentrations. In humans undergoing hemipancreatectomy, although most continue to have normal glucose tolerance, fasting blood glucose concentrations rise and the insulin response to oral glucose is impaired [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/16/2312?source=see_link\">",
"     \"Screening for diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemoglobin A1C (A1C, glycated hemoglobin) is also used for screening and identification of impaired glucose tolerance and diabetes. This method reflects the average 24-hour glucose level for the past 90 days and is not affected by an occasional high glucose level. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38758?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis of diabetes mellitus\", section on 'Hemoglobin A1C'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/16/2312?source=see_link&amp;anchor=H8#H8\">",
"     \"Screening for diabetes mellitus\", section on 'Hemoglobin A1C'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Oral glucose tolerance test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurements of blood glucose at specified times after the ingestion of glucose have been widely used in epidemiologic studies to assess the adequacy of insulin secretion and to define the presence or absence of diabetes or impairment of glucose tolerance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38758?source=see_link\">",
"     \"Diagnosis of diabetes mellitus\"",
"    </a>",
"    .) However, oral glucose tolerance tests (OGTT) are time-consuming and less reproducible than fasting plasma glucose measurements. Nonetheless, a two-hour glucose on the OGTT can still be used to diagnose impaired glucose tolerance. In addition, the OGTT is still used to screen for gestational diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9210?source=see_link\">",
"     \"Screening and diagnosis of diabetes mellitus during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Fasting serum insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fasting serum insulin concentration provides information about the subject's insulin sensitivity, but not about reductions in either beta cell mass or function. Serum insulin and blood glucose must be measured at the same time to evaluate insulin secretion properly. As an example, many patients with type 2 diabetes have higher fasting serum insulin concentrations than normal subjects, suggesting that they are oversecreting insulin. However, when the blood glucose concentration in the normal subject is raised to that of the patient with type 2 diabetes, the serum insulin concentration is much higher than in the diabetic patient. The degree of insulin resistance also needs to be considered; obese subjects with normal fasting blood glucose concentrations have fasting serum insulin concentrations several times higher than lean subjects with similar blood glucose concentrations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28567?source=see_link\">",
"     \"Insulin resistance: Definition and clinical spectrum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Intravenous glucose tolerance test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid intravenous injection of glucose results in a rapid rise in blood glucose concentrations to a peak in three to five minutes, followed by an exponential fall to normal. The rate of decrease between 10 and 30 minutes after the injection can be used to define the glucose disappearance constant, which is an index of glucose tolerance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Acute serum insulin response to glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amount of insulin released in the first 10 minutes after intravenous glucose administration (first-phase or acute serum insulin response to glucose [AIRgluc]) is independent of the prestimulus blood glucose concentration if it is &lt;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and thereby allows comparison of serum insulin responses between subjects, or in the same subject over time, without having to match basal blood glucose concentrations before glucose is given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/17\">",
"     17",
"    </a>",
"    ]. This is a fairly simple test that can be used to help define the risk for type 1 diabetes in susceptible subjects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/21/32087?source=see_link\">",
"     \"Prediction of type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Acute serum insulin responses to nonglucose stimuli",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, the magnitude of the acute serum insulin response to amino acids, neurotransmitters, and gut hormones is dependent upon the prestimulus blood glucose concentrations. Measurements of the acute serum insulin response to arginine (AIRarg), the slope of glucose potentiation of insulin secretion, and the maximum serum insulin response are useful and sensitive measures of beta cell dysfunction in patients with several disease states. As an example, a hallmark of type 2 diabetes is that patients with fasting glucose levels &gt;115",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    who do not have a first phase insulin response to intravenous glucose retain the first phase response to nonglucose stimuli, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    and arginine (",
"    <a class=\"graphic graphic_figure graphicRef77334 \" href=\"mobipreview.htm?7/11/7358\">",
"     figure 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the blood glucose concentration at which insulin secretion is half-maximal is a measure of the sensitivity of an individual's beta cells to the potentiating effects of glucose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/20\">",
"     20",
"    </a>",
"    ]. These studies require physiologic glucose clamp studies lasting several hours. Thus, these are used mostly in research studies to define the beta-cell dysfunction associated with experimental and pathologic conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Insulin sensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sensitivity or resistance to the actions of insulin varies widely among different subjects, even those with normal glucose metabolism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28567?source=see_link\">",
"     \"Insulin resistance: Definition and clinical spectrum\"",
"    </a>",
"    .) Interpretation of insulin secretion is much more meaningful if it is done in relation to insulin sensitivity. This can be performed by euglycemic glucose clamp studies or by a minimal modeling technique using frequent measurements of blood glucose after intravenous glucose administration (",
"    <a class=\"graphic graphic_figure graphicRef69265 \" href=\"mobipreview.htm?7/30/7662\">",
"     figure 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41702/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20578124\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insulin is a peptide hormone composed of 51 amino acids that is synthesized, packaged, and secreted by pancreatic beta cells. Pancreatic beta cells are found in the islets of Langerhans and are surrounded by alpha cells that secrete glucagon, smaller numbers of delta cells that secrete somatostatin, and PP cells that secrete pancreatic polypeptide (",
"      <a class=\"graphic graphic_figure graphicRef80502 \" href=\"mobipreview.htm?20/60/21447\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Insulin is synthesized as preproinsulin in the ribosomes of the rough endoplasmic reticulum. Preproinsulin is then cleaved to proinsulin, which is transported to the Golgi apparatus where it is packaged into secretory granules located close to the cell membrane. Proinsulin is cleaved into equimolar amounts of insulin and C-peptide in the secretory granules (",
"      <a class=\"graphic graphic_figure graphicRef60309 \" href=\"mobipreview.htm?3/62/4066\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Insulin synthesis and secretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary regulator of insulin secretion is glucose. Rapid increases in blood glucose concentration (eg, after bolus intravenous administration of glucose) cause a rapid burst of insulin secretion that peaks within three to five minutes and subsides within 10 minutes (called \"first-phase\" insulin release) (",
"      <a class=\"graphic graphic_figure graphicRef54816 \" href=\"mobipreview.htm?38/15/39166\">",
"       figure 4",
"      </a>",
"      ). If the blood glucose concentration remains high, then the rise in insulin secretion is sustained (called \"second-phase\" insulin release). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Insulin response to glucose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several metabolic methods of measuring insulin secretion and estimating beta cell mass, including fasting blood sugar, serum insulin concentration, oral and intravenous glucose tolerance tests, and arginine stimulation. In human experiments, measurements of the acute serum insulin response to glucose (AIRgluc) and arginine (AIRarg) correlate well with estimates of beta cell mass. These tests provide a better estimate of beta cell mass than fasting blood glucose and oral glucose tolerance tests (OGTT). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Measures of insulin secretion and beta-cell mass'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/1\">",
"      Goodner CJ, Walike BC, Koerker DJ, et al. Insulin, glucagon, and glucose exhibit synchronous, sustained oscillations in fasting monkeys. Science 1977; 195:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/2\">",
"      Bingley PJ, Matthews DR, Williams AJ, et al. Loss of regular oscillatory insulin secretion in islet cell antibody positive non-diabetic subjects. Diabetologia 1992; 35:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/3\">",
"      Yasuda K, Yamada Y, Inagaki N, et al. Expression of GLUT1 and GLUT2 glucose transporter isoforms in rat islets of Langerhans and their regulation by glucose. Diabetes 1992; 41:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/4\">",
"      Liang Y, Cushman SM, Whitesell RR, Matschinsky FM. GLUT1 is adequate for glucose uptake in GLUT2-deficient insulin-releasing beta-cells. Horm Metab Res 1997; 29:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/5\">",
"      Matschinsky F, Liang Y, Kesavan P, et al. Glucokinase as pancreatic beta cell glucose sensor and diabetes gene. J Clin Invest 1993; 92:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/6\">",
"      Matschinsky FM. Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 1996; 45:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/7\">",
"      Froguel P, Zouali H, Vionnet N, et al. Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. N Engl J Med 1993; 328:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/8\">",
"      Grupe A, Hultgren B, Ryan A, et al. Transgenic knockouts reveal a critical requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis. Cell 1995; 83:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/9\">",
"      Terauchi Y, Sakura H, Yasuda K, et al. Pancreatic beta-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose. J Biol Chem 1995; 270:30253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/10\">",
"      Koster JC, Marshall BA, Ensor N, et al. Targeted overactivity of beta cell K(ATP) channels induces profound neonatal diabetes. Cell 2000; 100:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/11\">",
"      Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 1995; 268:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/12\">",
"      Sperling MA, Menon RK. Hyperinsulinemic hypoglycemia of infancy. Recent insights into ATP-sensitive potassium channels, sulfonylurea receptors, molecular mechanisms, and treatment. Endocrinol Metab Clin North Am 1999; 28:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/13\">",
"      Pearson ER, Flechtner I, Nj&oslash;lstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006; 355:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/14\">",
"      Babenko AP, Polak M, Cav&eacute; H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006; 355:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/15\">",
"      Kulkarni RN, Br&uuml;ning JC, Winnay JN, et al. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 1999; 96:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/16\">",
"      Ferrannini E, Pilo A. Pattern of insulin delivery after intravenous glucose injection in man and its relation to plasma glucose disappearance. J Clin Invest 1979; 64:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/17\">",
"      McCulloch DK, Bingley PJ, Colman PG, et al. Comparison of bolus and infusion protocols for determining acute insulin response to intravenous glucose in normal humans. The ICARUS Group. Islet Cell Antibody Register User's Study. Diabetes Care 1993; 16:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/18\">",
"      Brunzell JD, Robertson RP, Lerner RL, et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976; 42:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/19\">",
"      Hollander PM, Asplin CM, Palmer JP. Glucose modulation of insulin and glucagon secretion in nondiabetic and diabetic man. Diabetes 1982; 31:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/20\">",
"      Ward WK, Bolgiano DC, McKnight B, et al. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 1984; 74:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/21\">",
"      Robertson RP. Estimation of beta-cell mass by metabolic tests: necessary, but how sufficient? Diabetes 2007; 56:2420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/22\">",
"      Bonner-Weir S, Trent DF, Weir GC. Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J Clin Invest 1983; 71:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/23\">",
"      Kendall DM, Sutherland DE, Najarian JS, et al. Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans. N Engl J Med 1990; 322:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/24\">",
"      Robertson RP, Porte D Jr. The glucose receptor. A defective mechanism in diabetes mellitus distinct from the beta adrenergic receptor. J Clin Invest 1973; 52:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41702/abstract/25\">",
"      Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev 1985; 6:45.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1785 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F9050627AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_46_41702=[""].join("\n");
var outline_f40_46_41702=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20578124\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INSULIN SYNTHESIS AND SECRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Role of glucose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Insulin response to glucose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MEASURES OF INSULIN SECRETION AND BETA-CELL MASS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fasting blood glucose and hemoglobin A1C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Oral glucose tolerance test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Fasting serum insulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Intravenous glucose tolerance test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Acute serum insulin response to glucose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Acute serum insulin responses to nonglucose stimuli",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Insulin sensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20578124\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1785\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1785|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/60/21447\" title=\"figure 1\">",
"      Islets of Langerhans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/62/4066\" title=\"figure 2\">",
"      Insulin processing in beta cell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/3/29757\" title=\"figure 3\">",
"      Glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/15/39166\" title=\"figure 4\">",
"      Acute insulin response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/14/6382\" title=\"figure 5\">",
"      Insulin response to arginine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/11/7358\" title=\"figure 6\">",
"      Insulin response IV glucose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/30/7662\" title=\"figure 7\">",
"      Euglycemic insulin clamp",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=related_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38758?source=related_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25511?source=related_link\">",
"      Insulin action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28567?source=related_link\">",
"      Insulin resistance: Definition and clinical spectrum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37816?source=related_link\">",
"      Neonatal hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/63/7162?source=related_link\">",
"      Pancreas and islet transplantation in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3866?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/21/32087?source=related_link\">",
"      Prediction of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9210?source=related_link\">",
"      Screening and diagnosis of diabetes mellitus during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/16/2312?source=related_link\">",
"      Screening for diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/23/6522?source=related_link\">",
"      Structure and function of the insulin receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35559?source=related_link\">",
"      Sulfonylureas and meglitinides in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_46_41703="Tattooed PET following preoperative EUS-FNT";
var content_f40_46_41703=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tattooed pancreatic endocrine tumor following preoperative endoscopic ultrasound-guided fine-needle tattooing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 581px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Intraoperative photo demonstrating tattooed pancreatic endocrine tumor (PET) following preoperative endoscopic ultrasound-guided fine-needle tattooing. The PET was excised with laparoscopic enucleation. Arrow denotes tattoo.",
"    <br>",
"     (B) Laparoscopic enucleation successfully removed the tumor with negative margins, while preserving the normal pancreatic parenchyma. Arrow denotes site of laparoscopic enucleation of PET.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_46_41703=[""].join("\n");
var outline_f40_46_41703=null;
var title_f40_46_41704="Clindamycin (systemic): Drug information";
var content_f40_46_41704=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clindamycin (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/49/35604?source=see_link\">",
"    see \"Clindamycin (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/1/8215?source=see_link\">",
"    see \"Clindamycin (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8007987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8008032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cleocin HCl&reg;;",
"     </li>",
"     <li>",
"      Cleocin Pediatric&reg;;",
"     </li>",
"     <li>",
"      Cleocin Phosphate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8008033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Clindamycin&reg;;",
"     </li>",
"     <li>",
"      Ava-Clindamycin;",
"     </li>",
"     <li>",
"      Clindamycin Injection, USP;",
"     </li>",
"     <li>",
"      Clindamycine;",
"     </li>",
"     <li>",
"      Dalacin&trade; C;",
"     </li>",
"     <li>",
"      Mylan-Clindamycin;",
"     </li>",
"     <li>",
"      PMS-Clindamycin;",
"     </li>",
"     <li>",
"      Riva-Clindamycin;",
"     </li>",
"     <li>",
"      Teva-Clindamycin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8008037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Lincosamide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8008117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual dose:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     150-450 mg/dose every 6-8 hours; maximum dose: 1800 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M., I.V.:",
"     </i>",
"     1.2-2.7 g/day in 2-4 divided doses; maximum dose: 4800 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Amnionitis:",
"     </b>",
"     <i>",
"      I.V.:",
"     </i>",
"     450-900 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Anthrax (unlabeled use):",
"     </b>",
"     <i>",
"      I.V.:",
"     </i>",
"     900 mg every 8 hours with ciprofloxacin or doxycycline",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Babesiosis (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Oral:",
"     </i>",
"     600 mg 3 times daily for 7-10 days with quinine (Wormser, 2006; Vannier, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     300-600 mg every 6 hours for 7-10 days with quinine (Wormser, 2006, Vannier, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Relapsing infection may require at least 6 weeks of therapy (Vannier, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Bacterial vaginosis (unlabeled use):",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"     300 mg twice daily for 7 days (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Bite wounds (canine):",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"     300 mg 4 times daily with a fluoroquinolone",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cellulitis due to MRSA (unlabeled use):",
"     </b>",
"     Oral: 300-450 mg 3 times daily for 5-10 days (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Complicated skin/soft tissue infection due to MRSA (unlabeled use):",
"     </b>",
"     I.V., Oral: 600 mg 3 times daily for 7-14 days (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Gangrenous pyomyositis:",
"     </b>",
"     <i>",
"      I.V.:",
"     </i>",
"     900 mg every 8 hours with penicillin G",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Group B streptococcus (neonatal prophylaxis) (unlabeled use):",
"     </b>",
"     I.V.: 900 mg every 8 hours until delivery  (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Malaria, severe (unlabeled use):",
"     </b>",
"     I.V.: Load: 10 mg/kg followed by 15 mg/kg/day  divided every 8 hours",
"     <i>",
"      plus",
"     </i>",
"     I.V. quinidine gluconate; switch to oral therapy (clindamycin",
"     <i>",
"      plus",
"     </i>",
"     quinine) when able for total clindamycin treatment duration of 7 days (",
"     <b>",
"      Note:",
"     </b>",
"     Quinine duration is region specific, consult CDC for current recommendations) (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Malaria, uncomplicated treatment (unlabeled use):",
"     </b>",
"     Oral: 20 mg/kg/day divided every 8 hours for 7 days",
"     <i>",
"      plus",
"     </i>",
"     quinine (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Orofacial/parapharyngeal space infections:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Oral:",
"     </i>",
"     150-450 mg every 6 hours for at least 7 days; maximum dose: 1800 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     600-900 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Osteomyelitis due to MRSA (unlabeled use):",
"     </b>",
"     <i>",
"      I.V., Oral:",
"     </i>",
"     600 mg 3 times daily for a minimum of 8 weeks (some experts combine with rifampin) (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pelvic inflammatory disease:",
"     </b>",
"     <i>",
"      I.V.:",
"     </i>",
"     900 mg every 8 hours with gentamicin (conventional or single daily dosing); 24 hours after clinical improvement may convert to oral doxycycline 100 mg twice daily",
"     <b>",
"      or",
"     </b>",
"     clindamycin 450 mg 4 times daily to complete 14 days of total therapy.  Avoid doxycycline if tubo-ovarian abscess is present (CDC, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pharyngitis, group A streptococci (IDSA recommendations):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Acute treatment in penicillin-allergic patients:",
"     </i>",
"     21 mg/kg/day divided every 8 hours (maximum: 300 mg per dose) for 10 days (Shulman, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Chronic carrier treatment:",
"     </i>",
"     20-30 mg/kg/day divided every 8 hours (maximum: 300 mg per dose) for 10 days (Shulman, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Pneumocystis jirovecii",
"      </i>",
"     </b>",
"     <b>",
"      pneumonia (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     600-900 mg  every 6-8 hours with primaquine for 21 days (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Oral:",
"     </i>",
"     300-450 mg every 6-8 hours with primaquine for 21 days (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pneumonia due to MRSA (unlabeled use):",
"     </b>",
"     <i>",
"      I.V., Oral:",
"     </i>",
"     600 mg 3 times daily for 7-21 days (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis against infective endocarditis (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     600 mg 30-60 minutes before procedure with no follow-up dose needed (Wilson, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M., I.V.:",
"     </i>",
"     600 mg 30-60 minutes before procedure. Intramuscular injections should be avoided in patients who are receiving anticoagulant therapy. In these circumstances, orally administered regimens should be given whenever possible. Intravenously administered antibiotics should be used for patients who are unable to tolerate or absorb oral medications (Wilson, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prophylaxis in total joint replacement patients undergoing dental procedures which produce bacteremia (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Oral:",
"     </i>",
"     600 mg 1 hour prior to procedure (ADA, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     600 mg 1 hour prior to procedure (for patients unable to take oral medication) (ADA, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prosthetic joint infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Chronic antimicrobial suppression, Staphylococci (oxacillin-susceptible) (alternative to cephalexin or cefadroxil) (unlabeled use):",
"     </i>",
"     Oral: 300 mg every 6 hours (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Propionibacterium acnes, treatment (alternative to penicillin G or ceftriaxone):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: 300-450 mg every 6 hours for 4-6 weeks (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: 600-900 mg every 8 hours for 4-6 weeks (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Septic arthritis due to MRSA (unlabeled use):",
"     </b>",
"     <i>",
"      I.V., Oral:",
"     </i>",
"     600 mg 3 times daily for 3-4 weeks  (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Toxic shock syndrome:",
"     </b>",
"     <i>",
"      I.V.:",
"     </i>",
"     900 mg every 8 hours with penicillin G or ceftriaxone",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Toxoplasmosis (HIV-exposed/positive; secondary prevention [unlabeled use]):",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"     600 mg every 8 hours (with pyrimethamine and leucovorin calcium) (CDC, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8008116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/1/8215?source=see_link\">",
"      see \"Clindamycin (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual dose:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: 8-40 mg/kg/day in 3-4 divided doses; Manufacturer&rsquo;s labeling: 8-20 mg/kg/day (as hydrochloride) or 8-25 mg/kg/day (as palmitate) in 3-4 divided doses; minimum dose of palmitate: 37.5 mg 3 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M., I.V.: Manufacturer&rsquo;s labeling: 20-40 mg/kg/day in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute bacterial rhinosinusitis (unlabeled use):",
"     </b>",
"     Oral: 30-40 mg/kg/day divided every 8 hours with concomitant cefixime or cefpodoxime for 10-14 days.",
"     <b>",
"      Note:",
"     </b>",
"     Recommended in patients with non-type I penicillin allergy, after failure of initial therapy or in patients at risk for antibiotic resistance (eg, daycare attendance, age &lt;2 years, recent hospitalization, antibiotic use within the past month) (Chow, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Anthrax (unlabeled use):",
"     </b>",
"     I.V.: 30 mg/kg/day divided every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Babesiosis (unlabeled use):",
"     </b>",
"     Oral: 20-40 mg/kg divided every 8 hours for 7-10 days",
"     <i>",
"      plus",
"     </i>",
"     quinine (",
"     <i>",
"      Medical Letter",
"     </i>",
"     , 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cellulitis due to MRSA (unlabeled use):",
"     </b>",
"     Oral: 10-13 mg/kg/dose every 6-8 hours for 5-10 days (maximum: 40 mg/kg/day) (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Complicated skin/soft tissue infection due to MRSA (unlabeled use):",
"     </b>",
"     I.V., Oral: 10-13 mg/kg/dose every 6-8 hours for 7-14 days (maximum: 40 mg/kg/day) (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Malaria, severe (unlabeled use):",
"     </b>",
"     I.V.: Load: 10 mg/kg followed by 15 mg/kg/day  divided every 8 hours",
"     <i>",
"      plus",
"     </i>",
"     I.V. quinidine gluconate; switch to oral therapy (clindamycin",
"     <i>",
"      plus",
"     </i>",
"     quinine) when able for total clindamycin treatment duration of 7 days (",
"     <b>",
"      Note:",
"     </b>",
"     Quinine duration is region specific, consult CDC for current recommendations) (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Malaria, uncomplicated treatment (unlabeled use):",
"     </b>",
"     Oral: 20 mg/kg/day divided every 8 hours for 7 days",
"     <i>",
"      plus",
"     </i>",
"     quinine (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Osteomyelitis due to MRSA (unlabeled use):",
"     </b>",
"     I.V., Oral: 10-13 mg/kg/dose every 6-8 hours for a minimum of 4-6 weeks (maximum: 40 mg/kg/day) (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pharyngitis, group A streptococci (IDSA recommendations):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Acute treatment in penicillin-allergic patients:",
"     </i>",
"     21 mg/kg/day divided every 8 hours (maximum: 300 mg per dose) for 10 days (Shulman, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Chronic carrier treatment:",
"     </i>",
"     20-30 mg/kg/day divided every 8 hours (maximum: 300 mg per dose) for 10 days (Shulman, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pneumonia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Community-acquired pneumonia (CAP) (IDSA/PIDS, 2011): Infants &gt;3 months and Children:",
"     <b>",
"      Note:",
"     </b>",
"     In children &ge;5 years, a macrolide antibiotic should be added if atypical pneumonia cannot be ruled out.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Group A",
"     <i>",
"      Streptococcus:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Moderate-to-severe infection (alternative to ampicillin/penicillin): I.V.: 40 mg/kg/day divided every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Mild infection, step-down therapy (alternative to amoxicillin/penicillin): Oral: 40 mg/kg/day divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Presumed bacterial (in addition to recommended antibiotic therapy),",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     moderate-to-severe (MICs to penicillin &le;2.0 mcg/mL) (alternative to ampicillin/penicillin): I.V.: 40 mg/kg/day divided every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      S. pneumoniae:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Moderate-to-severe infection (MICs to penicillin &ge;4.0 mcg/mL) (alternative to ceftriaxone): I.V.: 40 mg/kg/day divided every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Mild infection, step-down therapy (MICs to penicillin &ge;4.0 mcg/mL) (alternative to levofloxacin or linezolid): Oral: 30-40 mg/kg/day divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      S. aureus",
"     </i>",
"     (methicillin-susceptible):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Moderate-to-severe infection (alternative to cefazolin or oxacillin): I.V.:40 mg/kg/day divided every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Mild infection, step-down therapy (alternative to cephalexin): Oral: 30-40 mg/kg/day divided every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      S. aureus",
"     </i>",
"     (methicillin-resistant/clindamycin-susceptible):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Moderate-to-severe infection (preferred): I.V.:40 mg/kg/day divided every 6-8 hours; recommended duration: 7-21 days (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Mild infection, step-down therapy (preferred): Oral: 30-40 mg/kg/day divided every 6-8 hours; recommended duration: 7-21 days (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Healthcare-associated pneumonia (HAP) (methicillin-resistant/clindamycin-susceptible): Children: Oral, I.V.: 30-40 mg/kg/day divided every 6-8 hours for 7-21 days (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis against infective endocarditis (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: 20 mg/kg 30-60 minutes before procedure (Wilson, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M., I.V.: 20 mg/kg 30-60 minutes before procedure. Intramuscular injections should be avoided in patients who are receiving anticoagulant therapy. In these circumstances, orally administered regimens should be given whenever possible. Intravenously administered antibiotics should be used for patients who are unable to tolerate or absorb oral medications. (Wilson, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Septic arthritis due to MRSA (unlabeled use):",
"     </b>",
"     I.V., Oral: 10-13 mg/kg/dose every 6-8 hours for minimum of 3-4 weeks (maximum: 40 mg/kg/day) (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Toxoplasmosis (HIV-exposed/-positive; secondary prevention [unlabeled use]):",
"     </b>",
"     Oral: 20-30 mg/kg/day divided every 6-8 hours (",
"     <i>",
"      plus",
"     </i>",
"     pyrimethamine and leucovorin calcium) (CDC, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8008118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F8008119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required in renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8008120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic use: No adjustment required. Use caution with severe hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8008168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride [strength expressed as base]: 75 mg, 150 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cleocin HCl&reg;: 75 mg, 150 mg [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cleocin HCl&reg;: 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules for solution, oral, as palmitate hydrochloride [strength expressed as base]: 75 mg/5 mL (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cleocin Pediatric&reg;: 75 mg/5 mL (100 mL) [cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W, as phosphate [strength expressed as base]: 300 mg (50 mL); 600 mg (50 mL); 900 mg (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cleocin Phosphate&reg;: 300 mg (50 mL); 600 mg (50 mL); 900 mg (50 mL) [contains edetate disodium]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as phosphate [strength expressed as base]: 150 mg/mL (2 mL, 4 mL, 6 mL, 60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cleocin Phosphate&reg;: 150 mg/mL (2 mL, 4 mL, 6 mL, 60 mL) [contains benzyl alcohol, edetate disodium]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8008035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8008139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Deep I.M. sites, rotate sites; do not exceed 600 mg in a single injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.:",
"     <b>",
"      Never administer as bolus",
"     </b>",
"     ; administer by I.V. intermittent infusion over at least 10-60 minutes, at a rate",
"     <b>",
"      not",
"     </b>",
"     to exceed 30 mg/minute (do not exceed 1200 mg/hour); final concentration for administration should not exceed 18 mg/mL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with a full glass of water to minimize esophageal ulceration; give around-the-clock to promote less variation in peak and trough serum levels.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8008095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     R, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, amifostine, amiodarone, amphotericin B cholesteryl sulfate complex, amsacrine, anakinra, anidulafungin, aztreonam, bivalirudin, caffeine citrate, cisatracurium, cyclophosphamide, cyclosporine, dexmedetomidine, diltiazem, docetaxel, doxorubicin liposome, enalaprilat, esmolol, etoposide phosphate, fenoldopam, fentanyl, fludarabine, foscarnet, gemcitabine, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, labetalol, levofloxacin, linezolid, magnesium sulfate, melphalan, meperidine, midazolam, milrinone, morphine, multivitamins, nicardipine, ondansetron, oxytocin, pemetrexed, piperacillin/tazobactam, propofol, remifentanil, sargramostim, tacrolimus, teniposide, theophylline, thiotepa, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, azithromycin, caspofungin, doxapram, filgrastim, idarubicin, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Drotrecogin alfa, fluconazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Amikacin, aztreonam, caffeine citrate, dimenhydrinate, gentamicin, heparin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ceftriaxone, pantoprazole, tobramycin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8008044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible bacterial infections, mainly those caused by anaerobes, streptococci, pneumococci, and staphylococci; pelvic inflammatory disease (I.V.)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9606387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be useful in PCP; alternate treatment for toxoplasmosis; bacterial vaginosis (oral); alternate treatment for MRSA infections; alternate antibiotic for prophylaxis of infective endocarditis in patients who are allergic to penicillin and undergoing surgical or dental procedures (ACC/AHA guidelines); group B streptococcus (GBS) infection (maternal use for neonatal prophylaxis); treatment of severe or uncomplicated malaria; treatment of babesiosis; treatment of acute bacterial rhinosinusitis (ABRS) (pediatric) (in combination with a third-generation cephalosporin)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8007988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cleocin&reg; may be confused with bleomycin, Clinoril&reg;, Cubicin&reg;, Lincocin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Clindamycin may be confused with clarithromycin, Claritin&reg;, vancomycin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8008065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest (rare; I.V. administration), hypotension (rare; I.V. administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema multiforme (rare), exfoliative dermatitis (rare), pruritus, rash, Stevens-Johnson syndrome (rare), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, esophagitis, nausea, pseudomembranous colitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, eosinophilia (transient), neutropenia (transient), thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice, liver function test abnormalities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Induration/pain/sterile abscess (I.M.), thrombophlebitis (I.V.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Polyarthritis (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Renal dysfunction (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reactions (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8008053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clindamycin, lincomycin, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8008062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Colitis:",
"     <b>",
"      [U.S. Boxed Warning]: Can cause severe and possibly fatal colitis.",
"     </b>",
"     Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment. Use with caution in patients with a history of gastrointestinal disease. Discontinue drug if significant diarrhea, abdominal cramps, or passage of blood and mucus occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; monitor hepatic enzymes periodically as dosage adjustments may be necessary in patients with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Atopic patients: Use with caution in atopic patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Some products may contain benzyl alcohol which has been associated with \"gasping syndrome\" in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tartrazine: Some products may contain tartrazine, which may cause allergic reactions in certain individuals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not appropriate for use in the treatment of meningitis due to inadequate penetration into the CSF.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8008069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Systemic): Lincosamide Antibiotics may diminish the therapeutic effect of Erythromycin (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Kaolin: May decrease the absorption of Lincosamide Antibiotics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Lincosamide Antibiotics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8008089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Peak concentrations may be delayed with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease clindamycin levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8008047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8008048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Clindamycin crosses the placenta throughout pregnancy and at term, but use during pregnancy has not been shown to cause adverse fetal effects. Clindamycin pharmacokinetics are not affected by pregnancy. Clindamycin therapy is recommended in certain pregnant patients for prophylaxis of group B streptococcal disease in newborns, prophylaxis and treatment of",
"     <i>",
"      Toxoplasma gondii",
"     </i>",
"     encephalitis, or for the treatment of",
"     <i>",
"      Pneumocystis",
"     </i>",
"     pneumonia (PCP), bacterial vaginosis, or malaria.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8008050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8008052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of clindamycin transfer to human milk. The manufacturer does not recommend the use of clindamycin during breast-feeding. Nondose-related effects could include modification of bowel flora. One case of bloody stools in an infant occurred after a mother received clindamycin while breast-feeding; however, a casual relationship was not confirmed.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8008122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8008170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Cleocin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $251.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $494.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $1003.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Clindamycin HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (200): $119.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $119.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $371.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cleocin in D5W Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg/50 mL (50 mL): $10.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg/50 mL (50 mL): $15.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     900 mg/50 mL (50 mL): $19.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cleocin Phosphate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9 g/60 mL (60 mL): $114.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg/2 mL (2 mL): $4.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg/4 mL (4 mL): $10.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     900 mg/6 mL (6 mL): $13.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cleocin Phosphate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg/4 mL (4 mL): $10.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     900 mg/6 mL (6 mL): $13.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Clindamycin Phosphate in D5W Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg/50 mL (50 mL): $9.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg/50 mL (50 mL): $14.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     900 mg/50 mL (50 mL): $18.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Clindamycin Phosphate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9 g/60 mL (60 mL): $20.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg/2 mL (2 mL): $3.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg/4 mL (4 mL): $4.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     900 mg/6 mL (6 mL): $5.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Clindamycin Phosphate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg/2 mL (2 mL): $4.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg/4 mL (4 mL): $4.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     900 mg/6 mL (6 mL): $5.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Cleocin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg/5 mL (100 mL): $73.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Clindamycin Palmitate HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg/5 mL (100 mL): $62.03",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8008146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for changes in bowel frequency. Monitor for colitis and resolution of symptoms. During prolonged therapy monitor CBC, liver and renal function tests periodically.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acnocin (TH);",
"     </li>",
"     <li>",
"      Albiotin (ID);",
"     </li>",
"     <li>",
"      Aledo Gel (TW);",
"     </li>",
"     <li>",
"      BB (TW);",
"     </li>",
"     <li>",
"      Chinacin-T (TH);",
"     </li>",
"     <li>",
"      Cleocin HCl (AU, PK, TW);",
"     </li>",
"     <li>",
"      Cleocin T (TR, TW);",
"     </li>",
"     <li>",
"      Clidets (VE);",
"     </li>",
"     <li>",
"      Climadan (ID, SG);",
"     </li>",
"     <li>",
"      Clinacin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Clinbercin (ID);",
"     </li>",
"     <li>",
"      Clincin (TW);",
"     </li>",
"     <li>",
"      Clinda (DE);",
"     </li>",
"     <li>",
"      Clindac-A (IN);",
"     </li>",
"     <li>",
"      Clindacid (PY);",
"     </li>",
"     <li>",
"      Clindacin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, PE, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Clindal (PH);",
"     </li>",
"     <li>",
"      Clindalin (TH);",
"     </li>",
"     <li>",
"      Clindavid (TH);",
"     </li>",
"     <li>",
"      Clinott (TH);",
"     </li>",
"     <li>",
"      Cliz (PH);",
"     </li>",
"     <li>",
"      Dacin (SG);",
"     </li>",
"     <li>",
"      Daklin (PH);",
"     </li>",
"     <li>",
"      Dalacin (CR, DO, GT, HN, NI, PA, SV, TH);",
"     </li>",
"     <li>",
"      Dalacin C (AE, AT, AU, BE, BF, BG, BH, BJ, BR, CH, CI, CL, CN, CO, CY, CZ, DK, EC, EE, EG, ET, GB, GH, GM, GN, GR, HK, ID, IE, IL, IN, IQ, IR, IT, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, NZ, OM, PE, PH, PL, PT, QA, SA, SC, SD, SG, SL, SN, SY, TH, TN, TZ, UG, UY, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Dalacine (FR);",
"     </li>",
"     <li>",
"      Dalaclin (PH);",
"     </li>",
"     <li>",
"      Dalcap (IN);",
"     </li>",
"     <li>",
"      Damicine (CO);",
"     </li>",
"     <li>",
"      Damiclin V (CO);",
"     </li>",
"     <li>",
"      Euroclin (EC);",
"     </li>",
"     <li>",
"      Jutaclin (DE);",
"     </li>",
"     <li>",
"      Klimicin (CZ);",
"     </li>",
"     <li>",
"      Klincyn (PH);",
"     </li>",
"     <li>",
"      Klinda RX (TH);",
"     </li>",
"     <li>",
"      Klindamycin (TH);",
"     </li>",
"     <li>",
"      Lacin (TH);",
"     </li>",
"     <li>",
"      Lanacin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Lando (ID);",
"     </li>",
"     <li>",
"      Librodan (ID);",
"     </li>",
"     <li>",
"      Lindacin (TW);",
"     </li>",
"     <li>",
"      Luoqing (CL);",
"     </li>",
"     <li>",
"      Nildacin (ID);",
"     </li>",
"     <li>",
"      Potecin (PH);",
"     </li>",
"     <li>",
"      Qualiclinda (HK);",
"     </li>",
"     <li>",
"      Tidact (PH, TW);",
"     </li>",
"     <li>",
"      Todacin (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8008096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly binds to 50S ribosomal subunits preventing peptide bond formation thus inhibiting bacterial protein synthesis; bacteriostatic or bactericidal depending on drug concentration, infection site, and organism",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8008098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral, hydrochloride: Rapid (90%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: High concentrations in bone and urine; no significant levels in CSF, even with inflamed meninges",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : ~2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; forms metabolites (variable activity); Clindamycin phosphate is converted to clindamycin HCl (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Neonates: Premature: 8.7 hours; Full-term: 3.6 hours; Children: ~2 hours; Adults: ~2-3 hours; Elderly 4 hours (range: 3.4-5.1 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: Within 60 minutes; I.M.: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (10%) and feces (~4%) as active drug and metabolites",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abramowicz M, &ldquo;Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy",
"      </i>",
"      , 16th ed, New York, NY: Medical Letter, 2002.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Advisory Statement. Antibiotic Prophylaxis for Dental Patients With Total Joint Replacements. American Dental Association; American Academy of Orthopedic Surgeons,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1997, 128(7):1004-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/9231605/pubmed\" id=\"9231605\" target=\"_blank\">",
"        9231605",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/11533352 /pubmed\" id=\"11533352 \" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Dental Association and the American Academy of Orthopaedic Surgeons, \"Antibiotic Prophylaxis for Dental Patients With Total Joint Replacements,\"",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 2003, 134(7):895-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/12892448/pubmed\" id=\"12892448\" target=\"_blank\">",
"        12892448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al.  &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2013, 70(3):195-283.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/23327981/pubmed\" id=\"23327981\" target=\"_blank\">",
"        23327981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Diagnosis and Treatment of Malaria,&rdquo; Available at",
"      <a href=\"file://www.cdc.gov/malaria/diagnosis_treatment/index.html\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/diagnosis_treatment/index.html",
"      </a>",
"      . Last accessed August 26, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(4):1-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/19357635/pubmed\" id=\"19357635\" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Prevention of Perinatal Group B Streptococcal Disease, Revised Guidelines from CDC, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-10):1-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/21088663/pubmed\" id=\"21088663\" target=\"_blank\">",
"        21088663",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Sexually Transmitted Diseases Treatment Guidelines, 2006,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-11):1-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/16888612/pubmed\" id=\"16888612\" target=\"_blank\">",
"        16888612",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(8):e72-112.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/22438350/pubmed\" id=\"22438350\" target=\"_blank\">",
"        22438350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dajani AS, Taubert KA, Wilson W, et al, &ldquo;Prevention of Bacterial Endocarditis. Recommendations by the American Heart Association,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1997, 277(22):1794-801.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/9178793/pubmed\" id=\"9178793\" target=\"_blank\">",
"        9178793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      del Carmen Carrasco-Portugal M, Lujan M, and Flores-Murrieta FJ,  &ldquo;Evaluation of Gender in the Oral Pharmacokinetics of Clindamycin in Humans,&rdquo;",
"      <i>",
"       Biopharm Drug Dispos",
"      </i>",
"      , 2008, 29(7):427-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/18623043/pubmed\" id=\"18623043\" target=\"_blank\">",
"        18623043",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Parasitic Infections,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 2007, 5(suppl):e1-14.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Falagas ME and Gorbach SL, &ldquo;Clindamycin and Metronidazole,&rdquo;",
"      <i>",
"       Med Clin North Am",
"      </i>",
"      , 1995, 79(4):845-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/7791427/pubmed\" id=\"7791427\" target=\"_blank\">",
"        7791427",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hall G, Nord CE, and Heimdahl A, &ldquo;Elimination of Bacteraemia After Dental Extraction: Comparison of Erythromycin and Clindamycin for Prophylaxis of Infective Endocarditis,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1996, 37(4):783-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/8722544/pubmed\" id=\"8722544\" target=\"_blank\">",
"        8722544",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Katlama C, De Wit S, O'Doherty E, et al, &ldquo;Pyrimethamine-Clindamycin vs Pyrimethamine-Sulfadiazine as Acute and Long-Term Therapy for Toxoplasmic Encephalitis in Patients With AIDS,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1996, 22(2):268-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/8838183/pubmed\" id=\"8838183\" target=\"_blank\">",
"        8838183",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipsky BA, Berendt AR, Cornia PB, et al, \"2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(12):e132-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/22619242/pubmed\" id=\"22619242\" target=\"_blank\">",
"        22619242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu C, Bayer A, Cosgrove SE, et al, &ldquo;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      Infections in Adults and Children: Executive Summary,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 52(3):285-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/21217178/pubmed\" id=\"21217178\" target=\"_blank\">",
"        21217178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Luft BJ, Hafner R, Korzun AH, et al, &ldquo;Toxoplasmic Encephalitis in Patients With the Acquired Immunodeficiency Syndrome. Members of the ACTG 077p/ANRS 009 Study Team,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(14):995-1000.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/8366923/pubmed\" id=\"8366923\" target=\"_blank\">",
"        8366923",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2013, 56(1):e1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/23223583/pubmed\" id=\"23223583\" target=\"_blank\">",
"        23223583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Safrin S, Finkelstein DM, Feinberg J, et al, &ldquo;Comparison of Three Regimens for Treatment of Mild-to-Moderate",
"      <i>",
"       Pneumocystis carinii",
"      </i>",
"      Pneumonia in Patients With AIDS. A Double-Blind, Randomized, Trial of Oral Trimethoprim-Sulfamethoxazole, Dapsone-Trimethoprim, and Clindamycin-Primaquine. ACTG 108 Study Group,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1996, 124(9):792-802.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/8610948/pubmed\" id=\"8610948\" target=\"_blank\">",
"        8610948",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman ST, Bisno AL, Clegg HW, et al, &ldquo;Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 55(10):e86-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/22965026/pubmed\" id=\"22965026\" target=\"_blank\">",
"        22965026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smilack JD, Wilson WR, and Cockerill FR 3d, &ldquo;Tetracyclines, Chloramphenicol, Erythromycin, Clindamycin, and Metronidazole,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1991, 66(12):1270-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/1749296/pubmed\" id=\"1749296\" target=\"_blank\">",
"        1749296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Toma E, Thorne A, Singer J, et al, &ldquo;Clindamycin With Primaquine vs Trimethoprim-Sulfamethoxazole Therapy for Mild and Moderately Severe",
"      <i>",
"       Pneumocystis carinii",
"      </i>",
"      Pneumonia in Patients With AIDS: A Multicenter, Double-Blind, Randomized Trial (CTN 004). CTN-PCP Study Group,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1998, 27(3):524-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/9770152/pubmed\" id=\"9770152\" target=\"_blank\">",
"        9770152",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vannier E and Krause PJ, &ldquo;Human Babesiosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(25):2397-2407.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/22716978/pubmed\" id=\"22716978\" target=\"_blank\">",
"        22716978",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/17446442/pubmed\" id=\"17446442\" target=\"_blank\">",
"        17446442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wormser GP, Dattwyler RJ, Shapiro ED, et al, &ldquo;The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2006, 43(9):1089-134.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/17029130/pubmed\" id=\"17029130\" target=\"_blank\">",
"        17029130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wynn RL and Bergman SA, &ldquo;Antibiotics and Their Use in the Treatment of Orofacial Infections, Part I and Part II,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1994, 42(5):398-402, 498-502.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/7489869/pubmed\" id=\"7489869\" target=\"_blank\">",
"        7489869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wynn RL, &ldquo;Clindamycin: An Often Forgotten but Important Antibiotic,&rdquo;",
"      <i>",
"       AGD Impact",
"      </i>",
"      , 1994, 22:10.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yoshikawa TT, &ldquo;Antimicrobial Therapy for the Elderly Patient,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1990, 38(12):1353-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/46/41704/abstract-text/2254575/pubmed\" id=\"2254575\" target=\"_blank\">",
"        2254575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9064 Version 51.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-C38B34FA94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_46_41704=[""].join("\n");
var outline_f40_46_41704=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8007987\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008032\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008033\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008037\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008117\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008116\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008118\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008119\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008120\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008168\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008035\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008139\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008095\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008044\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606387\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8007988\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008065\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008053\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008062\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299057\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008069\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008089\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008047\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008048\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008050\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008052\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008122\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008170\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008146\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961961\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008096\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008098\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9064\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9064|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/49/35604?source=related_link\">",
"      Clindamycin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/1/8215?source=related_link\">",
"      Clindamycin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/46/5862?source=related_link\">",
"      Clindamycin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/21/2389?source=related_link\">",
"      Clindamycin (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/21/38229?source=related_link\">",
"      Clindamycin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_46_41705="Neonatal circumcision: Risks and benefits";
var content_f40_46_41705=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neonatal circumcision: Risks and benefits",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/46/41705/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/46/41705/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/46/41705/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/46/41705/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/46/41705/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/46/41705/contributors\">",
"     Duncan Wilcox, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/46/41705/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/46/41705/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/46/41705/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circumcision in the male refers to the surgical removal of the prepuce (ie, foreskin) of the penis. The procedure is centuries old and continues to be performed for a variety of religious, cultural, and medical reasons.",
"   </p>",
"   <p>",
"    Parents of newborn males often have questions about circumcision: Is it necessary? What are its benefits? What are its risks? In addition to these medical issues, other factors that influence parental decision-making include the father's circumcision status, opinions of family members and friends, a desire for conformity in their son's appearance, and the belief that the circumcised penis is easier to keep clean [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risks and benefits of circumcision will be reviewed here, with the focus on circumcision of neonates. Procedures for neonatal circumcision are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15256?source=see_link\">",
"     \"Techniques for neonatal circumcision\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1841994\">",
"    <span class=\"h2\">",
"     Normal penile development and anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15256?source=see_link&amp;anchor=H2#H2\">",
"     \"Techniques for neonatal circumcision\", section on 'Normal development and anatomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States is the only country in the developed world where the majority of male infants are circumcised for nonreligious reasons. Circumcision rates in the United States vary according to geographic area, socioeconomic status, religious affiliation, insurance coverage, hospital type, and racial and ethnic group. The incidence in 2008 was about 55 to 57 percent based on hospital coding data, but this is probably an underestimate of the true incidence of circumcised males, which is likely closer to 80 percent, due to miscoding and because some circumcisions are performed after hospital discharge or later in life for religious, medical or personal reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/4\">",
"     4",
"    </a>",
"    ]. Circumcision rates are highest in the Midwestern states (74 percent), followed by the Northeastern states (67 percent) and Southern states (61 percent), and are lowest in the Western states (30 percent).",
"   </p>",
"   <p>",
"    The overall incidence of circumcision of healthy newborn male infants appears to have decreased from the 1970s, but the decrease has not been linear: from 1988 to 2000, the rate of circumcision of newborn infants prior to hospital discharge increased by 6.8 percent per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], but then appeared to decrease by about 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Circumcision rates outside of the United States vary widely, from less than 5 percent to over 90 percent of males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no studies that give reliable data about the number of males who are circumcised after birth for elective or surgical indications. An Australian survey found that approximately 18 percent of males who were not circumcised as infants reported that they were circumcised subsequently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents should receive factually correct, nonbiased information about the potential medical benefits and risks of neonatal circumcision and should understand that the procedure is elective. This discussion needs to consider the social, cultural, and religious aspects of the procedure, and the parents&rsquo; personal preferences, which may be more important to them than a decision based on medical benefits alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/1-3,11,12\">",
"     1-3,11,12",
"    </a>",
"    ]. In cross-sectional studies performed in the United States, 40 to 67 percent of parents reported they chose to have their son circumcised because of its hygienic and medical benefits; 23 to 37 percent had the procedure performed for social reasons (eg, father circumcised); and 11 to 19 percent of procedures were performed for religious reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ideally, counseling is provided when parents first begin to consider circumcision, which may be early in pregnancy or before. Written informed consent is obtained prior to the procedure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15256?source=see_link&amp;anchor=H7#H7\">",
"     \"Techniques for neonatal circumcision\", section on 'Informed consent'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Parents who are considering deferring circumcision until their son reaches an age where he can make an informed decision should be informed that circumcision performed in adults has greater risks and costs, more postprocedure discomfort, and a longer recovery period than newborn circumcision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/17\">",
"     17",
"    </a>",
"    ]. It also delays protection from sexually transmitted infections, which is important if the male becomes sexually active before the procedure is performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     POTENTIAL BENEFITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circumcision has been associated with a number of medical benefits, including lower rates of urinary tract infection (UTI), penile cancer, penile inflammation, penile dermatoses, and sexually transmitted infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. A lower rate of UTI is the major benefit during infancy.",
"   </p>",
"   <p>",
"    In the uncircumcised male, the preputial space provides a warm moist environment that both traps pathogens and bodily secretions and is favorable to their survival and replication, while the foreskin itself is susceptible to microabrasions that are thought to facilitate acquisition and transmission of infection. In contrast, the keratinized glans of the circumcised male is thought to create an unfavorable environment for these processes. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Reduction in urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;UTI is uncommon in males at any age. The effect of circumcision on UTI has been studied primarily in infants because they have a higher prevalence of UTI than older males. UTIs in infants can result in pyelonephritis requiring hospitalization and, rarely, septicemia and death. In infants with congenital uropathy, UTI can have serious sequelae, such as renal scarring and lifelong renal insufficiency. If the urinary tract is normal, long-term sequelae from UTI are unlikely.",
"   </p>",
"   <p>",
"    Comparative studies consistently report that circumcised male infants have significantly fewer UTIs than uncircumcised male infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]; however, there are no data from a large randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/22\">",
"     22",
"    </a>",
"    ]. In a systematic review of 12 studies including data on over 400,000 males primarily under 1 year of age, circumcision reduced the risk of UTI by almost 90 percent (OR 0.13, 95% CI 0.08-0.20) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/21\">",
"     21",
"    </a>",
"    ]. Another meta-analysis found that among febrile male infants less than 3 months of age, the prevalence of UTI in circumcised and uncircumcised infants was 2.4 and 20.1 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/20\">",
"     20",
"    </a>",
"    ]. It is estimated that 7 to 14 of 1000 uncircumcised male infants will develop a UTI during the first year of life, compared with 1 to 2 of 1000 circumcised male infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/4\">",
"     4",
"    </a>",
"    ]. As discussed above, long-term sequelae from UTI are unlikely if the urinary tract is normal.",
"   </p>",
"   <p>",
"    There is some evidence that periurethral flora contains fewer pathogens after circumcision than before circumcision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Uncircumcised male infants under 6 months of age have higher numbers of uropathogenic bacteria bound to the mucosal surface of the foreskin and at the urethral meatus than infants who have been circumcised [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/25\">",
"     25",
"    </a>",
"    ]. This colonization probably plays a role in the pathogenesis of urinary infection. However, factors other than circumcision may affect the observed rate of UTI in these reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/26\">",
"     26",
"    </a>",
"    ]. As an example, most hospitalized premature infants are not circumcised. Since premature infants have a higher rate of UTI than term infants, the inclusion of premature infants in a series may confound the data. Other factors that can affect UTI rates include the method of urine collection, type and timing of circumcision, and breastfeeding status (protective effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/27\">",
"     27",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    Adult circumcised men have a lower rate of UTI than uncircumcised men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/28\">",
"     28",
"    </a>",
"    ]. The prevalence of UTIs in uncircumcised adult males increases with age and certain disease states, such as diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15479?source=see_link\">",
"     \"Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/47/26360?source=see_link\">",
"     \"Epidemiology and risk factors for urinary tract infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113620170\">",
"    <span class=\"h3\">",
"     Infants with congenital uropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In male infants with serious congenital uropathies such as high grade vesicoureteral reflux, posterior urethral valves, megaureters, and prune belly syndrome, reduction in urinary tract infections by circumcision may have greater potential benefit. Prospective randomized trials have not been performed, but the retrospective evidence described above supports this hypothesis. In my practice, I tell families that a circumcision has the potential to be beneficial, especially when the baby has an associated uropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Reduction in risk of some cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to uncircumcised men, circumcised men appear to have a lower risk of penile cancer, and their sexual partners may have a lower risk of cervical cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Penile cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squamous cell cancer of the penis is a rare disease. The age-adjusted incidence in the United States is less than 1 per 100,000 males, comparable to that in other developed countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review and meta-analysis found a strong protective effect of",
"    <span class=\"nowrap\">",
"     childhood/adolescent",
"    </span>",
"    circumcision on invasive penile cancer (OR&nbsp;0.33; 95% CI 0.13-0.83; 3 studies) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/32\">",
"     32",
"    </a>",
"    ]. In two studies, the protective effect did not persist when analyses were restricted to boys with no history of phimosis, suggesting at least some of the increased risk of cancer is related to phimosis, which can be the result of poor penile hygiene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/33\">",
"     33",
"    </a>",
"    ]. There was no association between circumcision and penile intraepithelial neoplasia and in situ penile cancer.",
"   </p>",
"   <p>",
"    The number of newborn circumcisions that would need to be performed to prevent one case of penile cancer has been estimated to range from 909 to 322,000, and 2 to 644 complications would be expected per cancer prevented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Given the low risk of penile cancer and the possibly modest reduction in risk with circumcision, it is unclear whether this benefit is clinically important when evaluated against the cost of the procedure and the risk of procedure related complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/13/26840?source=see_link&amp;anchor=H282027087#H282027087\">",
"     \"Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis\", section on 'Risk factors'",
"    </a>",
"    .) Furthermore, these data were obtained prior to widespread use of the human papillomavirus (HPV) vaccine for girls, as well as boys. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=see_link\">",
"     \"Recommendations for the use of human papillomavirus vaccines\"",
"    </a>",
"    .) Vaccination may reduce the prevalence of HPV related disease, diminishing the role of circumcision in prevention of these diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cervical cancer in partners",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cancer is more common in the sexual partners of uncircumcised men. A partial explanation for the link between cervical cancer and lack of male circumcision is that circumcised men have a lower prevalence of HPV infection than uncircumcised men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/37\">",
"     37",
"    </a>",
"    ] and uncircumcised men are more likely to transmit HPV to their partners (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Sexually transmitted infections (not including HIV)'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study that pooled data from 1913 couples enrolled in one of seven case-control studies, circumcised men were less likely than uncircumcised men to have HPV infection (OR 0.37, 95% CI 0.16-0.85 after adjustment of confounders) and male circumcision was associated with a trend for reduced risk of cervical HPV and cervical cancer (OR 0.75, 95% CI 0.49-1.14) in the female partner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/39\">",
"     39",
"    </a>",
"    ]. Among monogamous women, the reduced risk of cervical cancer was statistically significant when the male partner had engaged in high-risk sexual behaviors (early age at first sexual intercourse, a high lifetime number of sexual partners, sexual intercourse with prostitutes) (OR 0.18, 95% CI 0.04-0.89) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31065?source=see_link&amp;anchor=H4#H4\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\", section on 'Overview of HPV infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As discussed above, these data were obtained prior to widespread use of the HPV vaccine for girls, as well as boys. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=see_link\">",
"     \"Recommendations for the use of human papillomavirus vaccines\"",
"    </a>",
"    .) Vaccination may reduce the prevalence of HPV related disease, diminishing the role of circumcision in prevention of these diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case-control studies have reported that circumcised men have a lower rate of prostate cancer than uncircumcised men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. This could be related to multiple confounders; further investigation is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Reduction in penile inflammation and retractile disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;In case series, penile problems are described more often in uncircumcised males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. The best available data were reported by a prospective cohort study of 635 New Zealand boys followed from birth to age 8 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/42\">",
"     42",
"    </a>",
"    ]. The rates of penile inflammation and phimosis were higher in uncircumcised boys (penile inflammation: 14.4 versus 7.6 per 100 boys 0 to 8 years of age; phimosis 3.7 versus 0 per 100 boys 0 to 8 years of age).",
"   </p>",
"   <p>",
"    Properly performed neonatal circumcision prevents phimosis, paraphimosis and balanoposthitis. A reduction in penile inflammatory and retractile disorders is important because, although they can often be treated medically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/45-47\">",
"     45-47",
"    </a>",
"    ], chronic inflammation and repeated forceful retraction may cause scarring and secondary phimosis, which sometimes requires surgical intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/9,10,29,48\">",
"     9,10,29,48",
"    </a>",
"    ]. However, good penile hygiene also may prevent penile inflammatory and retractile disorders, highlighting the importance of teaching uncircumcised boys routine penile care and hygiene. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/18/11559?source=see_link\">",
"     \"Care of the uncircumcised penis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/23/24953?source=see_link\">",
"     \"Balanoposthitis in children: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29302?source=see_link\">",
"     \"Paraphimosis: Definition, pathophysiology, and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Reduction in sexually transmitted infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is high quality evidence that circumcision protects against acquisition of human immunodeficiency virus (HIV), HPV, and probably herpes simplex virus type 2 (HSV-2), and also some evidence that it may protect against trichomonas and chancroid infection, as well. Circumcision does not protect against infection from gonorrhea, chlamydia trachomatis, or syphilis. If only biological factors are considered, it is assumed that the warm, moist environment under the prepuce in uncircumcised men provides more favorable conditions for infection than the circumcised glans.",
"   </p>",
"   <p>",
"    A significant reduction in risk of acquiring sexually transmitted infections is an important medical benefit of circumcision. However, behavioral factors, such as having a small number of sexual partners and consistent, correct use of condoms are probably more important factors than circumcision status for protection against sexually transmissible diseases. In addition, the absolute reduction in sexually transmitted infection depends on the prevalence of these infections in the population, and would be small in populations with a low prevalence of infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35018?source=see_link\">",
"     \"Prevention of sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a systematic review of randomized trials performed in South Africa, Kenya, and Uganda, adult male circumcision reduced the acquisition of HIV by heterosexual men by 38 to 66 percent over 24 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/49\">",
"     49",
"    </a>",
"    ]. Over a dozen observational studies support these findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/4\">",
"     4",
"    </a>",
"    ]. It is presumed, but not proven, that neonatal circumcision would offer a similar benefit.",
"   </p>",
"   <p>",
"    Circumcision may significantly reduce HIV acquisition because the inner aspect of the foreskin appears to be richer in cells with HIV-1 receptors than the glans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Thus, removal of these target cells may reduce, but not eliminate, the risk of acquiring infection when the man is exposed to HIV.",
"   </p>",
"   <p>",
"    In Africa, the lack of circumcision appears to be one of several facilitating factors in HIV seroconversion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/2/13353?source=see_link&amp;anchor=H10#H10\">",
"     \"The stages and natural history of HIV infection\", section on 'Lack of circumcision'",
"    </a>",
"    .) The World Health Organization (WHO) has recommended that circumcision be considered as part of a comprehensive HIV prevention package that includes provision of voluntary HIV testing and counseling services, treatment for sexually transmitted infections, promotion of safer sex practices (delayed initiation of sexual activity, reduced numbers of sexual partners, avoidance of penetrative sex), and provision of male and female condoms and promotion of their correct and consistent use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/53\">",
"     53",
"    </a>",
"    ]. Additional research is required to develop male circumcision programs in resource poor settings, but there is increasing support for circumcision as a part of the preventative public health care plan for the prevention of HIV spread in Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of male circumcision on",
"    <span class=\"nowrap\">",
"     acquisition/transmission",
"    </span>",
"    of HIV in countries with low HIV prevalence is less clear. In particular, the number of male circumcisions that would need to be performed, the number of complications that would result, and the cost to prevent one case of HIV in countries with low HIV prevalence have not been estimated.",
"   </p>",
"   <p>",
"    It is important to remember that circumcision only reduces the risk of acquisition of HIV infection by about half and that there is no strong evidence that circumcised men who are HIV-infected are less likely to transmit the infection to their female or male partners [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/53\">",
"     53",
"    </a>",
"    ]. Consistent, correct use of condoms is highly effective for both preventing acquisition of and transmitting HIV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Sexually transmitted infections (not including HIV)",
"    </span>",
"    &nbsp;&mdash;&nbsp;An embedded study within the randomized South African trial discussed above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/55\">",
"     55",
"    </a>",
"    ] assessed the effect of circumcision on acquisition of high oncogenic risk HPV (HR-HPV), Neisseria gonorrhoeae, and Trichomonas vaginalis infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Urethral swabs and urine samples were analyzed using polymerase chain reaction (PCR).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Male circumcision had a protective effect on HR-HPV prevalence (intention-to-treat analysis, HR-HPV prevalence in the circumcision group 14.8 percent",
"      <span class=\"nowrap\">",
"       [94/637]",
"      </span>",
"      versus 22.3 percent",
"      <span class=\"nowrap\">",
"       [140/627]",
"      </span>",
"      in the control group; RR 0.66, 95% CI 0.51-0.86) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Male circumcision showed a strong trend in reducing the prevalence of trichomonas infection (intention to treat analysis OR 0.54, 95% CI 0.29-1.03), and the reduction became statistically significant in the &ldquo;as treated&rdquo; analysis (OR 0.49, 95% CI 0.25-0.93) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There was no evidence of a protective effect against Neisseria gonorrhoeae infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Ugandan randomized trials of adult male circumcision confirmed and extended these findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/58\">",
"     58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Male circumcision had a protective effect on HR-HPV prevalence (HR-HPV prevalence in the circumcision group 18 percent versus 27.9 percent in the control group; RR 0.65, 95% CI 0.46-0.90).",
"     </li>",
"     <li>",
"      Male circumcision had a protective effect on HSV-2 seroconversion (HSV-2 seroconversion in the circumcision group 7.8 percent versus 10.3 percent in the control group, RR 0.72, 95% CI 0.56-0.92).",
"     </li>",
"     <li>",
"      There was no evidence of a protective effect against syphilis infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies provide strong evidence that circumcision reduces the prevalence of HR-HPV among heterosexual men and explains why women with circumcised partners are at a lower risk of cervical cancer than women without circumcised partners. A systematic review of these studies and others affirmed these findings: circumcision was associated with reduced odds of genital HPV prevalence (OR 0.57, 95% CI 0.42-0.77; 21 studies, 8046 circumcised and 6336 uncircumcised men) and meta-analysis of the two trials discussed above that evaluated high-risk HPV prevalence yielded an odds ratio of 0.67 (95% CI 0.54-0.82) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/37\">",
"     37",
"    </a>",
"    ]. No associations were found between circumcision and genital HPV acquisition of new infections, genital HPV clearance, or genital warts.",
"   </p>",
"   <p>",
"    Based on these data, it appears that circumcision protects the male from some sexually transmitted infections including HIV, HPV, HSV-2, and probably trichomoniasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/55-58\">",
"     55-58",
"    </a>",
"    ]. The relationship between circumcision and chancroid and lymphogranuloma venereum (LGV) is unclear, but the best available data suggest a protective effect on chancroid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/59\">",
"     59",
"    </a>",
"    ] and possibly LGV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. A subsequent randomized trial in Kenya reported genital ulcer disease incidence was halved among circumcised men (RR 0.52, 95% CI 0.37-0.73), but had no effect on the incidence of HSV-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/62\">",
"     62",
"    </a>",
"    ]. A reduction in any infection associated with genital ulcers is important because the presence of these ulcers facilitates",
"    <span class=\"nowrap\">",
"     acquisition/transmission",
"    </span>",
"    of HIV.",
"   </p>",
"   <p>",
"    There is also evidence that urethral Mycoplasma genitalium infection is less prevalent in circumcised men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The balance of evidence does",
"    <strong>",
"     not",
"    </strong>",
"    show a significant relationship between circumcision status and",
"    <span class=\"nowrap\">",
"     acquisition/transmission",
"    </span>",
"    of syphilis, chlamydia trachomatis, or gonorrhea infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/64-69\">",
"     64-69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28875998\">",
"    <span class=\"h3\">",
"     Reduction in sexual transmission of infection to women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Females can benefit from male circumcision, as well. An analysis of the spouses of men enrolled in the Ugandan randomized trial of adult male circumcision for HIV prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/70\">",
"     70",
"    </a>",
"    ] found partners of circumcised men had lower rates of genital ulceration (adjusted prevalence risk ratio [aPRR] 0.78, 95% CI 0.61-0.99), trichomonas infection (aPRR 0.55, 95%CI 0.34-0.89), and bacterial vaginosis (aPRR 0.82, 95% CI 0.74-0.91) than partners of uncircumcised men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/71\">",
"     71",
"    </a>",
"    ]. Possible explanations for these findings are that circumcised men may be less susceptible to",
"    <span class=\"nowrap\">",
"     infection/colonization",
"    </span>",
"    with these organisms or the circumcised penis may be less likely to transmit these organisms than the uncircumcised penis.",
"   </p>",
"   <p>",
"    In contrast, a systematic review and meta-analysis of data from the one randomized trial and six longitudinal analyses provided weak evidence that male circumcision directly reduced the risk of HIV in women (summary RR 0.80, 95% CI 0.53-1.36) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/72\">",
"     72",
"    </a>",
"    ]. However, a definitive conclusion requires more data from randomized trials of circumcision among men infected with HIV in serodiscordant heterosexual relationships. Since this would involve enrolling 10,000 couples, it is not likely to be logistically feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Easier hygiene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Good genital hygiene (washing the entire penis, including the glans, with soap and water while bathing) is important for all males and is generally easier in the absence of a foreskin.",
"   </p>",
"   <p>",
"    Uncircumcised boys should be taught the importance of washing beneath the foreskin on a regular basis when the foreskin is fully retractable. Good hygiene may prevent many problems associated with the foreskin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/33\">",
"     33",
"    </a>",
"    ], but can be difficult to maintain in uncircumcised boys, even in developed countries. Studies of middle class British and Scandinavian schoolboys concluded that penile hygiene is usually not well-maintained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Care of the uncircumcised penis is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/18/11559?source=see_link\">",
"     \"Care of the uncircumcised penis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     POTENTIAL DISADVANTAGES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25561622\">",
"    <span class=\"h2\">",
"     Procedure related complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;An accurate complication rate is difficult to determine, as the largest studies are retrospective and based on coding diagnoses and inconsistent definitions. In addition, data have generally not been stratified to account for timing of the procedure, technique, provider type, setting, length of follow-up, timing of complications, and severity of complications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two studies that included a total of over 200,000 circumcisions performed in US hospitals, the rate of complications during and in the first month after the procedure was approximately 0.2 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/34,35\">",
"       34,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A systematic review identified 16 prospective studies of complications following neonatal and infant circumcision by a variety of providers from 12 countries and primarily using the Plastibell [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/75\">",
"       75",
"      </a>",
"      ]. The median frequency of any adverse event was 1.5 percent (range 0 to 16 percent) and the median frequency of any serious adverse event was 0 percent (range 0 to 2 percent); nine studies reported no serious adverse events, but three studies reported that 1 to 2 percent of boys had a serious complication. Complication rates were slightly lower in 10 retrospective studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Complications/sequelae",
"    </span>",
"    of circumcision are listed below and discussed in more detail separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/50/4903?source=see_link\">",
"     \"Complications of circumcision\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inadequate skin removal, which may result in an unsatisfactory cosmetic appearance and revision of the procedure. This is a common complaint, although the frequency is poorly documented in the literature.",
"     </li>",
"     <li>",
"      Bleeding, which is usually mild and controlled with local pressure, but surgical intervention and transfusion may be required on rare occasions.",
"     </li>",
"     <li>",
"      Infection, which is usually mild and treated by local antibiotics, but sepsis can occur and death has been reported.",
"     </li>",
"     <li>",
"      Urethral complications, including urethrocutaneous fistula and meatal stenosis. Meatal stenosis can occur when urine from a wet diaper irritates the exposed ventral urethral meatus of the circumcised penis.",
"     </li>",
"     <li>",
"      Glans injury, including penile amputation",
"     </li>",
"     <li>",
"      Removal of excessive skin, which may result in a denuded penile shaft",
"     </li>",
"     <li>",
"      Epidermal inclusion cyst",
"     </li>",
"     <li>",
"      Adhesions, which range from mild to dense (also referred to as skin bridges)",
"     </li>",
"     <li>",
"      Cicatrix (a circumferential scar that usually develops at the incision line and is often associated with a hidden penis)",
"     </li>",
"     <li>",
"      Anesthetic complications (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15256?source=see_link&amp;anchor=H8#H8\">",
"       \"Techniques for neonatal circumcision\", section on 'Pain control'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complications are more common among premature newborns, newborns with congenital anomalies, and circumcisions performed after the newborn period or by",
"    <span class=\"nowrap\">",
"     untrained/poorly",
"    </span>",
"    trained providers who may use nonsterile techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Sexual dissatisfaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prepuce contains specialized sensory mucosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/76\">",
"     76",
"    </a>",
"    ]; therefore, the end of the penis may become less sensitive and sexual sensation may be decreased when the foreskin is removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/77\">",
"     77",
"    </a>",
"    ]. However, most circumcised males do not describe psychological trauma or decreased sexual function, sensation, or desire as a result of the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/9,10,78-89\">",
"     9,10,78-89",
"    </a>",
"    ]. The best evidence of the lack of effect of circumcision on sexual satisfaction are two studies that assessed self-reported sexual satisfaction among men enrolled in a randomized trial of adult male circumcision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/84,90\">",
"     84,90",
"    </a>",
"    ]. There was no significant change in sexual satisfaction after the procedure and no change in sexual function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical excision of the foreskin is painful. Although pain control was not provided in the past, safe and effective methods of pain control exist and should be provided to all infants undergoing the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/28,91\">",
"     28,91",
"    </a>",
"    ]. The preferred method is subcutaneous ring or dorsal penile nerve block. Topical anesthetic creams are an acceptable alternative, but should be avoided in infants who are low birth weight because of a higher incidence of skin irritation in this population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15256?source=see_link&amp;anchor=H8#H8\">",
"     \"Techniques for neonatal circumcision\", section on 'Pain control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21682379\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the era before use of anesthesia for circumcision, infants were observed to be less interactive and feed less frequently after the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. This raised concerns that stress, pain, and fatigue related to circumcision may contribute to breastfeeding failure. However, changes in infant behavior do not appear to last longer than 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/93\">",
"     93",
"    </a>",
"    ], and anesthesia reduces procedure-related pain and its sequelae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. A longitudinal birth cohort study that examined the association between neonatal circumcision and breastfeeding found no evidence that neonatal circumcision disrupts exposure to, or outcomes of, breastfeeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OPINIONS OF ORGANIZATIONS AND GROUPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional societies and lay groups have expressed a wide range of views concerning the advantages and disadvantages of routine circumcision. Several pediatric and urologic experts feel that circumcision should be advocated as a prophylactic public health measure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/13,91,97-101\">",
"     13,91,97-101",
"    </a>",
"    ], and there is increasing commentary from the pediatric literature suggesting that male circumcision may be an effective prophylactic intervention for disease prevention in the United States and other countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. On the other hand, small, but vocal, groups have proposed the theory that all men who are circumcised may be emotionally harmed, but are unable to recognize their feelings. Other groups oppose circumcision on a human rights basis, saying the infant is not allowed to decide whether or not he wants to be circumcised and the procedure constitutes genital mutilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/99\">",
"     99",
"    </a>",
"    ]. In 2012, a German court in Cologne ruled that circumcising young boys represents grievous bodily harm, but was overruled by a higher court. Still others believe the procedure decreases sexual pleasure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 1996, the Canadian Paediatric Society (CPS) issued a clinical practice guideline which stated, \"The overall evidence of the benefits and harms of circumcision is so evenly balanced that it does not support recommending circumcision as a routine procedure for newborns\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/104\">",
"       104",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 2012, the",
"      <a class=\"external\" href=\"file://pediatrics.aappublications.org/content/early/2012/08/22/peds.2012-1990\">",
"       American Academy of Pediatrics",
"      </a>",
"      (AAP) task force on circumcision of the male infant concluded that \"the health benefits of newborn male circumcision outweigh the risks; furthermore, the benefits of newborn male circumcision justify access to this procedure for families who choose it. Specific benefits from male circumcision were identified for the prevention of urinary tract infections, acquisition of HIV, transmission of some sexually transmitted infections, and penile cancer. Male circumcision does not appear to adversely affect penile sexual",
"      <span class=\"nowrap\">",
"       function/sensitivity",
"      </span>",
"      or sexual satisfaction&rdquo; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/105\">",
"       105",
"      </a>",
"      ]. Compared to their previous statement, this statement is a stronger affirmation of the health benefits of circumcision. However, the AAP did not recommend routine circumcision. They said &ldquo;Parents should weigh the health benefits and risks in light of their own religious, cultural, and personal preferences, as the medical benefits alone may not outweigh these other considerations for individual families&rdquo; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The American College of Obstetricians and Gynecologists (ACOG) endorsed the conclusions of the AAP discussed above [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 2012, the American Urological Association (AUA) reaffirmed their 2007 policy that stated, &ldquo;The American Urological Association, Inc",
"      <sup>",
"       &reg;",
"      </sup>",
"      (AUA) believes that neonatal circumcision has potential medical benefits and advantages as well as disadvantages and risks&hellip; is generally a safe procedure when performed by an experienced operator&hellip; When circumcision is being discussed with parents and informed consent obtained, medical benefits and risks, and ethnic, cultural, religious and individual preferences should be considered. The risks and disadvantages of circumcision are encountered early whereas the advantages and benefits are prospective&rdquo; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/107\">",
"       107",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, as discussed above (see",
"    <a class=\"local\" href=\"#H14\">",
"     'HIV infection'",
"    </a>",
"    above), the World Health Organization (WHO) has recommended that male circumcision be considered as part of a comprehensive human immunodeficiency virus (HIV) prevention package in Africa and other countries with high HIV prevalence and low rates of male circumcision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/53\">",
"     53",
"    </a>",
"    ]. They stated that a human rights-based approach to promotion of male circumcision requires measures that ensure that the procedure be carried out safely, with informed consent, and without coercion or discrimination, and have published guidance for providing these services [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41705/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/36/29249?source=see_link\">",
"       \"Patient information: Circumcision in baby boys (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/48/41729?source=see_link\">",
"       \"Patient information: Caring for an uncircumcised penis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/5/1107?source=see_link\">",
"       \"Patient information: Circumcision in baby boys (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Male circumcision (removal of the prepuce or foreskin) is almost always an elective procedure performed for religious, cultural, or medical reasons. The prevalence varies across the world. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Background'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parents of newborn males should be provided with accurate, unbiased, written information about the potential risks and benefits of circumcision. This information should be in a language that they understand and they should have the opportunity to discuss this information with the operating practitioner prior to deciding whether or not to have their infant son circumcised. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest neonatal circumcision, as the health benefits of circumcision outweigh the risks (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Benefits of circumcision in men include reduction in the rates of urinary tract infection (UTI), penile cancer, some sexually transmitted infections, penile inflammatory and retractile disorders, as well as easier hygiene. These benefits, which extend over a lifetime, need to be weighed against the potential risks of the circumcision procedure, which are often short-term, and in the context of the low incidence of UTIs and penile cancer in uncircumcised men. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Potential benefits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In Africa, where the prevalence of human immunodeficiency virus (HIV) is high, circumcision of adult men reduced the risk of acquiring HIV infection by 50 to 60 percent. The impact of male circumcision on",
"      <span class=\"nowrap\">",
"       acquisition/transmission",
"      </span>",
"      of HIV in areas of low HIV prevalence is less clear. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'HIV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Circumcision protects the male from some sexually transmitted infections including human papilloma virus (HPV), genital ulcer disease, and probably trichomoniasis. The balance of evidence does not show a significant relationship between circumcision and",
"      <span class=\"nowrap\">",
"       acquisition/transmission",
"      </span>",
"      of syphilis, chlamydia, or gonorrhea infection. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Sexually transmitted infections (not including HIV)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Male circumcision confers benefits to female partners by reductions in cervical cancer and acquisition of some sexually transmitted infections and bacterial vaginosis. (See",
"      <a class=\"local\" href=\"#H28875998\">",
"       'Reduction in sexual transmission of infection to women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Procedure-related complications are uncommon and serious complications are rare. (See",
"      <a class=\"local\" href=\"#H25561622\">",
"       'Procedure related complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Neonatal circumcision. Report 10 of the Council on Scientific Affairs (I-99). www.ama-assn.org/ama/pub/category/13585.html (Accessed on September 14, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/2\">",
"      Waldeck SE. Social norm theory and male circumcision: why parents circumcise. Am J Bioeth 2003; 3:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/3\">",
"      Xu B, Goldman H. Newborn circumcision in Victoria, Australia: reasons and parental attitudes. ANZ J Surg 2008; 78:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/4\">",
"      Blank S, Brady M, Buerk E, et al. Male circumcision. Pediatrics 2012; 130:e756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/5\">",
"      Nelson CP, Dunn R, Wan J, Wei JT. The increasing incidence of newborn circumcision: data from the nationwide inpatient sample. J Urol 2005; 173:978.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov/nchs/products/pubs/pubd/hestats/circumcisions/circumcisions.htm (Accessed on September 07, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Trends in in-hospital newborn male circumcision--United States, 1999-2010. MMWR Morb Mortal Wkly Rep 2011; 60:1167.",
"     </a>",
"    </li>",
"    <li>",
"     Halperin DT, Timberg C. Update of chart in 'Male Circumcision and HIV Prevention: 10 Years and Counting' Circs.org. 2012; available at: file://www.circs.org/library/HalperinTimberg",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/9\">",
"      Badger, J. Circumcision. What you think. Australian Forum 1989; 2:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/10\">",
"      Badger, J. The great circumcision report part 2. Australian Forum 1989; 2:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/11\">",
"      Binner SL, Mastrobattista JM, Day MC, et al. Effect of parental education on decision-making about neonatal circumcision. South Med J 2002; 95:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/12\">",
"      Wang ML, Macklin EA, Tracy E, et al. Updated parental viewpoints on male neonatal circumcision in the United States. Clin Pediatr (Phila) 2010; 49:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/13\">",
"      Adler R, Ottaway MS, Gould S. Circumcision: we have heard from the experts; now let's hear from the parents. Pediatrics 2001; 107:E20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/14\">",
"      Tiemstra JD. Factors affecting the circumcision decision. J Am Board Fam Pract 1999; 12:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/15\">",
"      Walton RE, Ostbye T, Campbell MK. Neonatal male circumcision after delisting in Ontario. Survey of new parents. Can Fam Physician 1997; 43:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/16\">",
"      Turini GA 3rd, Reinert SE, McQuiston LD, Caldamone AA. Circumcision: a study of current parental decision-making. Med Health R I 2006; 89:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/17\">",
"      Morris BJ, Waskett JH, Banerjee J, et al. A 'snip' in time: what is the best age to circumcise? BMC Pediatr 2012; 12:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/18\">",
"      Mallon E, Hawkins D, Dinneen M, et al. Circumcision and genital dermatoses. Arch Dermatol 2000; 136:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/19\">",
"      Malone P, Steinbrecher H. Medical aspects of male circumcision. BMJ 2007; 335:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/20\">",
"      Shaikh N, Morone NE, Bost JE, Farrell MH. Prevalence of urinary tract infection in childhood: a meta-analysis. Pediatr Infect Dis J 2008; 27:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/21\">",
"      Singh-Grewal D, Macdessi J, Craig J. Circumcision for the prevention of urinary tract infection in boys: a systematic review of randomised trials and observational studies. Arch Dis Child 2005; 90:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/22\">",
"      Jagannath VA, Fedorowicz Z, Sud V, et al. Routine neonatal circumcision for the prevention of urinary tract infections in infancy. Cochrane Database Syst Rev 2012; 11:CD009129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/23\">",
"      G&uuml;n��ar C, Kurutepe S, Alparslan O, et al. The effect of circumcision status on periurethral and glanular bacterial flora. Urol Int 2004; 72:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/24\">",
"      Aridogan IA, Ilkit M, Izol V, et al. Glans penis and prepuce colonisation of yeast fungi in a paediatric population: pre- and postcircumcision results. Mycoses 2009; 52:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/25\">",
"      Wiswell TE, Miller GM, Gelston HM Jr, et al. Effect of circumcision status on periurethral bacterial flora during the first year of life. J Pediatr 1988; 113:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/26\">",
"      Circumcision policy statement. American Academy of Pediatrics. Task Force on Circumcision. Pediatrics 1999; 103:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/27\">",
"      Pisacane A, Graziano L, Mazzarella G, et al. Breast-feeding and urinary tract infection. J Pediatr 1992; 120:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/28\">",
"      Spach DH, Stapleton AE, Stamm WE. Lack of circumcision increases the risk of urinary tract infection in young men. JAMA 1992; 267:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/29\">",
"      Fakjian N, Hunter S, Cole GW, Miller J. An argument for circumcision. Prevention of balanitis in the adult. Arch Dermatol 1990; 126:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/30\">",
"      Barnholtz-Sloan JS, Maldonado JL, Pow-sang J, et al. Incidence trends in primary malignant penile cancer. Urol Oncol 2007; 25:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/31\">",
"      Frisch M, Friis S, Kjaer SK, Melbye M. Falling incidence of penis cancer in an uncircumcised population (Denmark 1943-90). BMJ 1995; 311:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/32\">",
"      Larke NL, Thomas SL, dos Santos Silva I, Weiss HA. Male circumcision and penile cancer: a systematic review and meta-analysis. Cancer Causes Control 2011; 22:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/33\">",
"      Krueger H, Osborn L. Effects of hygiene among the uncircumcised. J Fam Pract 1986; 22:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/34\">",
"      Wiswell TE, Geschke DW. Risks from circumcision during the first month of life compared with those for uncircumcised boys. Pediatrics 1989; 83:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/35\">",
"      Christakis DA, Harvey E, Zerr DM, et al. A trade-off analysis of routine newborn circumcision. Pediatrics 2000; 105:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/36\">",
"      Learman LA. Neonatal circumcision: a dispassionate analysis. Clin Obstet Gynecol 1999; 42:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/37\">",
"      Albero G, Castellsagu&eacute; X, Giuliano AR, Bosch FX. Male circumcision and genital human papillomavirus: a systematic review and meta-analysis. Sex Transm Dis 2012; 39:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/38\">",
"      Aynaud O, Piron D, Bijaoui G, Casanova JM. Developmental factors of urethral human papillomavirus lesions: correlation with circumcision. BJU Int 1999; 84:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/39\">",
"      Castellsagu&eacute; X, Bosch FX, Mu&ntilde;oz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002; 346:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/40\">",
"      Ross RK, Shimizu H, Paganini-Hill A, et al. Case-control studies of prostate cancer in blacks and whites in southern California. J Natl Cancer Inst 1987; 78:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/41\">",
"      Ewings P, Bowie C. A case-control study of cancer of the prostate in Somerset and east Devon. Br J Cancer 1996; 74:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/42\">",
"      Fergusson DM, Lawton JM, Shannon FT. Neonatal circumcision and penile problems: an 8-year longitudinal study. Pediatrics 1988; 81:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/43\">",
"      Herzog LW, Alvarez SR. The frequency of foreskin problems in uncircumcised children. Am J Dis Child 1986; 140:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/44\">",
"      Kaplan GW. Complications of circumcision. Urol Clin North Am 1983; 10:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/45\">",
"      DeVries CR, Miller AK, Packer MG. Reduction of paraphimosis with hyaluronidase. Urology 1996; 48:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/46\">",
"      Wright JE. The treatment of childhood phimosis with topical steroid. Aust N Z J Surg 1994; 64:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/47\">",
"      Ashfield JE, Nickel KR, Siemens DR, et al. Treatment of phimosis with topical steroids in 194 children. J Urol 2003; 169:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/48\">",
"      Stenram A, Malmfors G, Okmian L. Circumcision for phimosis--indications and results. Acta Paediatr Scand 1986; 75:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/49\">",
"      Siegfried N, Muller M, Deeks JJ, Volmink J. Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev 2009; :CD003362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/50\">",
"      McCoombe SG, Short RV. Potential HIV-1 target cells in the human penis. AIDS 2006; 20:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/51\">",
"      Donoval BA, Landay AL, Moses S, et al. HIV-1 target cells in foreskins of African men with varying histories of sexually transmitted infections. Am J Clin Pathol 2006; 125:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/52\">",
"      Patterson BK, Landay A, Siegel JN, et al. Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol 2002; 161:867.",
"     </a>",
"    </li>",
"    <li>",
"     UNAIDS. Safe, voluntary, informed male circumcision and comprehensive HIV prevention programming. March 2008. (Accessed December 15, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/54\">",
"      Katz IT, Wright AA. Circumcision--a surgical strategy for HIV prevention in Africa. N Engl J Med 2008; 359:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/55\">",
"      Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2:e298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/56\">",
"      Auvert B, Sobngwi-Tambekou J, Cutler E, et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis 2009; 199:14.",
"     </a>",
"    </li>",
"    <li>",
"     Auvert, B, Sobngwi-Tambekou, J, Puren, A, et al. Effect of male circumcision on human papilloma virus, neisseria gonorrhoeae and trichomonas vaginalis infections in men: results from a randomized controlled trial (abstract). Presented at the XVII international AIDS conference. August 2008, Mexico City. available at www.aids2008.org/Pag/Abstracts.aspx?SID=288&amp;AID=15881.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/58\">",
"      Tobian AA, Serwadda D, Quinn TC, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009; 360:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/59\">",
"      Weiss HA, Thomas SL, Munabi SK, Hayes RJ. Male circumcision and risk of syphilis, chancroid, and genital herpes: a systematic review and meta-analysis. Sex Transm Infect 2006; 82:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/60\">",
"      Van Howe RS. Genital ulcerative disease and sexually transmitted urethritis and circumcision: a meta-analysis. Int J STD AIDS 2007; 18:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/61\">",
"      Langeni T. Male circumcision and sexually transmitted infections in Botswana. J Biosoc Sci 2005; 37:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/62\">",
"      Mehta SD, Moses S, Parker CB, et al. Circumcision status and incident herpes simplex virus type 2 infection, genital ulcer disease, and HIV infection. AIDS 2012; 26:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/63\">",
"      Mehta SD, Gaydos C, Maclean I, et al. The effect of medical male circumcision on urogenital Mycoplasma genitalium among men in Kisumu, Kenya. Sex Transm Dis 2012; 39:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/64\">",
"      Dickson NP, van Roode T, Herbison P, Paul C. Circumcision and risk of sexually transmitted infections in a birth cohort. J Pediatr 2008; 152:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/65\">",
"      Gray R, Azire J, Serwadda D, et al. Male circumcision and the risk of sexually transmitted infections and HIV in Rakai, Uganda. AIDS 2004; 18:2428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/66\">",
"      Diseker RA 3rd, Peterman TA, Kamb ML, et al. Circumcision and STD in the United States: cross sectional and cohort analyses. Sex Transm Infect 2000; 76:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/67\">",
"      Mattson CL, Campbell RT, Bailey RC, et al. Risk compensation is not associated with male circumcision in Kisumu, Kenya: a multi-faceted assessment of men enrolled in a randomized controlled trial. PLoS One 2008; 3:e2443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/68\">",
"      Talukdar A, Khandokar MR, Bandopadhyay SK, Detels R. Risk of HIV infection but not other sexually transmitted diseases is lower among homeless Muslim men in Kolkata. AIDS 2007; 21:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/69\">",
"      Reynolds SJ, Shepherd ME, Risbud AR, et al. Male circumcision and risk of HIV-1 and other sexually transmitted infections in India. Lacnet 2004; 363:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/70\">",
"      Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/71\">",
"      Gray RH, Kigozi G, Serwadda D, et al. The effects of male circumcision on female partners' genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda. Am J Obstet Gynecol 2009; 200:42.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/72\">",
"      Weiss HA, Hankins CA, Dickson K. Male circumcision and risk of HIV infection in women: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/73\">",
"      Oster J. Further fate of the foreskin. Incidence of preputial adhesions, phimosis, and smegma among Danish schoolboys. Arch Dis Child 1968; 43:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/74\">",
"      Kalcev, B. Circumcision and personal hygiene in school boys. Med Officer 1964; 122:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/75\">",
"      Weiss HA, Larke N, Halperin D, Schenker I. Complications of circumcision in male neonates, infants and children: a systematic review. BMC Urol 2010; 10:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/76\">",
"      Taylor JR, Lockwood AP, Taylor AJ. The prepuce: specialized mucosa of the penis and its loss to circumcision. Br J Urol 1996; 77:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/77\">",
"      Boyle GJ, Bensley GA. Adverse sexual and psychological effects of male infant circumcision. Psychol Rep 2001; 88:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/78\">",
"      Laumann EO, Masi CM, Zuckerman EW. Circumcision in the United States. Prevalence, prophylactic effects, and sexual practice. JAMA 1997; 277:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/79\">",
"      Schlossberger NM, Turner RA, Irwin CE Jr. Early adolescent knowledge and attitudes about circumcision: methods and implications for research. J Adolesc Health 1992; 13:293.",
"     </a>",
"    </li>",
"    <li>",
"     Masters WH, Johnson VE. Human Sexual Response, Little, Brown and Company, Boston 1966.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/81\">",
"      Fink KS, Carson CC, DeVellis RF. Adult circumcision outcomes study: effect on erectile function, penile sensitivity, sexual activity and satisfaction. J Urol 2002; 167:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/82\">",
"      Collins S, Upshaw J, Rutchik S, et al. Effects of circumcision on male sexual function: debunking a myth? J Urol 2002; 167:2111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/83\">",
"      Payne K, Thaler L, Kukkonen T, et al. Sensation and sexual arousal in circumcised and uncircumcised men. J Sex Med 2007; 4:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/84\">",
"      Kigozi G, Watya S, Polis CB, et al. The effect of male circumcision on sexual satisfaction and function, results from a randomized trial of male circumcision for human immunodeficiency virus prevention, Rakai, Uganda. BJU Int 2008; 101:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/85\">",
"      Bleustein CB, Fogarty JD, Eckholdt H, et al. Effect of neonatal circumcision on penile neurologic sensation. Urology 2005; 65:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/86\">",
"      Senol MG, Sen B, Karademir K, et al. The effect of male circumcision on pudendal evoked potentials and sexual satisfaction. Acta Neurol Belg 2008; 108:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/87\">",
"      Waldinger MD, Quinn P, Dilleen M, et al. A multinational population survey of intravaginal ejaculation latency time. J Sex Med 2005; 2:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/88\">",
"      Senkul T, I��erI C, ��en B, et al. Circumcision in adults: effect on sexual function. Urology 2004; 63:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/89\">",
"      Richters J, Smith AM, de Visser RO, et al. Circumcision in Australia: prevalence and effects on sexual health. Int J STD AIDS 2006; 17:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/90\">",
"      Krieger JN, Mehta SD, Bailey RC, et al. Adult male circumcision: effects on sexual function and sexual satisfaction in Kisumu, Kenya. J Sex Med 2008; 5:2610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/91\">",
"      Schoen EJ, Wiswell TE, Moses S. Reply to Carole M. Lannon and the task force on circumcision. Pediatrics 2001; 108:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/92\">",
"      Howard CR, Howard FM, Weitzman ML. Acetaminophen analgesia in neonatal circumcision: the effect on pain. Pediatrics 1994; 93:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/93\">",
"      Marshall RE, Porter FL, Rogers AG, et al. Circumcision: II. Effects upon mother-infant interaction. Early Hum Dev 1982; 7:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/94\">",
"      Brady-Fryer B, Wiebe N, Lander JA. Pain relief for neonatal circumcision. Cochrane Database Syst Rev 2004; :CD004217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/95\">",
"      Dixon S, Snyder J, Holve R, Bromberger P. Behavioral effects of circumcision with and without anesthesia. J Dev Behav Pediatr 1984; 5:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/96\">",
"      Fergusson DM, Boden JM, Horwood LJ. Neonatal circumcision: effects on breastfeeding and outcomes associated with breastfeeding. J Paediatr Child Health 2008; 44:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/97\">",
"      Weiss GN, Weiss EB. A perspective on controversies over neonatal circumcision. Clin Pediatr (Phila) 1994; 33:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/98\">",
"      Schoen EJ. The status of circumcision of newborns. N Engl J Med 1990; 322:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/99\">",
"      Poland RL. The question of routine neonatal circumcision. N Engl J Med 1990; 322:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/100\">",
"      Schoen EJ, Wiswell TE, Moses S. New policy on circumcision--cause for concern. Pediatrics 2000; 105:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/101\">",
"      Weiss GN. Prophylactic neonatal surgery and infectious diseases. Pediatr Infect Dis J 1997; 16:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/102\">",
"      Flynn P, Havens P, Brady M, et al. Male circumcision for prevention of HIV and other sexually transmitted diseases. Pediatrics 2007; 119:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/103\">",
"      Dickerman JD, American Academy of Pediatrics. Circumcision in the time of HIV: when is there enough evidence to revise the American Academy of Pediatrics' policy on circumcision? Pediatrics 2007; 119:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/104\">",
"      Neonatal circumcision revisited. Fetus and Newborn Committee, Canadian Paediatric Society. CMAJ 1996; 154:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41705/abstract/105\">",
"      American Academy of Pediatrics Task Force on Circumcision. Circumcision policy statement. Pediatrics 2012; 130:585.",
"     </a>",
"    </li>",
"    <li>",
"     The American College of Obstetricians and Gynecologists Endorses AAP Policy Statement on Circumcision. file://www.aap.org/en-us/about-the-aap/aap-press-room/Pages/New-Benefits-Point-to-Greater-Benefits-of-Infant-Circumcision-But-Final-Say-is-Still-Up-to-parents-Says-AAP.aspx?nfstatus=401&amp;nftoken=00000000-0000-0000-0000-000000000000&amp;nfstatusdescription=ERROR%3a+No+local+token (Accessed on August 28, 2012).",
"    </li>",
"    <li>",
"     American Urological Association. Circumcision file://www.auanet.org/content/aua-policies/policy-statements/c/circumcision.cfm (Accessed on April 15, 2013).",
"    </li>",
"    <li>",
"     World Health Organization. Male circumcision quality assurance: a guide to enhancing the safety and quality of services. 2008",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6716 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.123.134.1-8BED796ECD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_46_41705=[""].join("\n");
var outline_f40_46_41705=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1841994\">",
"      Normal penile development and anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      POTENTIAL BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Reduction in urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H113620170\">",
"      - Infants with congenital uropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Reduction in risk of some cancers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Penile cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cervical cancer in partners",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Reduction in penile inflammation and retractile disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Reduction in sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - HIV infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Sexually transmitted infections (not including HIV)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28875998\">",
"      - Reduction in sexual transmission of infection to women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Easier hygiene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      POTENTIAL DISADVANTAGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25561622\">",
"      Procedure related complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Sexual dissatisfaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21682379\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OPINIONS OF ORGANIZATIONS AND GROUPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15479?source=related_link\">",
"      Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/23/24953?source=related_link\">",
"      Balanoposthitis in children: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/13/26840?source=related_link\">",
"      Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/18/11559?source=related_link\">",
"      Care of the uncircumcised penis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31065?source=related_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/50/4903?source=related_link\">",
"      Complications of circumcision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/47/26360?source=related_link\">",
"      Epidemiology and risk factors for urinary tract infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29302?source=related_link\">",
"      Paraphimosis: Definition, pathophysiology, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/48/41729?source=related_link\">",
"      Patient information: Caring for an uncircumcised penis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/5/1107?source=related_link\">",
"      Patient information: Circumcision in baby boys (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/36/29249?source=related_link\">",
"      Patient information: Circumcision in baby boys (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35018?source=related_link\">",
"      Prevention of sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15256?source=related_link\">",
"      Techniques for neonatal circumcision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/2/13353?source=related_link\">",
"      The stages and natural history of HIV infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_46_41706="Cardiotoxicity of anthracycline-like chemotherapy agents";
var content_f40_46_41706=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiotoxicity of anthracycline-like chemotherapy agents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/46/41706/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/46/41706/contributors\">",
"     Justin Floyd, DO",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/46/41706/contributors\">",
"     James P Morgan, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/46/41706/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/46/41706/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/46/41706/contributors\">",
"     David G Poplack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/46/41706/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/46/41706/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/46/41706/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/46/41706/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer patients who are undergoing chemotherapy have an increased risk of developing cardiovascular complications, and the risk is even greater if there is a known history of heart disease. Among the serious clinical cardiac complications that have been reported are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Arrhythmias",
"     </li>",
"     <li>",
"      Myocardial necrosis causing a dilated cardiomyopathy",
"     </li>",
"     <li>",
"      Vasoocclusion or vasospasm resulting in angina or myocardial infarction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A wide range of chemotherapy agents have been associated with cardiotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The anthracyclines and related compounds (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    , and the anthraquinone",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    ) are some of the most frequently implicated agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiotoxicity associated with anthracyclines will be reviewed here. Cardiovascular complications of other classes of chemotherapy agents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=see_link\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42232?source=see_link\">",
"     \"Cardiotoxicity of trastuzumab\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the initial trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    , chemotherapy-induced myelosuppression was usually a dose-limiting factor, thereby preventing the administration of sufficiently high doses to cause cardiotoxicity. With the emergence of more intensive regimens and better supportive care, cardiomyopathy and heart failure were recognized as complications of prolonged treatment. The development of noninvasive monitoring techniques allowed the recognition of subclinical toxicity in a much larger number of patients exposed to anthracyclines.",
"   </p>",
"   <p>",
"    Anthracycline cardiotoxicity can be divided into",
"    <span class=\"nowrap\">",
"     acute/subacute",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     late/chronic:",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Acute/subacute",
"      </span>",
"      cardiovascular complications can arise any time from the initiation of therapy to several weeks after treatment termination:",
"     </li>",
"     <li>",
"      Chronic cardiotoxicity, which is typically manifested as clinical heart failure or subclinical decline in myocardial function, may present early, within one year after termination of chemotherapy, or late-delayed, becoming evident beyond one year posttreatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of its timing, chronic cardiomyopathy generally begins as asymptomatic diastolic or systolic dysfunction, and progresses to heart failure, which may be fatal. (See",
"    <a class=\"local\" href=\"#H292515\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The incidence of chronic cardiotoxicity is most closely related to the cumulative dose of anthracycline administered. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A variety of approaches have been taken to decrease the risk of cardiotoxicity while maintaining efficacy. These include altered schedules of drug administration, modifications of the anthracycline molecule, and adjunctive treatment with beta-adrenergic blockers or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Approaches for reducing the risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    None of these approaches have been completely successful, and patients who have received anthracyclines remain at risk for the development of cardiomyopathy, particularly with higher cumulative doses. Long-term monitoring is required for optimal medical management. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Pretreatment assessment and subsequent monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16386025\">",
"    <span class=\"h1\">",
"     ACUTE TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute or subacute cardiotoxicity may present as electrocardiographic abnormalities, arrhythmias (both supraventricular and ventricular), heart block (including Mobitz type II second degree AV block and complete heart block), ventricular dysfunction, an increase in plasma brain natriuretic peptide (a marker of increased cardiac filling pressures and heart failure), or a pericarditis-myocarditis syndrome (particularly with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/3-13\">",
"     3-13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Brain natriuretic peptide'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overall, acute cardiotoxicity is a relatively uncommon event. In a German cohort of 1697 patients receiving a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -based regimen for lymphoma, 55 (3.2 percent) developed acute cardiac side effects, which included atrial fibrillation (n = 12), acute heart failure (n = 5), myocarditis (n = 2), and myocardial infarction (n = 1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/9\">",
"     9",
"    </a>",
"    ]. Most of these events are not life-threatening and they resolve within one week. Cardiovascular monitoring is not typically recommended or required during anthracycline administration in patients with normal ventricular function by history, physical examination, or noninvasive studies.",
"   </p>",
"   <p>",
"    Higher rates were of subacute toxicity have been reported in studies of elderly patients receiving CHOP or a CHOP-like regimen for treatment of lymphoma; in two such studies, rates of cardiotoxicity (decline in LVEF, atrial fibrillation, acute pulmonary edema, cardiac ischemia) during chemotherapy were 11 and 21 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Some studies suggest that acute myocardial injury can be used to predict the future development and severity of ventricular dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/16\">",
"     16",
"    </a>",
"    ]. However, the relationship between acute toxicity and the subsequent development of chronic cardiotoxicity is unclear. Additional clinical trials are required to determine if blocking acute toxicity (eg, through use of an angiotensin II receptor blocker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/5\">",
"     5",
"    </a>",
"    ]) decreases the risk of subsequently developing early or late cardiotoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16386125\">",
"    <span class=\"h1\">",
"     CHRONIC CARDIOTOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiomyopathy, the manifestation of chronic cardiotoxicity, is a dose-limiting side effect of anthracyclines. The magnitude of excess risk attributed to use of anthracyclines was shown in a meta-analysis of eight trials comparing an anthracycline-containing versus a non-anthracycline-containing chemotherapy regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/17\">",
"     17",
"    </a>",
"    ]. Use of anthracyclines was associated with a significantly increased risk of both clinical (odds ratio [OR] 5.43, 95% CI 2.34-12.62) and subclinical cardiotoxicity (OR 6.25, 95% CI 2.58-15.13). An analysis of four studies also showed that the rate of cardiac-related deaths, though infrequent, was also significantly higher when an anthracycline was used (OR 4.94, 95% CI 1.23-19.87).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H292515\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, chronic anthracycline-related cardiotoxicity typically presents early, within one year after termination of chemotherapy. The peak time for the appearance of symptoms of heart failure is about three months after the last anthracycline dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Mortality in these early series was high (60 percent); more recently, survival in patients who develop heart failure has improved due to more aggressive medical management, including the availability of medications such as angiotensin converting enzyme (ACE) inhibitors and beta blockers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The onset of symptomatic heart failure can occur more than a decade after the last anthracycline dose. In adults,",
"    <span class=\"nowrap\">",
"     late/delayed",
"    </span>",
"    toxicity is primarily of concern in clinical situations where anthracyclines are used as part of a curative or adjuvant regimen. &nbsp;",
"   </p>",
"   <p>",
"    Late toxicity has been seen in survivors of childhood malignancy treated with an anthracycline. In this setting, late heart failure is usually manifest as a nonischemic dilated cardiomyopathy, but a substantial number of survivors have subclinical cardiac dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In one study, 5 of 115 children exposed to anthracycline developed overt heart failure within 11 years after completion of therapy; 57 percent had echocardiographic evidence of impaired LV function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Issues in children'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The risk seems lower in adults, particularly in women who received adjuvant anthracycline therapy with cumulative doses &lt;300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for early stage breast cancer. Other causes of heart failure should be sought in adults who develop a late cardiomyopathy. An important caveat is that the relationship of remote cardiac events to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    may be difficult to discern in breast cancer survivors, and this may have led to an underreporting of events in the literature. Thus, anthracycline-induced cardiomyopathy is always a possibility. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41496?source=see_link\">",
"     \"Acute side effects of adjuvant chemotherapy for early stage breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of late heart failure also appears to be increased in elderly women who are treated with adjuvant chemotherapy containing anthracyclines, compared to those receiving chemotherapy without anthracyclines and those not given chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13226?source=see_link\">",
"     \"General principles on the treatment of early stage and locally advanced breast cancer in older women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of its timing, chronic cardiomyopathy generally begins with asymptomatic diastolic or systolic dysfunction, and progresses to clinical heart failure, which may be fatal. Although treatable, cumulative cardiotoxicity is a result of permanent loss of cardiomyocytes and is generally not reversible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although anthracycline-related cardiotoxicity is a well-known adverse effect of this drug class, its underlying mechanism has been difficult to elucidate. Myocyte damage has previously been attributed to the production of toxic oxygen free radicals and an increase in oxidative stress, which cause lipid peroxidation of membranes, leading to vacuolation, irreversible damage, and myocyte replacement by fibrous tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. However, the &ldquo;reactive oxygen species&rdquo; hypothesis has been called into question by studies in which treatment with a scavenger of reactive oxygen species has failed to prevent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -related cardiotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/3,27\">",
"     3,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, more recent data implicate the topoisomerase-II (Top2) enzyme. In cancer cells,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    &rsquo;s cellular target is the enzyme Top2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/28\">",
"     28",
"    </a>",
"    ]. Doxorubicin binds both Top2 and DNA to form the ternary Top2-doxorubicin-DNA cleavage complex, which triggers cell death. There are two Top2 enzymes, Top2-alpha and Top2-beta. Top2-alpha is a known marker of cellular proliferation and overexpressed in tumors but not in quiescent tissues; it is thought to represent the molecular basis of doxorubicin antitumor activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adult mammalian cardiomyocytes express Top2-beta, but not alpha [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/30\">",
"     30",
"    </a>",
"    ]. However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    also interacts with Top2-beta, and the Top2-beta-doxorubicin-DNA complex can induce DNA double strand breaks, leading to cell death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/31\">",
"     31",
"    </a>",
"    ]. The hypothesis that doxorubicin-mediated cardiomyopathy is mediated by Top2-beta in cardiomyocytes is supported by murine studies showing that cardiomyocyte-specific deletion of the gene",
"    <em>",
"     Top2b",
"    </em>",
"    (which encodes the Top2-beta enzyme) protects cardiomyocytes from doxorubicin-induced DNA double strand breaks and transcriptome changes that are responsible for the formation of reactive oxygen species, and protects mice from the development of doxorubicin-induced progressive heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of risk factors for the development of chronic anthracycline cardiotoxicity have been identified. The strongest predictor is cumulative dose. However, age at the time of drug exposure, concomitant administration of other cardiotoxic chemotherapeutic agents (particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    ), concurrent or prior chest irradiation, and preexisting cardiovascular disease (including coronary artery disease, hypertension, peripheral vascular disease, diabetes) are also well-recognized risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/3,18,19,33,34\">",
"     3,18,19,33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Longer duration of survival is also a risk factor for cardiac toxicity, emphasizing the importance of monitoring for long-term effects in the growing population of cancer survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/34\">",
"     34",
"    </a>",
"    ]. Pediatric studies indicate a continuous deterioration of cardiac function for up to 30 years after treatment. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Issues in children'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Cumulative dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of anthracycline-related cardiotoxicity is strongly correlated to cumulative dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/19\">",
"     19",
"    </a>",
"    ]. As an example, in one study of 3941 patients treated with anthracyclines, 88 developed symptomatic heart failure during follow-up, and the incidence ranged from 0.14 percent in those who received &lt;400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    to 7 percent of those who received 550",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    and 18 percent beyond 700",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent data suggested that the incidence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -related cardiotoxicity was underestimated in these studies. A report of 630 patients treated with doxorubicin alone in three controlled trials estimated that as many as 26 percent of patients receiving a cumulative doxorubicin dose of 550",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    would develop heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these observations, it has been generally recommended that cumulative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    doses be limited to 450 to 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    in adults. However, there is variable sensitivity to anthracyclines among patients, with some tolerating doses as high as 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    and others experiencing cardiotoxicity at doses lower that 300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/7\">",
"     7",
"    </a>",
"    ]. The factors that determine interindividual variability in sensitivity to the cardiotoxic effects of anthracyclines are not well understood. However, early data suggest that inherited polymorphisms in one of the carbonyl reductase genes that catalyze the metabolism of anthracyclines to cardiotoxic metabolites may be involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/37\">",
"     37",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"   </p>",
"   <p>",
"    Thus, although limiting the lifetime cumulative dose of anthracyclines is an important means of preventing cardiotoxicity, surveillance of myocardial function during and after therapy, with early detection of adverse cardiac effects, remains the principal method of preventing anthracycline cardiotoxicity. Therapy can be stopped at a lower cumulative dose if there is evidence of cardiotoxicity. Conversely, treatment to higher cumulative doses may be possible in the absence of cardiotoxicity, if indicated for tumor management. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Pretreatment assessment and subsequent monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age extremes predispose to cardiotoxicity at lower cumulative anthracycline doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/36\">",
"     36",
"    </a>",
"    ]. In older patients, preexisting heart disease (including hypertension) is a risk factor for anthracycline cardiotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/33\">",
"     33",
"    </a>",
"    ]. However, it is not clear whether pre-existing heart disease increases susceptibility to anthracycline-induced damage, or whether there is less functional reserve to tolerate additional myocardial damage.",
"   </p>",
"   <p>",
"    Children are more susceptible to anthracycline cardiotoxicity, which is consistently observed at lower cumulative doses than in adults. In one long-term follow-up study, 32 percent of children who received &gt;410",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    presented with some degree of LV function impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/20\">",
"     20",
"    </a>",
"    ] (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Issues in children'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior mediastinal irradiation may increase the susceptibility to anthracycline cardiotoxicity by inducing endothelial cell damage and compromising coronary artery blood flow. This risk of cardiotoxicity is particularly important in women who have received prior chest wall irradiation for left-sided breast cancer. The magnitude of the increased risk may depend upon the anthracycline dose. In one study, conventional dose adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (cumulative planned doxorubicin dose 225",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , either alone or in combination with nonconcurrent locoregional radiation, was not associated with an increased risk of cardiac events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/38\">",
"     38",
"    </a>",
"    ]. However, higher doses of adjuvant doxorubicin (cumulative planned doses 450",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    were associated with a three- to fourfold greater risk of cardiac events compared to the lower dose group, especially in patients treated with higher dose-volumes of cardiac radiation.",
"   </p>",
"   <p>",
"    Concurrent irradiation also increases risk; at least in the setting of breast cancer, adjuvant therapy with an anthracycline-containing regimen is never administered concurrently with breast or chest wall irradiation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=see_link&amp;anchor=H1404371166#H1404371166\">",
"     \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\", section on 'Sequencing chemotherapy and radiation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential increased risk of thoracic radiation therapy in patients previously treated with anthracyclines is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=see_link\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Concomitant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of nonanthracycline agents that also cause cardiotoxicity may result in synergistic toxicity when anthracyclines are given concurrently. The most important agents in this regard are the taxanes (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    ; cardiotoxicity of these agents is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=see_link&amp;anchor=H16#H16\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\", section on 'Taxanes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42232?source=see_link&amp;anchor=H39983118#H39983118\">",
"     \"Cardiotoxicity of trastuzumab\", section on 'Incidence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and total body radiation prior to bone marrow transplantation is itself capable of causing myocardial damage. Thus, in patients with prior anthracycline treatment or mediastinal radiation, the risks of developing cardiotoxicity at the time of bone marrow transplantation are even greater [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34664?source=see_link\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Approaches for reducing the risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to limiting the lifetime cumulative dose of anthracycline, other approaches to reducing the risk of cardiotoxicity have included the use of infusional rather than bolus administration schedules, the development of structural analogs, liposome encapsulation of the anthracycline molecule, and the use of adjunctive cardioprotective agents. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Cumulative dose'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition, intensive monitoring of myocardial function during treatment has been used to detect the earliest evidence of cardiotoxicity and prevent the development of more severe heart failure. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Pretreatment assessment and subsequent monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Infusion protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infusional administration of anthracyclines over six hours or more may lower the incidence of cardiotoxicity compared to bolus therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/17,40-43\">",
"     17,40-43",
"    </a>",
"    ]. In a meta-analysis of four randomized trials comparing infusional versus bolus schedules of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , bolus administration significantly increased the risk of clinical cardiotoxicity (OR 4.13, 95% CI 1.75-9.72) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/17\">",
"     17",
"    </a>",
"    ]. A similar pattern was also seen for subclinical cardiotoxicity (OR 3.04, 95% CI 1.66-5.58). &nbsp;",
"   </p>",
"   <p>",
"    These data are derived from adult studies. Whether infusional as compared to bolus regimens are associated with reduced long-term cardiotoxicity in survivors of childhood cancer is less certain. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Issues in children'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Despite the potential benefit of prolonged infusion schedules, most",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    is still administered via bolus therapy. In diseases where prolonged infusion with doxorubicin-based regimens have demonstrated efficacy, the frequent need for hospitalization and placement of a central venous catheter makes this approach less attractive to patients and less cost effective. In addition, at least one trial has raised concerns about an increased risk of metastasis and death in patients treated with infusional rather than bolus doxorubicin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/40\">",
"     40",
"    </a>",
"    ]. However, others, including the meta-analysis described above, have not found significant differences in response rates, remission or survival duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/17,44,45\">",
"     17,44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18282?source=see_link&amp;anchor=H9#H9\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\", section on 'VAD chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Structural modifications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modifications have been made to the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    molecule in an attempt to reduce cardiotoxicity without loss of antitumor efficacy. The two most widely used structural analogs are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    . Although many of these analogs are less cardiotoxic than doxorubicin, each has the potential to cause cardiotoxicity and has a suggested lifetime cumulative dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h4\">",
"     Epirubicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     Epirubicin",
"    </a>",
"    is less cardiotoxic than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    on a mg per mg basis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]; it is considered the preferred anthracycline for solid tumor chemotherapy in some institutions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. In a meta-analysis of 13 studies comparing doxorubicin with epirubicin, use of epirubicin significantly decreased the risks of both clinical (OR 0.39, 95% CI 0.2-0.78) and subclinical cardiotoxicity (OR 0.30, 95% CI 0.16-0.57) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The US FDA-approved",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    labeling recommends that the maximal cumulative dose of epirubicin be limited to 900",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    to minimize the risk of myocardial dysfunction. However, this dose may be too high, particularly in older patients and those with other risk factors for heart failure. This was illustrated in a competing risks analysis of data on 1097 patients receiving epirubicin for breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/53\">",
"     53",
"    </a>",
"    ]. The cumulative dose of epirubicin that carried a 5 percent risk of heart failure was much lower than 900",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    in many groups, including those over age 60 at the start of epirubicin, those with a predisposition to heart disease (including prior treatment with endocrine therapy, previous mediastinal irradiation, history of diabetes, hypertension, or obesity) and individuals with higher predicted breast cancer mortality. Recommended maximal cumulative doses of epirubicin associated with no more than a 5 percent risk of heart failure for each category of patient are presented in the table (",
"    <a class=\"graphic graphic_table graphicRef56455 \" href=\"mobipreview.htm?31/54/32621\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h4\">",
"     Mitoxantrone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"     Mitoxantrone",
"    </a>",
"    , an anthraquinone that is structurally related to the anthracyclines, was also developed to lessen cardiac toxicity while retaining broad spectrum antitumor activity. The previously described meta-analysis included 15 trials comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and mitoxantrone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/17\">",
"     17",
"    </a>",
"    ]. Compared to mitoxantrone, the use of doxorubicin was associated with a significantly higher rate of clinical cardiotoxicity (OR 2.88, 95% CI 1.29-6.44) but there was little difference between the treatment groups for subclinical cardiotoxicity.",
"   </p>",
"   <p>",
"    The recommended maximum dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    is 140",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Up to this level, the incidence of a subclinical decline in LVEF is estimated to be 13 percent and the incidence of overt cardiac failure is 2.6 percent. At cumulative doses above 160",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    there is a significant increase in the incidence of heart failure. Like the other anthracyclines, mitoxantrone-induced heart failure responds to standard medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Prognosis and treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Liposome encapsulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incorporation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    into liposomes permits substantially higher cumulative doses with efficacy equivalent to the free anthracyclines but a lower incidence of heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/57-60\">",
"     57-60",
"    </a>",
"    ] and myocardial damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. In the previously described meta-analysis, liposomal compared to conventional doxorubicin significantly decreased the risk of clinical (OR 0.18, 95% CI 0.08-0.38), and subclinical cardiotoxicity (relative risk [RR] 0.31, 95% CI 0.20-0.48) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/17\">",
"     17",
"    </a>",
"    ]. However, in one trial comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     liposomal doxorubicin",
"    </a>",
"    versus free",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    , there was little difference between the two drugs for any cardiotoxic event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Dexrazoxane",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     Dexrazoxane",
"    </a>",
"    is an EDTA-like chelator that may prevent anthracycline damage by binding to iron that is released from intracellular storage secondary to lipid peroxidation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/63\">",
"     63",
"    </a>",
"    ]. However, the actual mechanism underlying the cardioprotective effect of dexrazoxane against anthracycline cardiotoxicity remains uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Mechanisms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    was addressed in a meta-analysis of six randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/17\">",
"     17",
"    </a>",
"    ]. Dexrazoxane given with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    significantly reduced the incidence of clinical (OR 0.21, 95% CI 0.13 -0.33) and subclinical cardiotoxicity (OR 0.33, 95% CI 0.20-0.55). There is no reported experience with using dexrazoxane in conjunction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    or liposomal anthracyclines.",
"   </p>",
"   <p>",
"    Despite the apparent cardiac benefit, a number of issues have created uncertainty about the role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    in both adults and children, including the possibility of a lower response rate to chemotherapy:",
"   </p>",
"   <p>",
"    In some trials conducted in women receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    for breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/65-68\">",
"     65-68",
"    </a>",
"    ], concerns have been raised about the possibility that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    may interfere with cancer therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/69\">",
"     69",
"    </a>",
"    ] or enhance myelosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. However, multiple other randomized trials and two pooled analyses have not confirmed these findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/66,72,73\">",
"     66,72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cardioprotective effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    is observed whether the drug is started initially or after 300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    . Since most patients with metastatic disease develop doxorubicin resistance before they reach cumulative doses that place them at high risk for heart failure, the use of dexrazoxane is generally deferred until after cumulative doses of 300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    are reached.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h4\">",
"     ASCO guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Society of Clinical Oncology (ASCO) has published detailed guidelines for the adjunctive use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    in patients with breast cancer and other malignancies and for monitoring therapy, which were updated in 2008 (",
"    <a class=\"graphic graphic_table graphicRef70814 \" href=\"mobipreview.htm?9/33/9757\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Key points from these guidelines that apply to adults include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"       Dexrazoxane",
"      </a>",
"      can be considered for patients being treated for metastatic disease who have received a cumulative dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      &ge;300",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      and may benefit from continued treatment. Dexrazoxane can also be considered for use in patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      For patients who had previously received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      in an adjuvant setting, the data are unclear since such patients were not included in the original",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"       dexrazoxane",
"      </a>",
"      clinical trials. The possibility that dexrazoxane may reduce the objective tumor response rates needs to be balanced against the risk of cardiotoxicity if additional anthracyclines are administered.",
"     </li>",
"     <li>",
"      For adults who will receive anthracyclines in an adjuvant setting,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"       dexrazoxane",
"      </a>",
"      is",
"      <strong>",
"       not",
"      </strong>",
"      recommended outside a clinical trial setting, because of concerns about potential impact on antitumor efficacy.",
"     </li>",
"     <li>",
"      Patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"       dexrazoxane",
"      </a>",
"      with an anthracycline require continued close monitoring. Anthracycline treatment should be discontinued if there is a significant decrease in the left ventricular ejection fraction (LVEF) or evidence of heart failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guidelines are not available for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    use in patients with cardiac risk factors.",
"   </p>",
"   <p>",
"    Guidelines for use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    in children are addressed below. (See",
"    <a class=\"local\" href=\"#H38\">",
"     'Cardioprotection with dexrazoxane'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal studies have suggested that concurrent administration of the beta blocker",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    may protect against the cardiotoxicity of anthracyclines. Further support for this possibility comes from a small randomized trial of 50 patients undergoing anthracycline chemotherapy for a variety of malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/74\">",
"     74",
"    </a>",
"    ]. Patients were randomly assigned to carvedilol, 12.5 mg daily, or placebo. All patients underwent echocardiography prior to and six months after chemotherapy. Among the patients assigned to carvedilol, there was no change in the mean LVEF after chemotherapy (70 percent before and after therapy). In contrast, patients assigned to placebo had a statistically significant absolute reduction in LVEF of 17 percent (69 to 52 percent).",
"   </p>",
"   <p>",
"    Interpretation of these results is hampered by a major discrepancy in the reported anthracycline doses that were administered during the five month period of the study (515 to 520",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and 770 to 790",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ). All of the regimens received by these patients included no more than 50 or 60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of doxorubicin or epirubicin administered every three to four weeks, and these large cumulative anthracycline doses could not have been administered over a five month period. Given this concern, as well as the small size of the study, additional clinical trials will be required before concluding that any beta blocker can reduce cardiotoxicity in patients receiving anthracycline-type drugs.",
"   </p>",
"   <p>",
"    Despite this uncertainty, some clinicians start high-risk patients (elderly, hypertension, concurrent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    ) on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    or another beta blocker prior to starting an anthracycline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     ACE inhibitors and ARBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) have been shown to improve outcomes and slow disease progression in patients with left ventricular systolic dysfunction due to a variety of causes. The role of these agents in the treatment of patients with chemotherapy-induced cardiotoxicity is addressed below. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Prognosis and treatment'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A separate question relates to the potential protective effect of ACE inhibitors and ARBs for preventing the development of left ventricular dysfunction in patients at risk after receiving a variety of high-dose chemotherapy regimens. A possible protective effect of an ACE inhibitor was suggested in a randomized trial of patients who received a variety of chemotherapy regimens and who had an increase in serum troponin T shortly after chemotherapy; only a minority included an anthracycline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/75\">",
"     75",
"    </a>",
"    ]. The results of this trial are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=see_link&amp;anchor=H53#H53\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional data in patients receiving anthracyclines are needed before preemptive use of an ACE inhibitor or an ARB during anthracycline therapy can be adopted into clinical practice. A randomized trial, the PRADA trial, is underway in which patients receiving adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    chemotherapy with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    will be randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/48/38663?source=see_link\">",
"     candesartan",
"    </a>",
"    (an ARB), a beta blocker (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ), and matching placebos in a 2 x 2 factorial design [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Pretreatment assessment and subsequent monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;A baseline cardiovascular examination along with careful cardiovascular management of risk factors such as hypertension or hyperlipidemia is an important and often overlooked component of pretreatment assessment. Referral to a cardiologist for formal cardiac risk assessment and management may be needed.",
"   </p>",
"   <p>",
"    Monitoring of cardiac function is highly recommended before, during, and after anthracycline-containing chemotherapy to detect subclinical cardiac damage, although there are no clear guidelines from any expert group on the frequency or optimal method of LVEF assessment, or the best parameter to follow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Noninvasive monitoring of LVEF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequently used approach to monitor cardiac function and its impairment by chemotherapy is evaluation of LVEF. Echocardiography and radionuclide angiography are the standard approaches for noninvasive monitoring of LVEF in patients receiving anthracyclines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h4\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite problems with variability with measurements, echocardiography is generally preferred over radionuclide techniques for monitoring LVEF during and after potentially cardiotoxic chemotherapy due to its widespread availability and the absence of radiation exposure. Monitoring of LVEF is the most commonly used method for assessing early anthracycline-related cardiotoxicity, although a decrease in LVEF is a relatively late manifestation of myocardial damage. Other echocardiographic parameters that have been monitored include the older measure of fractional shortening, as well as newer and more sensitive tissue Doppler and speckle tracking indices of myocardial mechanics (eg, strain) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/77-79\">",
"     77-79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two-dimensional (2D) echocardiography is the most widely available method for monitoring LVEF. Advantages include portability and capability of assessing other measures of myocardial dysfunction as well as other cardiac lesions (such as valve disease). Limitations of 2D echocardiography include problems with reproducibility and dependence upon adequate acoustic windows.",
"   </p>",
"   <p>",
"    Three-dimensional (3D) echocardiography is a potential alternative that, when available, offers greater reproducibility than 2D techniques and produces LVEF values similar to those obtained by radionuclide ventriculography and cardiac magnetic resonance imaging (CMR) although it requires adequate acoustic windows. The superior reproducibility of serial testing with 3D noncontrast echocardiography measures of LVEF compared to 2D echocardiography (noncontrast and contrast) measures was illustrated by a study in 56 women undergoing chemotherapy for breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/80\">",
"     80",
"    </a>",
"    ]. Only patients with stable global longitudinal strain were included in the study. During serial testing at up to five time points at three month time intervals, the minimum detectable change in LVEF as measured by noncontrast 3D was 0.06 (eg, a change in LVEF from 50 to 44 percent), whereas the minimum detectable change by 2D methods was 0.13 to 0.19 (ie, a change in LVEF from 50 to 37 or 31 percent).",
"   </p>",
"   <p>",
"    Thresholds for normal LVEF should be based upon modality- and analysis-specific and population appropriate normative data. The potential risk of missing patients with borderline depressed systolic function was suggested by a study that compared echocardiography and CMR in 114 adult survivors of childhood cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/81\">",
"     81",
"    </a>",
"    ]. Using a 2D echocardiography threshold of &lt;50 percent for detecting impaired LVEF (as defined by an LVEF of &lt;50 percent by CMR) had a much lower sensitivity (25 percent) than did use of a threshold of &lt;60 percent to define abnormal LVEF (sensitivity 75 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further evaluation (eg, by CMR or radionuclide ventriculography) is warranted in patients who have a borderline depressed LVEF by echocardiography, or if echocardiography images are suboptimal or indeterminate. The use of noninvasive methods to assess left ventricular systolic function is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/21/11610?source=see_link\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13145?source=see_link\">",
"     \"Contrast echocardiography: Clinical applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h4\">",
"     Radionuclide angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of resting global left ventricular function using either first pass or equilibrium multigated blood pool imaging (MUGA scan) is an established technique for monitoring anthracycline cardiotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/82\">",
"     82",
"    </a>",
"    ]. However, it is used less often than echocardiography. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/21/11610?source=see_link&amp;anchor=H2#H2\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\", section on 'Radionuclide ventriculography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We use radionuclide ventriculography rather than echocardiography to monitor anthracycline cardiotoxicity if patients have poor windows on echocardiogram (obese, left sided locally advanced breast cancer).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3664395\">",
"    <span class=\"h4\">",
"     Cardiac MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging may be useful in selected patients for monitoring changes in cardiac structure and function induced by cancer drug exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. It may be particularly helpful for quantification of ventricular function when echocardiography or radionuclide results are suboptimal or conflicting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/21/11610?source=see_link&amp;anchor=H27#H27\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\", section on 'Cardiovascular magnetic resonance imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293787\">",
"    <span class=\"h4\">",
"     Predictive value of early changes in cardiac function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance of ventricular function by echocardiography or RVG is performed to detect asymptomatic declines in ventricular systolic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic function reflecting early cardiotoxicity that may progress to symptomatic disease with continued therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/21,82,85-88\">",
"     21,82,85-88",
"    </a>",
"    ]. One limitation of this approach is that a latent period may precede manifestations of cardiotoxicity. Some investigators advocate the use of myocardial stress and strain rates as identified by echocardiography to identify patients at risk for subsequent cardiac toxicity. This approach needs further validation prior to widespread implementation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/21/11610?source=see_link&amp;anchor=H18#H18\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\", section on 'Assessment of myocardial strain and strain-rate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characteristics of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    cardiotoxicity and the ability of serial LVEF measurements to identify early toxicity before the onset of clinical symptoms was shown in one report in which serial RVGs were performed in 51 patients treated with doxorubicin for various types of tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/82\">",
"     82",
"    </a>",
"    ]. Five developed clinical signs of heart failure at doxorubicin doses ranging from 490 to 715",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    Absolute declines in the LVEF of 15 to 22 percent were noted before the development of heart failure, which was clinically manifest only when the LVEF was below 30 percent (",
"    <a class=\"graphic graphic_figure graphicRef68340 \" href=\"mobipreview.htm?32/48/33550\">",
"     figure 1",
"    </a>",
"    ). Six patients had an asymptomatic absolute decline in LVEF of &le;15 percent at doxorubicin doses of 460 to 900",
"    <span class=\"nowrap\">",
"     mg/",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    Doxorubicin was discontinued, and none of the six patients progressed to symptomatic heart failure (",
"    <a class=\"graphic graphic_figure graphicRef68340 \" href=\"mobipreview.htm?32/48/33550\">",
"     figure 1",
"    </a>",
"    ). Repeat measurement of LVEF several months after stopping doxorubicin showed a modest improvement in LVEF in all patients. Thus, these patients appeared to have mild toxicity which partially reversed when the doxorubicin was stopped.",
"   </p>",
"   <p>",
"    Another report studied 282 patients at high risk for the development of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    cardiotoxicity who were monitored by serial RVG using standard guidelines (",
"    <a class=\"graphic graphic_table graphicRef58738 \" href=\"mobipreview.htm?42/21/43355\">",
"     table 3",
"    </a>",
"    ). Among the 70 patients in whom the guidelines were followed completely, only two (3 percent) developed heart failure. In contrast, heart failure developed in 44 of 212 high-risk patients (21 percent) in whom the guidelines were incompletely followed (",
"    <a class=\"graphic graphic_figure graphicRef74770 \" href=\"mobipreview.htm?31/52/32589\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A similar correlation between early findings on noninvasive monitoring and late cardiotoxicity has been reported in most [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/82,85,88-90\">",
"     82,85,88-90",
"    </a>",
"    ], but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. At least one prospective blinded trial failed to demonstrate that monitoring of cardiac function by RVG during anthracycline therapy was predictive of future anthracycline-induced cardiotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonetheless, noninvasive monitoring during therapy is a widely accepted medical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H503425356\">",
"    <span class=\"h4\">",
"     Guidelines for monitoring and drug discontinuation from expert groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive monitoring of cardiac function during anthracycline therapy is endorsed by the American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    College of Cardiology",
"    <span class=\"nowrap\">",
"     (AHA/ACC)",
"    </span>",
"    in conjunction with the American Society for Nuclear Cardiology and the American Society for Echocardiography (ASE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/91,92\">",
"     91,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of echocardiography at baseline and for reevaluation examinations to monitor patients exposed to anthracyclines was given a class I recommendation by a 2003 task force of the ACC, the AHA, and the ASE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, these guidelines do not provide information on the optimal parameter to be followed, how frequently monitoring should be done, or the appropriate manner in which to proceed after a patient had an abnormal reading. There is no consensus on these issues and few formal guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The two main echocardiographic parameters that have been most often followed are left ventricular ejection fraction (left ventricular stroke volume divided by left ventricular end-diastolic volume times 100 percent) and left ventricular fractional shortening ([end-diastolic dimension minus end-systolic dimension] divided by end-diastolic dimension). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/21/11610?source=see_link&amp;anchor=H15#H15\">",
"       \"Noninvasive methods for measurement of left ventricular systolic function\", section on 'Quantitative evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The US FDA-approved labeling guidelines for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      suggest an assessment of electrocardiogram",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      systolic ejection fraction prior to each planned course of daunorubicin. (See",
"      <a class=\"local\" href=\"#H68453504\">",
"       'Electrocardiographic changes'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      ASCO guidelines for use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"       dexrazoxane",
"      </a>",
"      in conjunction with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      include recommendations for cardiac monitoring after a cumulative dose of 400",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      is reached; monitoring should be repeated after 500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      cumulative dose, and thereafter after every 50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef70814 \" href=\"mobipreview.htm?9/33/9757\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/65\">",
"       65",
"      </a>",
"      ]. Discontinuation of anthracycline and dexrazoxane is recommended in patients who have a decrease in LVEF to below the lower limit of normal or who develop clinical heart failure.",
"     </li>",
"     <li>",
"      The US FDA-approved labeling for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      indicates that in adults, a 10 percent decline in LVEF to below the lower limit of normal, or an absolute LVEF 45 percent, or a 20 percent decline in LVEF at any level is indicative of deterioration of cardiac function. In children, they endorse the use of an absolute decrease in fractional shortening by &ge;10 percent from baseline, or to &lt;29 percent, or an absolute decrease in LVEF by &ge;10 percent from baseline or to &lt;55 percent as an indications to discontinue anthracycline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/93\">",
"       93",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Specific guidelines are not available for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      . Guidelines for drug discontinuation based upon LVEF are available for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      when used for the treatment of multiple sclerosis, but not for other indications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In adults, an absolute fractional shortening &lt;26 percent has been proposed as a threshold below which anthracyclines should be discontinued [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/95\">",
"       95",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We follow the ASCO guidelines for monitoring even in patients not receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    . If patients are at high risk for cardiotoxicity (ie, elderly, history of hypertension) and are receiving high doses of anthracycline per cycle (eg, &ge;50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ), we repeat an echocardiogram after the fourth cycle, and then follow the ASCO guidelines as indicated above. We follow the FDA-approved labeling guidelines for indications to discontinue anthracycline therapy based upon myocardial function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293801\">",
"    <span class=\"h4\">",
"     Do all patients require a baseline assessment of LVEF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another controversial area on which there is no consensus is whether all patients receiving treatment with an anthracycline require a baseline assessment of LVEF. Several authors have suggested that patients who are scheduled to receive &lt;300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    total dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (eg, in the adjuvant setting for early breast cancer) without other concurrent cardiotoxic drugs without underlying cardiac risk factors have a low enough risk of cardiotoxicity that baseline cardiac assessment is not needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/96-98\">",
"     96-98",
"    </a>",
"    ]. One retrospective review addressing this issue studied 592 patients undergoing curative-intent surgery for stage I, II, or III breast cancer over a one-year period, 238 of whom received adjuvant chemotherapy, 94 percent with an anthracycline-based regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/98\">",
"     98",
"    </a>",
"    ]. While 80 percent of those receiving adjuvant chemotherapy underwent pretreatment assessment of LVEF, only 5 percent received abnormal results, and all were smokers. Scan results influenced treatment decisions in only 2 percent of cases, all of whom were aged 65 or older. The authors concluded that the data did not support routine baseline assessment of LVEF in younger, perhaps premenopausal women without underlying cardiac risk factors who are not candidates for adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    However, this approach is not widely accepted and clinical practice is variable. While some institutions delete the baseline assessment of LVEF in women under the age of 65 who lack cardiac risk factors and who will be receiving an anthracycline-based adjuvant regimen without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , others continue to perform baseline assessment in all women who will be receiving adjuvant chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68453504\">",
"    <span class=\"h4\">",
"     Electrocardiographic changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain electrocardiographic changes such as a decrease &ge;30 percent in limb lead QRS voltage may serve as an early predictor of drug-induced cardiomyopathy in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/41,99\">",
"     41,99",
"    </a>",
"    ]. However, assessment of LVEF is more commonly performed for surveillance during therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Cardiac biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A decrease in LVEF occurs when the compensatory ability of the myocardium has been impaired; such a decline is actually a marker of advanced damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/100\">",
"     100",
"    </a>",
"    ]. There is increasing interest in exploring the clinical utility of alternative measures of heart function such as cardiac biomarkers (troponins T and I, B-type natriuretic peptide [BNP]) which may give an early indication of cardiac damage and increased risk for a cardiac event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h4\">",
"     Serum troponins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of serum troponins is useful to confirm the diagnosis of myocardial injury, including acute myocardial infarction and myocarditis. In an animal model, troponin T was released from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -damaged myocytes, and the serum concentrations of troponin T correlated with the dose of drug received as well as the degree of myocardial damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/101\">",
"     101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical studies are limited, but several suggest that elevations in troponin T",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    I may be an early marker of acute myocardial injury in patients receiving potentially cardiotoxic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/16,102-107\">",
"     16,102-107",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 41 adults with various hematologic malignancies in whom serum troponin T and LVEF were serially measured after anthracycline-containing chemotherapy, patients with elevated serum troponins during treatment had a significantly greater posttreatment decrease in the LVEF (10 versus 2 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, in a study of 204 patients receiving high-dose chemotherapy for a variety of malignancies, those who had elevated levels of serum troponin I during chemotherapy had significantly lower LVEF at seven months as compared to baseline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/16\">",
"       16",
"      </a>",
"      ]. In contrast, for those who did not have elevated troponin levels, LVEF returned to baseline at seven months following a transient reduction at three months (",
"      <a class=\"graphic graphic_figure graphicRef78622 \" href=\"mobipreview.htm?28/12/28877\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A correlation between persistently elevated levels of postchemotherapy troponin I and cardiotoxicity was shown in a series of 703 patients undergoing high-dose chemotherapy for a variety of malignancies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/105\">",
"       105",
"      </a>",
"      ]. There was a significantly higher rate of adverse cardiac events (defined as death resulting from a cardiac cause, acute pulmonary edema, overt heart failure, asymptomatic LVEF decline &ge;25 percent, or life-threatening tachyarrhythmias or conduction disturbance requiring a permanent pacemaker) among those who had persistently elevated troponin I levels one month after the end of chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, others have failed to detect any changes in cardiac troponins during or following anthracycline treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/108-113\">",
"     108-113",
"    </a>",
"    ], even in the presence of mild heart dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/112,114\">",
"     112,114",
"    </a>",
"    ]. The discrepancy in these clinical findings could be attributed to many factors, including diversity of the initial disease, the specific cumulative anthracycline dose, the variable timing of when the samples were drawn for troponin assay relative to anthracycline administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/103,115,116\">",
"     103,115,116",
"    </a>",
"    ], imprecision in LVEF estimates, and the use of immunoassays with different cutoff levels.",
"   </p>",
"   <p>",
"    Thus, while early identification of patients at risk for acute anthracycline-related cardiac toxicity through the use of biomarkers such as troponin holds promise for identification of patients who might benefit from preventive strategies (eg, an ACE inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/75\">",
"     75",
"    </a>",
"    ]), there is insufficient available evidence to support this approach. There are no clinical settings in which serial monitoring of serum troponin levels could be considered a standard approach for patients receiving potentially cardiotoxic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/117\">",
"     117",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'ACE inhibitors and ARBs'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h4\">",
"     Brain natriuretic peptide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain natriuretic peptide (BNP) is secreted by the ventricles of the heart in response to excessive stretch. BNP is co-secreted along with a biologically inactive N-terminal amino acid fragment, NT-pro-BNP. Elevated levels of BNP are an established biomarker for the diagnosis of heart failure; their high sensitivity makes these tests particularly useful for excluding heart failure (high negative predictive value). However, there are limitations to widespread use as a screen for heart failure, due to their low specificity and the wide variability of measured levels. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, interest has grown in the use of BNP and NT-pro-BNP as biomarkers for early cardiac dysfunction in anthracycline-treated adults and children. The data are more consistent than with cardiac troponins. With few exceptions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/118,119\">",
"     118,119",
"    </a>",
"    ], persistently elevated levels of BNP and NT-pro-BNP posttreatment correlate well with echocardiographic indices of myocardial dysfunction in most studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/113-115,118,120-125\">",
"     113-115,118,120-125",
"    </a>",
"    ]. However, the wide variability and overlap of BNP and NT-pro-BNP levels among patients with preserved versus impaired cardiac function makes it difficult to establish accurate cutoff values to identify subclinical heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/119,122\">",
"     119,122",
"    </a>",
"    ]. Furthermore, BNP cannot replace cardiac imaging studies for monitoring acute anthracycline-induced systolic and diastolic dysfunction during therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/114,118\">",
"     114,118",
"    </a>",
"    ]. In one study, 68 percent of cases with LVEF &lt;50 percent would have been missed if monitoring was based solely on the presence of a BNP level &gt;100",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    a value below which heart failure is generally unlikely. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In several studies, persistently increased posttreatment BNP levels have been shown to predict the development of late anthracycline cardiotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/87,113,126-128\">",
"     87,113,126-128",
"    </a>",
"    ]. While routine monitoring of BNP in these patients might serve to identifying a group of high-risk patients who need closer follow-up, whether outcomes will be improved by earlier diagnosis and more intensive monitoring requires prospective study.",
"   </p>",
"   <p>",
"    Thus, BNP and NT-pro-BNP may be of incremental diagnostic value to imaging modalities in monitoring for late anthracycline cardiotoxicity, and some cancer centers are beginning to incorporate them into cardiovascular monitoring programs for patients treated with these drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/121\">",
"     121",
"    </a>",
"    ]. However, this is not a widespread practice. The utility of BNP and NT-pro-BNP as diagnostic and predictive tools for cardiac dysfunction in patients treated with anthracyclines remains to be clarified in larger clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Role of endomyocardial biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endomyocardial biopsy is considered to be the most sensitive and specific means of evaluating anthracycline cardiotoxicity and permits direct assessment of the presence and extent of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/129\">",
"     129",
"    </a>",
"    ]. Characteristic electron microscopy findings include depletion of myofibrillary bundles, myofibrillar lysis, distortion and disruption of the Z-lines, mitochondrial disruption, and intramyocyte vacuolization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/130\">",
"     130",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7592?source=see_link\">",
"     \"Endomyocardial biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, endomyocardial biopsy has important limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The procedure is invasive and requires transvenous biopsy-catheter insertion. This procedure carries a small risk for arrhythmias, bleeding, and cardiac chamber perforation.",
"     </li>",
"     <li>",
"      Autopsy studies have shown wide variability in myocardial involvement. At times, the cardiac injury may be limited to one ventricle or to just one or more walls within a ventricle. Thus, the three to five biopsy specimens routinely taken from the right side of the ventricular septum may not represent an adequate sample to exclude toxicity. This limitation makes the diagnosis of cardiotoxicity very specific but less sensitive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Considerable expertise is required to interpret biopsy samples, and there is significant variability in interpretation between pathologists.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For these reasons, endomyocardial biopsy is best restricted to patients in whom the noninvasive techniques fail to provide information, or in very high risk patients in whom greater specificity is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Prognosis and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of anthracycline-induced cardiomyopathy in adults appears to be related to the severity of cardiac symptoms when cardiotoxicity is first diagnosed. Patients who present with clinical symptoms have a worse prognosis than those diagnosed with an asymptomatic decrease in LVEF.",
"   </p>",
"   <p>",
"    Whether patients with left ventricular dysfunction due to chemotherapy respond to medical therapy for left ventricular dysfunction and heart failure due to other causes is not clear (eg, beta blockers and ACE inhibitors). Similarly, it is not known whether the prophylactic use of such medications will reduce the risk of developing left ventricular dysfunction and heart failure. Nevertheless, patients with anthracycline-induced LV dysfunction should receive treatment that is consistent with heart failure guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/131\">",
"     131",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H23\">",
"     'Beta blockers'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H24\">",
"     'ACE inhibitors and ARBs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The prognosis and response to medical treatment are illustrated by the following observational series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The value of treatment with angiotensin-converting enzyme (ACE) inhibitors was demonstrated in a prospective series of women who were monitored for evidence of left ventricular dysfunction while they received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      for metastatic breast cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/86\">",
"       86",
"      </a>",
"      ]. Seven of eight women treated with an ACE inhibitor had a sustained increase in LVEF of &ge;15 percent. In contrast, there was only one such response among 33 cases treated with a digitalis preparation plus a diuretic. There were no deaths.",
"     </li>",
"     <li>",
"      In contrast, two earlier series included a total of 77 patients who developed symptomatic heart failure after either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      , predominantly for metastatic breast cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/46,132\">",
"       46,132",
"      </a>",
"      ]. Patients were not treated with ACE inhibitors, and there were 25 deaths (32 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the data are limited, these results support the use of ACE inhibitors as first-line therapy for both asymptomatic left ventricular dysfunction and overt heart failure due to systolic dysfunction. In patients with anthracycline-induced cardiomyopathy and heart failure who are refractory to optimal medical management, advanced approaches to management of heart failure should be considered, including cardiac resynchronization therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/133\">",
"     133",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28601?source=see_link\">",
"     \"Evaluation and management of asymptomatic left ventricular systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Issues in children",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Cardiotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of anthracycline-containing chemotherapy and direct or indirect mediastinal irradiation has been highly successful in most children with leukemia and lymphoma. Although the development of severe late heart failure is uncommon, subtle changes in both systolic and diastolic function are more frequent in long-term survivors, and childhood cancer survivors are at risk for premature cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiotoxicity in long-term survivors of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -based therapy for pediatric cancer was first reported in 1991, and its incidence and risk factors are being elucidated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/20,21,77,88,134-144\">",
"     20,21,77,88,134-144",
"    </a>",
"    ]. Among the identified risk factors are anthracycline dose, use of mediastinal radiotherapy, age at treatment, time since treatment, and female sex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/21,88,126,135,138-141,143\">",
"     21,88,126,135,138-141,143",
"    </a>",
"    ]. Children with Down syndrome who receive anthracycline treatment for acute myeloid leukemia may be at particularly high risk of developing cardiomyopathy, which may be related to the high incidence of congenital heart disease in this group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/145\">",
"     145",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with adults, the main risk factor in children is the total anthracycline dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/20,143,146\">",
"     20,143,146",
"    </a>",
"    ]. In contrast to adults, the use of infusional as compared to bolus administration schedules has not been associated with reduced cardiotoxicity in childhood cancer survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/147-149\">",
"     147-149",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following illustrate both the frequency and progressive worsening of late cardiac abnormalities in children treated with anthracyclines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis from the Childhood Cancer Survivor Study included 14,358 cancer survivors (five years or longer) who were diagnosed at age &le;21 (average age 8 at diagnosis), and whose long-term cardiovascular status (average 27 years of age at follow-up, range 8 to 51) was compared to a control group of 3899 siblings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/134\">",
"       134",
"      </a>",
"      ]. In a preliminary report, compared to their siblings, cancer survivors were more likely to report heart failure (relative risk [RR] 5.7), myocardial infarction (RR 4.9), atherosclerosis (RR 10.2), pericardial (RR 6.3) and valvular disease (RR 4.8), and ever having had coronary angiography (RR 2.6). Cumulative anthracycline exposure &ge;250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      increased the risk of reported heart failure, pericardial and valvular disease, and coronary angiography compared to unexposed survivors.",
"     </li>",
"     <li>",
"      The reported incidence of subclinical myocardial dysfunction in long-term survivors of childhood cancer is between 18 and 57 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/21,77,88\">",
"       21,77,88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The progressive worsening of cardiac abnormalities over time was shown in a report of 201",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      -treated long-term survivors who were evaluated by echocardiography from four to 20 years after treatment completion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/88\">",
"       88",
"      </a>",
"      ]. Of the 56 patients who were followed for 10 years or more ( median anthracycline dose of 495",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      38 percent had abnormal findings; compared with 18 percent (26 of 145) of those evaluated after less than 10 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Cardioprotection with dexrazoxane",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     Dexrazoxane",
"    </a>",
"    , a topoisomerase II inhibitor with a distinct mechanism of action, may protect against acute and delayed anthracycline-related myocardial injury in children as well as adults. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Dexrazoxane'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Protection against cardiotoxicity with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    in children was initially demonstrated in a small trial, in which 38 sarcoma patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    with or without dexrazoxane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/150\">",
"     150",
"    </a>",
"    ]. The incidence of subclinical cardiotoxicity was significantly lower with dexrazoxane (22 versus 67 percent), and the cumulative dose of doxorubicin was higher (410 versus 310",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ).",
"    </span>",
"   </p>",
"   <p>",
"    The utility of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    was further supported by a larger trial in which 206 children with newly-diagnosed acute lymphoblastic leukemia (ALL) were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    alone or preceded by dexrazoxane as part of their overall treatment regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/116,151,152\">",
"     116,151,152",
"    </a>",
"    ]. The cumulative dose of doxorubicin was limited to 300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    to minimize the risk of cardiotoxicity.",
"   </p>",
"   <p>",
"    Children receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    were one-half as likely to have elevated serum troponin T levels, an indicator of myocardial injury, at any time during therapy or after its completion (21 versus 50 percent in those not given dexrazoxane) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/105\">",
"     105",
"    </a>",
"    ]. Five years after the completion of chemotherapy, left ventricular wall thickness and wall thickness to dimension ratio were preserved in those receiving dexrazoxane compared to those receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/137\">",
"     137",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Noninvasive monitoring of LVEF'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, there were no significant differences between the two groups in left ventricular fractional shortening (a measure of left ventricular function); subgroup analysis showed a significant preservation of function in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    -treated girls but not boys. The cardiac anatomic differences did not translate into a difference in short-term clinical events. At a median follow-up of 8.7 years, no patients in either group had clinical heart failure.",
"   </p>",
"   <p>",
"    The trial also provided some evidence that adjunctive therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    did not inhibit the efficacy of antileukemic therapy. In the latest report, event-free survival was similar with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    plus dexrazoxane (76 versus 77 percent with doxorubicin alone) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/152\">",
"     152",
"    </a>",
"    ]. Additional longer-term data is required to determine whether dexrazoxane prevents late cardiotoxicity.",
"   </p>",
"   <p>",
"    Concerns have also been raised as to the possibility of second malignancies in children, although the available data are conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two trials conducted by the Pediatric Oncology Group in children with Hodgkin lymphoma suggested an increased risk of second malignancies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/153\">",
"       153",
"      </a>",
"      ]. Overall 478 were randomly assigned to combination chemotherapy regimens with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"       dexrazoxane",
"      </a>",
"      . Among the 239 patients receiving dexrazoxane, there were eight children with second malignancies (four with acute myeloid leukemia (AML), two with myelodysplastic syndrome, and one each with osteosarcoma and papillary carcinoma) compared to only two of the 239 patients not receiving dexrazoxane.",
"     </li>",
"     <li>",
"      In contrast, at least three other reports do not find an association between",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"       dexrazoxane",
"      </a>",
"      use and second malignancies in children:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the phase III trial in children with ALL described above [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/116,151\">",
"       116,151",
"      </a>",
"      ], no increased incidence of second malignancies was observed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/154\">",
"       154",
"      </a>",
"      ]. At a median follow-up of 6.2 years, two children had developed melanoma, one of whom had received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"       dexrazoxane",
"      </a>",
"      and one who had not.",
"     </li>",
"     <li>",
"      A published report from the Dana Farber Cancer Institute ALL Consortium that included children treated on three separate chemotherapy trials in which there was a randomization to receive or not receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"       dexrazoxane",
"      </a>",
"      , there were no second malignant neoplasms in the dexrazoxane-treated patients, after a median follow-up of 9.6 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/155\">",
"       155",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A multicenter retrospective cohort study using the Pediatric Health information System database included 15,532 pediatric cancer patients exposed to anthracyclines, of whom 1404 received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"       dexrazoxane",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/156\">",
"       156",
"      </a>",
"      ]. In a preliminary report presented at the 2012 meeting of the American Society of Clinical Oncology, the unadjusted incidence of secondary AML in dexrazoxane exposed and unexposed individuals was not different (1.21 versus 1.54 percent). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, the available evidence suggests that use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    in children receiving anthracyclines is safe, and not associated with an increased risk of second malignant neoplasms or inferior cancer outcomes.",
"   </p>",
"   <p>",
"    The",
"    <a class=\"external\" href=\"file://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/06/WC500108013.pdf\">",
"     European Medicines Agency",
"    </a>",
"    recommends against use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    in individuals under the age of 18 because of concerns about second malignancies and potential interference with anticancer therapy. Updated 2008 ASCO guidelines conclude that there is insufficient evidence to make a recommendation for use of dexrazoxane in the treatment of pediatric malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/65\">",
"     65",
"    </a>",
"    ]. However, in our view, the balance of data supports the safety of dexrazoxane in children receiving anthracyclines. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Dexrazoxane'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Guidelines for posttreatment monitoring of cancer survivors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The necessity and effectiveness of screening for late cardiotoxicity in childhood cancer survivors is increasingly validated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/144,157,158\">",
"     144,157,158",
"    </a>",
"    ]. Periodic assessment of LVEF using either echocardiogram or RVG was recommended in guidelines developed by the Cardiology Committee of the Children's Cancer Study Group for monitoring acute and late manifestations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    cardiotoxicity in childhood cancer survivors (",
"    <a class=\"graphic graphic_algorithm graphicRef58765 \" href=\"mobipreview.htm?10/27/10687\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/78\">",
"     78",
"    </a>",
"    ] as well as other expert groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/159\">",
"     159",
"    </a>",
"    ]. A parallel set of guidelines have been published by the Children's Oncology Group for childhood cancer survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/157,160\">",
"     157,160",
"    </a>",
"    ] and is available online [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/161\">",
"     161",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies to ascertain cardiotoxicity in children have usually been performed using echocardiography, since this technique is more widely available and does not involve radiation. The guidelines acknowledge the greater reproducibility of RVG and recommend its use in high risk patients, defined as those who have received higher anthracycline doses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy with exposure above 10 Gy. High-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography in anthracycline-treated survivors of cancer may be useful in detecting subclinical cardiotoxicity in asymptomatic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/162\">",
"     162",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, interest is increasing in the use of serial plasma assay for the N-terminal fragment of the prohormone for brain (B-type) natriuretic peptide (NT-proBNP) or N-terminal pro-ANP as a predictor for the development of late cardiotoxicity in these children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/126,128,163\">",
"     126,128,163",
"    </a>",
"    ]. However, published guidelines from the Children's Oncology Group for long-term follow-up of survivors of childhood, adolescent or young adult cancers who have received anthracyclines do not include serial assay of any cardiac biomarkers, just periodic assessment of LVEF using either echocardiography or RVG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/161\">",
"     161",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Cardiac biomarkers'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in adults, angiotensin converting enzyme (ACE) inhibitors are recommended as the first-line therapy for both asymptomatic left ventricular dysfunction and overt heart failure due to systolic dysfunction in children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28601?source=see_link\">",
"     \"Evaluation and management of asymptomatic left ventricular systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ACE inhibitors have shown possible value in the short-term management of children with left ventricular dysfunction, but their long-term effectiveness in slowing the decline in cardiac function in anthracycline-exposed pediatric cancer survivors is less clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/164\">",
"     164",
"    </a>",
"    ]. Although ACE inhibitors may be beneficial compared to placebo, they do not prevent progressive cardiac dysfunction in all patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 135 pediatric cancer survivors who had evidence of a decline in cardiac function identified at any time after anthracycline exposure were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/165\">",
"       165",
"      </a>",
"      ]. At a median follow-up of 2.8 years, there were no significant differences in exercise performance between the two groups, but there was a significant reduction in left ventricular end-systolic wall stress during the first year in the treated group. Six of seven patients with cardiac deterioration during this period were receiving placebo.",
"     </li>",
"     <li>",
"      A second observational study consisted of 18 children treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      for either asymptomatic left ventricular dysfunction or heart failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/166\">",
"       166",
"      </a>",
"      ]. By six years after starting enalapril, all six children who originally had heart failure and three of 12 with asymptomatic left ventricular dysfunction either died or required cardiac transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16385821\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of anthracyclines and related compounds (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    , and the anthraquinone",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    ) is hindered by their cardiotoxicity. Cardiovascular complications may be observed acutely or subacutely (any time from the initiation of therapy to several weeks after treatment termination), or later:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute or subacute cardiotoxicity, which can occur anytime from treatment initiation to several weeks after termination, may present as electrocardiographic abnormalities, arrhythmias (mainly atrial fibrillation) ventricular dysfunction, an increase in plasma brain natriuretic peptide (BNP), or a pericarditis-myocarditis syndrome. These events are rare and seldom of clinical importance since they usually resolve within a week. (See",
"      <a class=\"local\" href=\"#H16386025\">",
"       'Acute toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dose-limiting chronic cardiotoxicity may present early (within one year after termination of chemotherapy), or",
"      <span class=\"nowrap\">",
"       late/delayed",
"      </span>",
"      (developing more than one year, and sometimes more than ten years after treatment). Chronic cardiomyopathy generally manifests as asymptomatic decline in left ventricular ejection fraction (LVEF), or diastolic or systolic dysfunction, progressing to heart failure. The number of patients who have heart failure is much lower than the number who have asymptomatic decline in LVEF on noninvasive testing. (See",
"      <a class=\"local\" href=\"#H292515\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The incidence of chronic cardiotoxicity is related to the cumulative dose. The risk is also higher in patients with underlying heart disease, exposure in childhood, concurrent use of other cardiotoxic agents, prior or concurrent chest irradiation, and in those undergoing hematopoietic cell transplantation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293175\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approaches to reducing the risk of anthracycline cardiotoxicity include limiting lifetime cumulative dose, infusional rather than bolus administration schedules, use of less cardiotoxic structural analogs, liposomal encapsulation, the use of adjunctive cardioprotective agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    and beta blockers. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Approaches for reducing the risk'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For adults, we recommend that the lifetime cumulative dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      be limited to 450 to 500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      in adults (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We recommend limiting the maximal cumulative",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      dose to 800 to 900",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Safe treatment to higher doses may be possible in patients treated concurrently with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"       dexrazoxane",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"       Dexrazoxane",
"      </a>",
"      is an EDTA chelator that significantly reduces the risk of chronic cardiotoxicity when used with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      . In keeping with ASCO guidelines (",
"      <a class=\"graphic graphic_table graphicRef70814 \" href=\"mobipreview.htm?9/33/9757\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/65\">",
"       65",
"      </a>",
"      ], we suggest the use of dexrazoxane in patients being treated for metastatic disease who have received a cumulative dose of doxorubicin &ge;300",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      and may benefit from continued treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      For adults who will receive anthracyclines in an adjuvant setting, we suggest not using dexrazoxane outside of a clinical trial setting, because of concerns about potential impact on antitumor efficacy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      For children being treated for a pediatric malignancy, there is insufficient evidence to advise against the use of dexrazoxane, and its use should be considered in children. However, in contrast to adults, there are no specific guidelines on when to start dexrazoxane in children, and practice is variable (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The benefit of other cardioprotectants (eg, beta-blockers such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      , and ACE inhibitors) remains uncertain; despite the lack of data we suggest that high-risk patients (elderly, hypertension, receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      doses &ge;50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per cycle, concurrent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      ) be started on a beta blocker such as carvedilol before starting therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Beta blockers'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'ACE inhibitors and ARBs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293211\">",
"    <span class=\"h2\">",
"     Surveillance during therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether all patients require a baseline echocardiogram or radionuclide (RVG) prior to receiving an anthracycline is controversial and clinical practice is variable. While most cardiologists (including the authors) suggest a baseline echocardiogram or RVG for all patients who are initiating therapy with an anthracycline, many oncologists who treat breast cancer do not perform a baseline evaluation of LVEF for women under the age of 65 who lack cardiac risk factors and who will be receiving an adjuvant anthracycline-containing regimen (total dose &lt;300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H503425356\">",
"     'Guidelines for monitoring and drug discontinuation from expert groups'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=see_link\">",
"     \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients receiving anthracyclines require close monitoring during therapy. We suggest a repeat evaluation of LVEF after a cumulative total dose of 300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    . ASCO guidelines for use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    in conjunction with doxorubicin include recommendations for cardiac monitoring after a cumulative dose of 400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    is reached, with monitoring repeated after 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    cumulative dose, and thereafter after every 50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef70814 \" href=\"mobipreview.htm?9/33/9757\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/65\">",
"     65",
"    </a>",
"    ]. We agree with these guidelines. In addition, we suggest a repeat echocardiogram after four cycles of anthracycline-based chemotherapy (ie, R-CHOP) in high-risk patients when high doses of an anthracycline are being used (eg, &ge;50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    doxorubicin per cycle).",
"   </p>",
"   <p>",
"    The FDA-approved labeling for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    recommends drug discontinuation for the following (see",
"    <a class=\"local\" href=\"#H503425356\">",
"     'Guidelines for monitoring and drug discontinuation from expert groups'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In adults:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       Doxorubicin",
"      </a>",
"      should be discontinued if there is evidence of clinical heart failure, a &ge;10 percent decline in LVEF to below the lower limit of normal, or to an absolute LVEF 45 percent, or a 20 percent decline in LVEF at any level.",
"     </li>",
"     <li>",
"      In children:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       Doxorubicin",
"      </a>",
"      treatment should be discontinued if there is a drop in fractional shortening by an absolute value of &ge;10 percent or below 29 percent; or a decline in LVEF of 10 percentage points, or an LVEF below 55 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68457550\">",
"    <span class=\"h2\">",
"     Posttreatment monitoring of cancer survivors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic assessment of LVEF using either echocardiogram or RVG is recommended in guidelines developed by the Cardiology Committee of the Children's Cancer Study Group for monitoring for late manifestations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    cardiotoxicity in childhood cancer survivors (",
"    <a class=\"graphic graphic_algorithm graphicRef58765 \" href=\"mobipreview.htm?10/27/10687\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/78\">",
"     78",
"    </a>",
"    ]. A parallel set of guidelines have been published by the Children's Oncology Group for childhood cancer survivors and is available online [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/46/41706/abstract/161\">",
"     161",
"    </a>",
"    ]. There are no corresponding guidelines for posttreatment monitoring in adults.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/1\">",
"      Floyd JD, Nguyen DT, Lobins RL, et al. Cardiotoxicity of cancer therapy. J Clin Oncol 2005; 23:7685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/2\">",
"      Monsuez JJ, Charniot JC, Vignat N, Artigou JY. Cardiac side-effects of cancer chemotherapy. Int J Cardiol 2010; 144:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/3\">",
"      Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/4\">",
"      Isner JM, Ferrans VJ, Cohen SR, et al. Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy. Am J Cardiol 1983; 51:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/5\">",
"      Nakamae H, Tsumura K, Terada Y, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 2005; 104:2492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/6\">",
"      Guglin M, Aljayeh M, Saiyad S, et al. Introducing a new entity: chemotherapy-induced arrhythmia. Europace 2009; 11:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/7\">",
"      Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/8\">",
"      Barrett-Lee PJ, Dixon JM, Farrell C, et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol 2009; 20:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/9\">",
"      Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005; 112:3754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/10\">",
"      Doroshow JH. Doxorubicin-induced cardiac toxicity. N Engl J Med 1991; 324:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/11\">",
"      Steinberg JS, Cohen AJ, Wasserman AG, et al. Acute arrhythmogenicity of doxorubicin administration. Cancer 1987; 60:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/12\">",
"      Rudzinski T, Ciesielczyk M, Religa W, et al. Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverter-defibrillator. Europace 2007; 9:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/13\">",
"      Kilickap S, Akgul E, Aksoy S, et al. Doxorubicin-induced second degree and complete atrioventricular block. Europace 2005; 7:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/14\">",
"      Luminari S, Montanini A, Caballero D, et al. Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Ann Oncol 2010; 21:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/15\">",
"      Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients &gt; or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/16\">",
"      Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/17\">",
"      Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010; 10:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/18\">",
"      Von Hoff DD, Rozencweig M, Layard M, et al. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 1977; 62:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/19\">",
"      Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/20\">",
"      Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/21\">",
"      van der Pal HJ, van Dalen EC, Hauptmann M, et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med 2010; 170:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/22\">",
"      Singal PK, Deally CM, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol 1987; 19:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/23\">",
"      Adderley SR, Fitzgerald DJ. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem 1999; 274:5038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/24\">",
"      Dowd NP, Scully M, Adderley SR, et al. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 2001; 108:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/25\">",
"      Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 1997; 11:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/26\">",
"      Li T, Singal PK. Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation 2000; 102:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/27\">",
"      Martin E, Thougaard AV, Grauslund M, et al. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology 2009; 255:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/28\">",
"      Tewey KM, Rowe TC, Yang L, et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/29\">",
"      Lyu YL, Lin CP, Azarova AM, et al. Role of topoisomerase IIbeta in the expression of developmentally regulated genes. Mol Cell Biol 2006; 26:7929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/30\">",
"      Capranico G, Tinelli S, Austin CA, et al. Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta 1992; 1132:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/31\">",
"      Lyu YL, Kerrigan JE, Lin CP, et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 2007; 67:8839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/32\">",
"      Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012; 18:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/33\">",
"      Hershman DL, McBride RB, Eisenberger A, et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:3159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/34\">",
"      Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007; 25:3991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/35\">",
"      Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 1981; 102:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/36\">",
"      Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97:2869.",
"     </a>",
"    </li>",
"    <li>",
"     Blanco J, Sun C, Landier W, et al. Anthracycline-related cardiomyopathy in childhood cancer survivors and association with polymorphisms in the carbonyl reductase genes: A Children's Oncology Group study (abstract 9512). J Clin Oncol 2010; 28:681s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/38\">",
"      Shapiro CL, Hardenbergh PH, Gelman R, et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 1998; 16:3493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/39\">",
"      Armenian SH, Sun CL, Francisco L, et al. Late congestive heart failure after hematopoietic cell transplantation. J Clin Oncol 2008; 26:5537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/40\">",
"      Casper ES, Gaynor JJ, Hajdu SI, et al. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 1991; 68:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/41\">",
"      Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer 1990; 65:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/42\">",
"      Zalupski M, Metch B, Balcerzak S, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst 1991; 83:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/43\">",
"      van Dalen EC, van der Pal HJ, Caron HN, Kremer LC. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev 2006; :CD005008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/44\">",
"      Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/45\">",
"      Speyer JL, Green MD, Dubin N, et al. Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. Am J Med 1985; 78:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/46\">",
"      Ryberg M, Nielsen D, Skovsgaard T, et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998; 16:3502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/47\">",
"      Neidhart JA, Gochnour D, Roach R, et al. A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol 1986; 4:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/48\">",
"      Henderson IC, Allegra JC, Woodcock T, et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/49\">",
"      Bennett JM, Muss HB, Doroshow JH, et al. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 1988; 6:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/50\">",
"      Kaklamani VG, Gradishar WJ. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer? Clin Breast Cancer 2003; 4 Suppl 1:S26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/51\">",
"      Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/52\">",
"      Nair R, Ramakrishnan G, Nair NN, et al. A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma. Cancer 1998; 82:2282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/53\">",
"      Ryberg M, Nielsen D, Cortese G, et al. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 2008; 100:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/54\">",
"      Saletan S. Mitoxantrone: an active, new antitumor agent with an improved therapeutic index. Cancer Treat Rev 1987; 14:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/55\">",
"      Posner LE, Dukart G, Goldberg J, et al. Mitoxantrone: an overview of safety and toxicity. Invest New Drugs 1985; 3:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/56\">",
"      Schell FC, Yap HY, Blumenschein G, et al. Potential cardiotoxicity with mitoxantrone. Cancer Treat Rep 1982; 66:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/57\">",
"      Young AM, Dhillon T, Bower M. Cardiotoxicity after liposomal anthracyclines. Lancet Oncol 2004; 5:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/58\">",
"      Gabizon AA, Lyass O, Berry GJ, Wildgust M. Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest 2004; 22:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/59\">",
"      Andreopoulou E, Gaiotti D, Kim E, et al. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol 2007; 18:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/60\">",
"      Yildirim Y, Gultekin E, Avci ME, et al. Cardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m2 in patients with recurrent ovarian and peritoneal cancer. Int J Gynecol Cancer 2008; 18:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/61\">",
"      Berry G, Billingham M, Alderman E, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998; 9:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/62\">",
"      Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000; 11:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/63\">",
"      Seifert CF, Nesser ME, Thompson DF. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother 1994; 28:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/64\">",
"      Popelov&aacute; O, Sterba M, Haskov&aacute; P, et al. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death. Br J Cancer 2009; 101:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/65\">",
"      Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/66\">",
"      Seymour L, Bramwell V, Moran LA. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 1999; 3:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/67\">",
"      Lopez M, Vici P, Di Lauro K, et al. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 1998; 16:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/68\">",
"      Swain SM. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. Semin Oncol 1998; 25:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/69\">",
"      Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997; 15:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/70\">",
"      Curran CF, Narang PK, Reynolds RD. Toxicity profile of dexrazoxane (Zinecard, ICRF-187, ADR-529, NSC-169780), a modulator of doxorubicin cardiotoxicity. Cancer Treat Rev 1991; 18:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/71\">",
"      Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/72\">",
"      Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 2004; 130:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/73\">",
"      van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2011; :CD003917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/74\">",
"      Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006; 48:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/75\">",
"      Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114:2474.",
"     </a>",
"    </li>",
"    <li>",
"     Information on the PRADA trial available online at file://www.clinicaltrials.gov/ct2/show/NCT01434134?term=PRADA&amp;rank=2 (Accessed on December 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/77\">",
"      Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23:2629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/78\">",
"      Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 1992; 89:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/79\">",
"      DeCara JM. Early detection of chemotherapy-related left ventricular dysfunction. Curr Cardiol Rep 2012; 14:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/80\">",
"      Thavendiranathan P, Grant AD, Negishi T, et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 2013; 61:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/81\">",
"      Armstrong GT, Plana JC, Zhang N, et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012; 30:2876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/82\">",
"      Kremer LC, Caron HN. Anthracycline cardiotoxicity in children. N Engl J Med 2004; 351:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/83\">",
"      Kuittinen T, Husso-Saastamoinen M, Sipola P, et al. Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2005; 36:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/84\">",
"      Oberholzer K, Kunz RP, Dittrich M, Thelen M. [Anthracycline-induced cardiotoxicity: cardiac MRI after treatment for childhood cancer]. Rofo 2004; 176:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/85\">",
"      Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 2002; 86:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/86\">",
"      Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002; 13:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/87\">",
"      Meinardi MT, van Veldhuisen DJ, Gietema JA, et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 2001; 19:2746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/88\">",
"      Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/89\">",
"      Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987; 82:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/90\">",
"      Gottdiener JS, Mathisen DJ, Borer JS, et al. Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med 1981; 94:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/91\">",
"      Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003; 108:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/92\">",
"      Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). Circulation 2003; 108:1404.",
"     </a>",
"    </li>",
"    <li>",
"     file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17003 (Accessed on August 23, 2010).",
"    </li>",
"    <li>",
"     FDA-approved drug labeling for mitoxantrone available online at  file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=23983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/95\">",
"      Lee BH, Goodenday LS, Muswick GJ, et al. Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol 1987; 9:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/96\">",
"      Sabel MS, Levine EG, Hurd T, et al. Is MUGA scan necessary in patients with low-risk breast cancer before doxorubicin-based adjuvant therapy? Multiple gated acquisition. Am J Clin Oncol 2001; 24:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/97\">",
"      Porea TJ, Dreyer ZE, Bricker JT, Mahoney DH Jr. Evaluation of left ventricular function in asymptomatic children about to undergo anthracycline-based chemotherapy for acute leukemia: an outcome study. J Pediatr Hematol Oncol 2001; 23:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/98\">",
"      Jeyakumar A, DiPenta J, Snow S, et al. Routine cardiac evaluation in patients with early-stage breast cancer before adjuvant chemotherapy. Clin Breast Cancer 2012; 12:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/99\">",
"      Ali MK, Buzdar AU, Ewer MS, et al. Noninvasive cardiac evaluation of patients receiving adriamycin-containing adjuvant chemotherapy (FAC) for stage II or III breast cancer. J Surg Oncol 1983; 23:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/100\">",
"      Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol 2008; 26:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/101\">",
"      Herman EH, Zhang J, Lipshultz SE, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999; 17:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/102\">",
"      Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997; 96:2641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/103\">",
"      Auner HW, Tinchon C, Linkesch W, et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003; 82:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/104\">",
"      Cardinale D, Sandri MT, Martinoni A, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002; 13:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/105\">",
"      Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109:2749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/106\">",
"      Specchia G, Buquicchio C, Pansini N, et al. Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J Lab Clin Med 2005; 145:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/107\">",
"      Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010; 28:3910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/108\">",
"      Kremer LC, Bastiaansen BA, Offringa M, et al. Troponin T in the first 24 hours after the administration of chemotherapy and the detection of myocardial damage in children. Eur J Cancer 2002; 38:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/109\">",
"      Raderer M, Kornek G, Weinl&auml;nder G, Kastner J. Serum troponin T levels in adults undergoing anthracycline therapy. J Natl Cancer Inst 1997; 89:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/110\">",
"      Fink FM, Genser N, Fink C, et al. Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Med Pediatr Oncol 1995; 25:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/111\">",
"      Kismet E, Varan A, Ayabakan C, et al. Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatr Blood Cancer 2004; 42:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/112\">",
"      Mathew P, Suarez W, Kip K, et al. Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study. Cancer Invest 2001; 19:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/113\">",
"      Soker M, Kervancioglu M. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J 2005; 26:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/114\">",
"      Dodos F, Halbsguth T, Erdmann E, Hoppe UC. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 2008; 97:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/115\">",
"      Germanakis I, Anagnostatou N, Kalmanti M. Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity. Pediatr Blood Cancer 2008; 51:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/116\">",
"      Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/117\">",
"      Bryant J, Picot J, Baxter L, et al. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review. Eur J Cancer 2007; 43:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/118\">",
"      Vogelsang TW, Jensen RJ, Hesse B, Kjaer A. BNP cannot replace gated equilibrium radionuclide ventriculography in monitoring of anthracycline-induced cardiotoxity. Int J Cardiol 2008; 124:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/119\">",
"      Tikanoja T, Riikonen P, Perkki&ouml; M, Helenius T. Serum N-terminal atrial natriuretic peptide (NT-ANP) in the cardiac follow-up in children with cancer. Med Pediatr Oncol 1998; 31:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/120\">",
"      Mavinkurve-Groothuis AM, Kapusta L, Nir A, Groot-Loonen J. The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature. Pediatr Hematol Oncol 2008; 25:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/121\">",
"      Lenihan DJ, Esteva FJ. Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer. Oncologist 2008; 13:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/122\">",
"      Aggarwal S, Pettersen MD, Bhambhani K, et al. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatr Blood Cancer 2007; 49:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/123\">",
"      Nousiainen T, Vanninen E, Jantunen E, et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 2002; 251:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/124\">",
"      Thelander B. Trauma and dissociation. Perspect Psychiatr Care 2001; 37:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/125\">",
"      Snowden JA, Hill GR, Hunt P, et al. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant 2000; 26:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/126\">",
"      Poutanen T, Tikanoja T, Riikonen P, et al. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol 2003; 21:2349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/127\">",
"      Sandri MT, Salvatici M, Cardinale D, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 2005; 51:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/128\">",
"      Germanakis I, Kalmanti M, Parthenakis F, et al. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Int J Cardiol 2006; 108:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/129\">",
"      Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 2007; 116:2216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/130\">",
"      Meinardi MT, van der Graaf WT, van Veldhuisen DJ, et al. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 1999; 25:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/131\">",
"      Yoon GJ, Telli ML, Kao DP, et al. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol 2010; 56:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/132\">",
"      Haq MM, Legha SS, Choksi J, et al. Doxorubicin-induced congestive heart failure in adults. Cancer 1985; 56:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/133\">",
"      Ajijola OA, Nandigam KV, Chabner BA, et al. Usefulness of cardiac resynchronization therapy in the management of Doxorubicin-induced cardiomyopathy. Am J Cardiol 2008; 101:1371.",
"     </a>",
"    </li>",
"    <li>",
"     Mulrooney DA, Yeazel M, Mitby P, et al. Cardiovascular disease in adult survivors of childhood and adolescent cancer: A report from the Childhood Cancer Survivor Study (CCSS) (abstract). J Clin Oncol 2008; 26:504s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/135\">",
"      Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol 1998; 16:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/136\">",
"      Bu'Lock FA, Mott MG, Oakhill A, Martin RP. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology. Br Heart J 1995; 73:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/137\">",
"      Green DM, Grigoriev YA, Nan B, et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group. J Clin Oncol 2001; 19:1926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/138\">",
"      Kremer LC, van der Pal HJ, Offringa M, et al. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002; 13:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/139\">",
"      Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/140\">",
"      Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 1995; 24:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/141\">",
"      Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998; 25:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/142\">",
"      Pein F, Sakiroglu O, Dahan M, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer 2004; 91:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/143\">",
"      van Dalen EC, van der Pal HJ, Kok WE, et al. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer 2006; 42:3191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/144\">",
"      Hudson MM, Rai SN, Nunez C, et al. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol 2007; 25:3635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/145\">",
"      O'Brien MM, Taub JW, Chang MN, et al. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421. J Clin Oncol 2008; 26:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/146\">",
"      Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 2003; 97:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/147\">",
"      Lipshultz SE, Miller TL, Lipsitz SR, et al. Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes. Pediatrics 2012; 130:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/148\">",
"      Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 2002; 20:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/149\">",
"      Gupta M, Steinherz PG, Cheung NK, Steinherz L. Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers. Med Pediatr Oncol 2003; 40:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/150\">",
"      Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996; 14:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/151\">",
"      Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/152\">",
"      Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010; 11:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/153\">",
"      Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 2007; 25:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/154\">",
"      Barry EV, Vrooman LM, Dahlberg SE, et al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol 2008; 26:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/155\">",
"      Vrooman LM, Neuberg DS, Stevenson KE, et al. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer 2011; 47:1373.",
"     </a>",
"    </li>",
"    <li>",
"     Walker DM, et al. Dexrazoxane exposure and risk of secondary acute muyeloid leukemia in pediatric cancer patients (abstract). J Clin Oncol 30, 2012 (suppl; abstr 1504). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=92998 (Accessed on July 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/157\">",
"      Shankar SM, Marina N, Hudson MM, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics 2008; 121:e387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/158\">",
"      Jannazzo A, Hoffman J, Lutz M. Monitoring of anthracycline-induced cardiotoxicity. Ann Pharmacother 2008; 42:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/159\">",
"      Sieswerda E, Postma A, van Dalen EC, et al. The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors. Ann Oncol 2012; 23:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/160\">",
"      Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 22:4979.",
"     </a>",
"    </li>",
"    <li>",
"     Long-term follow-up guidelines from the Children's Oncology Group www.survivorshipguidelines.org/pdf/LTFUGuidelines.pdf (Accessed on May 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/162\">",
"      Hamada H, Ohkubo T, Maeda M, Ogawa S. Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer. Pediatr Int 2006; 48:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/163\">",
"      Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 2012; 30:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/164\">",
"      Lipshultz SE, Colan SD. Cardiovascular trials in long-term survivors of childhood cancer. J Clin Oncol 2004; 22:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/165\">",
"      Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004; 22:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/46/41706/abstract/166\">",
"      Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002; 20:4517.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2810 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_46_41706=[""].join("\n");
var outline_f40_46_41706=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16385821\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16386025\">",
"      ACUTE TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16386125\">",
"      CHRONIC CARDIOTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H292515\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Cumulative dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Concomitant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Approaches for reducing the risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Infusion protocols",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Structural modifications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Epirubicin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Mitoxantrone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Liposome encapsulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Dexrazoxane",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ASCO guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - ACE inhibitors and ARBs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Pretreatment assessment and subsequent monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Noninvasive monitoring of LVEF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Radionuclide angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3664395\">",
"      Cardiac MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H293787\">",
"      Predictive value of early changes in cardiac function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H503425356\">",
"      Guidelines for monitoring and drug discontinuation from expert groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H293801\">",
"      Do all patients require a baseline assessment of LVEF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H68453504\">",
"      Electrocardiographic changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Cardiac biomarkers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Serum troponins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Brain natriuretic peptide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Role of endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Issues in children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Cardiotoxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Cardioprotection with dexrazoxane",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Guidelines for posttreatment monitoring of cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16385821\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293175\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293211\">",
"      Surveillance during therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68457550\">",
"      Posttreatment monitoring of cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2810\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2810|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?10/27/10687\" title=\"algorithm 1\">",
"      Doxorubicin monitoring children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2810|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/48/33550\" title=\"figure 1\">",
"      LVEF reversible doxo cardiotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/52/32589\" title=\"figure 2\">",
"      Preventing doxorubicin toxicity - Impact of following guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/12/28877\" title=\"figure 3\">",
"      Troponin LVEF chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2810|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/54/32621\" title=\"table 1\">",
"      Epirub cum dose cardiotox",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/33/9757\" title=\"table 2\">",
"      Guidelines use dexrazoxane",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/21/43355\" title=\"table 3\">",
"      Doxorubicin cardiac monitoring",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41496?source=related_link\">",
"      Acute side effects of adjuvant chemotherapy for early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=related_link\">",
"      Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42232?source=related_link\">",
"      Cardiotoxicity of trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13145?source=related_link\">",
"      Contrast echocardiography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7592?source=related_link\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28601?source=related_link\">",
"      Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13226?source=related_link\">",
"      General principles on the treatment of early stage and locally advanced breast cancer in older women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34664?source=related_link\">",
"      Hematopoietic support after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18282?source=related_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/21/11610?source=related_link\">",
"      Noninvasive methods for measurement of left ventricular systolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_46_41707="Down syndrome screening PI";
var content_f40_46_41707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F66116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F66116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Select the statement that best describes your values and preferences to help decide which screening test is best for you",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"70%\">",
"     </colgroup>",
"     <colgroup width=\"30%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Statement",
"       </td>",
"       <td class=\"subtitle1\">",
"        Screening test to consider",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. \"I want the result of my screening test as early as possible in the pregnancy, while the pregnancy is still private and I have options of early prenatal diagnosis (chorionic villus sampling) because I would terminate an affected pregnancy.\"",
"       </td>",
"       <td>",
"        First-trimester screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. \"I want to have the test with the lowest chance of a screen positive result.\"",
"       </td>",
"       <td>",
"        Integrated screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. \"I would consider an amniocentesis if my test result shows a high chance of Down syndrome, but not a CVS because it has a higher risk for procedure-related complications.\"",
"       </td>",
"       <td>",
"        Integrated screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. \"I have been very anxious and want my results as soon as possible, whether or not I would terminate an affected pregnancy.\"",
"       </td>",
"       <td>",
"        First-trimester screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. \"I am already in my second trimester of pregnancy.\"",
"       </td>",
"       <td>",
"        Triple or quad screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. \"Nuchal translucency ultrasound is not available in my area.\"",
"       </td>",
"       <td>",
"        Serum-only integrated screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. \"Chorionic villus sampling is not available in my area.\"",
"       </td>",
"       <td>",
"        Integrated screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. \"My pregnancy is considered high risk for a chromosomal abnormality because of my age, my family history, a finding on my ultrasound exam, or a positive result on a screening test done on my blood.\"",
"       </td>",
"       <td>",
"        Plasma DNA screening",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_46_41707=[""].join("\n");
var outline_f40_46_41707=null;
var title_f40_46_41708="Dyspareunia differential dx1";
var content_f40_46_41708=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnoses for physical causes of dyspareunia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Location affected",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Important history",
"       </td>",
"       <td class=\"subtitle1\">",
"        Source of dyspareunia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments and Caveats",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"8\">",
"        Vulva and Vestibule",
"       </td>",
"       <td>",
"        Dermatitis (eczema)",
"       </td>",
"       <td>",
"        Atopic history, other eczema",
"       </td>",
"       <td>",
"        Erythema, scaling, fissuring",
"       </td>",
"       <td>",
"        Look for Candida also",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatosis: lichen sclerosus",
"       </td>",
"       <td>",
"        Itching, recent or lifelong, soreness, possibly no symptoms",
"       </td>",
"       <td>",
"        Fissures, ulceration, scarring",
"       </td>",
"       <td>",
"        Look for Candida also",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatosis: lichen planus",
"       </td>",
"       <td>",
"        Itching, irritation, burning",
"       </td>",
"       <td>",
"        Erosions, ulcers, scarring",
"       </td>",
"       <td>",
"        Many drugs exacerbate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulcerative disease: herpes simplex or zoster, chancroid, Crohn's, aphthae, Behcet's",
"       </td>",
"       <td>",
"        Episodic outbreaks",
"       </td>",
"       <td>",
"        Ulceration varying in size, tenderness",
"       </td>",
"       <td>",
"        Behcet's very rare, involves oral ulcers, uveitis, other systems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Labial hypertrophy",
"       </td>",
"       <td>",
"        Irritation w/physical activity",
"       </td>",
"       <td>",
"        Elongation of labia",
"       </td>",
"       <td>",
"        Look for vestibulitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Female circumcision",
"       </td>",
"       <td>",
"        Ethnicity and country of origin",
"       </td>",
"       <td>",
"        Absence of clitoris and prepuce, labial fusion",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Generalized dyesthesia (Vulvodynia)",
"       </td>",
"       <td>",
"        Episodic or virtually constant burning, stinging, soreness irritation, rawness",
"       </td>",
"       <td>",
"        Often no findings; or erythema and edema, areas of hyper or hypoesthesia",
"       </td>",
"       <td>",
"        Long history of unsuccessful urinary tract, yeast, bacterial vaginosis treatments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiation",
"       </td>",
"       <td>",
"        History of gyn or urinary tumor",
"       </td>",
"       <td>",
"        Pallor, alopecia, loss of elasticity",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Urethra and bladder",
"       </td>",
"       <td>",
"        Urinary tract infection",
"       </td>",
"       <td>",
"        Dysuria, frequency, urgency",
"       </td>",
"       <td>",
"        Tenderness over bladder",
"       </td>",
"       <td>",
"        Negative cultures suggests vulvodynia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urethral diverticulum",
"       </td>",
"       <td>",
"        Dysuria, dribbling, pain with penetration",
"       </td>",
"       <td>",
"        Urethral tenderness, mass",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interstitial cystitis",
"       </td>",
"       <td>",
"        Pelvic pain, dysuria, urgency, frequency, nocturia",
"       </td>",
"       <td>",
"        Tenderness over bladder, along anterior vaginal wall",
"       </td>",
"       <td>",
"        Look for vestibulodynia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Elizabeth Gunther Stewart, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_46_41708=[""].join("\n");
var outline_f40_46_41708=null;
var title_f40_46_41709="Survival after heart transp";
var content_f40_46_41709=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Survival after heart transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 297px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data from the Registry of the International Society for Heart and Lung Transplantation of 70,702 adult and pediatric heart transplants performed between January 1982 and June 2005. The half-life for survival was 10.0 years. The half-life for patients surviving the first year was 13.0 years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Taylor, DO, Edwards, LB, Boucek, MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report--2007. J Heart Lung Transplant 2007; 26:769.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_46_41709=[""].join("\n");
var outline_f40_46_41709=null;
var title_f40_46_41710="Contents: Critical care neurology";
var content_f40_46_41710=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?0/63/1022\">",
"       Neurology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Critical care neurology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Critical care neurology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Cardiovascular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/57/17305\">",
"           Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/20/26952\">",
"           Cardiac complications of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/26/18853\">",
"           Drug treatment of hypertensive emergencies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/27/41398\">",
"           Malignant hypertension and hypertensive encephalopathy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/47/3834\">",
"           Neurologic complications of cardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/7/2168\">",
"           Prevention of neurologic complications of cardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/28/29130\">",
"           Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/56/32650\">",
"           Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/54/10087\">",
"           Stroke-related pulmonary complications and abnormal respiratory patterns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/11/18614\">",
"           Treatment of specific hypertensive emergencies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Encephalopathy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/1/36889\">",
"           Acute toxic-metabolic encephalopathy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/10/39081\">",
"           Diagnosis of delirium and confusional states",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/56/19337\">",
"           Hypoxic-ischemic brain injury: Evaluation and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/53/10074\">",
"           Osmotic demyelination syndrome and overly rapid correction of hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/34/18986\">",
"           Overview of the treatment of hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/33/28185\">",
"           Prevention and treatment of delirium and confusional states",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/48/38664\">",
"           Air embolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/55/39801\">",
"           Eclampsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/39/33402\">",
"           Evaluation and management of elevated intracranial pressure in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/21/25942\">",
"           Fat embolism syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/32/44552\">",
"           Infections of central nervous system shunts and other devices",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/61/20441\">",
"           Management of moderate and severe alcohol withdrawal syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/8/10377\">",
"           Suicidal ideation and behavior in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/44/43720\">",
"           Use of neuromuscular blocking medications in critically ill patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neuromuscular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/22/5481\">",
"           Clinical features and diagnosis of Guillain-Barr������ syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/6/40038\">",
"           Pathogenesis of Guillain-Barr������ syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/36/41543\">",
"           Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/28/42439\">",
"           Respiratory complications of spinal cord injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/20/35142\">",
"           Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/16/265\">",
"           Treatment and prognosis of Guillain-Barr������ syndrome in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Respiratory failure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/43/25271\">",
"           Neurogenic pulmonary edema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/36/41543\">",
"           Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/28/42439\">",
"           Respiratory complications of spinal cord injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/20/35142\">",
"           Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/54/10087\">",
"           Stroke-related pulmonary complications and abnormal respiratory patterns",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Seizures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/55/39801\">",
"           Eclampsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/9/25753\">",
"           Evaluation of the first seizure in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/61/20441\">",
"           Management of moderate and severe alcohol withdrawal syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/61/43994\">",
"           Pharmacology of antiepileptic drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/11/19642\">",
"           Status epilepticus in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Stroke",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/57/17305\">",
"           Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/20/26952\">",
"           Cardiac complications of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/17/40216\">",
"           Clinical diagnosis of stroke subtypes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/63/9208\">",
"           Etiology and classification of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/39/38522\">",
"           Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/29/33242\">",
"           Initial assessment and management of acute stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/26/6570\">",
"           Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/47/28410\">",
"           Overview of the evaluation of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/8/41098\">",
"           Reperfusion therapy for acute ischemic stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/28/29130\">",
"           Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/56/32650\">",
"           Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/54/10087\">",
"           Stroke-related pulmonary complications and abnormal respiratory patterns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/54/37738\">",
"           Treatment of aneurysmal subarachnoid hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/40/25225\">",
"           Unruptured intracranial aneurysms",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-97B1725831-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f40_46_41710=[""].join("\n");
var outline_f40_46_41710=null;
var title_f40_46_41711="Prenatal ultrasound normal renal Doppler";
var content_f40_46_41711=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound normal renal Doppler",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tulin Ozcan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_46_41711=[""].join("\n");
var outline_f40_46_41711=null;
